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Abstract 
 
The idiosyncratic nature of drug hypersensitivity reactions poses a major clinical 
problem as they are difficult to predict and can be severe in nature. β-lactam antibiotics 
provide the cornerstone of treatment for pulmonary exacerbations in patients with 
cystic fibrosis (CF). Unfortunately, their use is complicated due to a high rate of 
delayed-type hypersensitivity reactions. This body of work was undertaken to 
investigate the chemical and cellular mechanisms of β-lactam-induced T-cell mediated 
hypersensitivity. 
Approximately 20% of patients with CF develop multiple drug hypersensitivity (MDH). 
Peripheral mononuclear blood cells (PBMCs) isolated from 4 patients, but not controls, 
were activated with three drugs (piperacillin, meropenem & aztreonam). T-cell clones 
were isolated from the MDH patients and characterised for phenotype, function and 
cross reactivity. Piperacillin-, meropenem- and aztreonam-responsive T-cell clones 
(mainly CD4+) proliferated and released IFN-γ following drug stimulation. Clones were 
drug-specific; cross reactivity was not observed. All 3 drugs formed structurally 
distinct haptenic structures with specific lysine residues on HSA in a time- and 
concentration-dependent manner.  
β-lactam antibiotics are widely thought to activate immune cells through the covalent 
modification of proteins, but the link between conjugate formation and an immune 
response is still to be defined.  T-cell clones from piperacillin hypersensitive patients 
were stimulated by piperacillin-pulsed antigen presenting cells (APCs) in a time 
dependent manner and T-cell responses were inhibited following inhibition of protein 
processing. Synthetic conjugates generated via two methods were investigated. 
Conjugates were similar in terms of sites of modification and relative level of binding at 
each site. Conjugate 1 did not stimulate T-cells while responses were observed with 
conjugate 2. The higher concentration of unbound piperacillin detected in conjugate 2 
led to the hypothesis that HSA conjugates may facilitate the transfer of piperacillin to 
appropriate binding sites on MHC molecules to initiate a T-cell response.  
T-cell clones were subsequently generated from PBMC cultured with piperacillin 
conjugate 1. Several clones were stimulated with conjugate 1, but not the parent drug 
highlighting the existence of T-cells with specificity against different drug-derived 
antigens. 
Using a synthetic piperacillin-modified HSA peptide (PIP-K541 peptide) as a standard, 
a novel mass spectrometric method was developed to quantify the level of piperacillin 
protein binding needed to activate T-cells. Levels of PIP-K541 in patient plasma ranged 
from 2.5-6.5%. In vitro modification ranged from low (1%) coinciding with weak 
proliferative responses piperacillin-specific T-cell clones to high at around 4%. From 
these experiments it was possible to estimate that 2.8% modification of albumin is 
sufficient for effective T-cell activation. 
The β-lactam antibiotic flucloxacillin is associated with a high incidence of liver 
reactions. Genome-wide association studies identified HLA-B*57:01 as an important 
susceptibility factor. CD8+ T-cell clones from patients with liver injury were activated 
by flucloxacillin to proliferate and secrete cytokines in an HLA-B*57:01 restricted and 
dose-dependent manner. T-cell activation was detected with both soluble drug and 
drug-pulsed APC. In contrast, clones from volunteers were only activated with soluble 
drug and the response was not HLA-B*57:01 restricted.  
This work quantifies β-lactam-protein binding in patients and relates this to T-cell 
activation. Furthermore, the immunological studies show that T-cells from 
hypersensitive patients are activated via multiple pathways.
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1.1 Introduction 
β-lactam antibiotics comprise one of the most common groups of therapies used 
to treat bacterial infections (Cho et al., 2014) yet the high rate of 
hypersensitivity reactions, particularly in patients with cystic fibrosis, is a major 
health concern. Immune-mediated reactions are often difficult to predict and 
can be severe or even fatal and thus are a significant problem for clinicians and 
in the drug development pathway. Furthermore, recent studies have reported 
that for a number of adverse drug reactions susceptibility is increased with 
possession of particular human leukocyte antigen, or HLA, alleles.  
A number of β-lactam antibiotics were investigated throughout this thesis both 
with and without genetic associations. The molecular basis, and mechanisms 
involved in these immune-mediated adverse reactions are not fully understood. 
This work has been developed to elucidate the mechanisms and involvement of 
drug-specific T-cells in the pathogenesis of β-lactam hypersensitivity and drug-
induced liver injury.  
The immune system is one of the most complex systems within the human body 
comprising a wide range of cells and molecules with explicit roles in order to 
defend the host. This chapter introduces the main components that make up the 
immune system providing a general base knowledge of the pathways involved 
in keeping the human body healthy. As with any drug, before administration to 
patients the relative risk-benefit must always be considered. As a “foreign 
substance” there is a significant risk of the body treating drugs as a harmful 
entity and so, in some cases, the immune system will respond as such. Thus 
drug hypersensitivity reactions are seen. The clinical manifestations of drug 
hypersensitivity and the molecular pathways for T-cell activation by drugs are 
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detailed in this chapter. The chapter then progresses to factors that can 
influence the development of drug hypersensitivity with a particular focus on 
HLA associations. Finally, a brief introduction into the methods and β-lactam 
antibiotics used in hypersensitivity research, and specifically in this thesis, are 
detailed.  
1.2 The immune system 
The human body’s self defence mechanism against various pathogens, viruses, 
bacterial infections and some chemical toxins is an intricate mix of cells and 
molecules that make up the immune system. Its job is to recognise and protect 
the host from harmful invading pathogens. Furthermore, discrimination 
between an individual’s own cells and those that pose a potential threat is 
essential for the prevention of autoimmune disorders. 
The nature of the immune response is usually divided into two categories – 
innate or adaptive. Innate immunity is characterised as an immediate yet non-
specific response whereas adaptive immunity is a targeted, pathogen specific 
response.  
1.2.1 Innate immunity 
The innate immune system provides the first line of defence against invading 
microbes and pathogens that are likely to cause infection. As the early defence 
mechanism, innate immunity provides an initial and rapid generalised 
response.  
The first barrier between the host and harmful microbes from the external 
environment is a physical one. The skin and epithelial linings of the 
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gastrointestinal and respiratory tracts are parts of the innate system, which are 
constantly active. The other components are ready and waiting to provide a 
quick response to an invading microbe.  
The innate immune system is limited in the number of microbial products or 
pathogen associated molecular patterns (PAMPs) that it can recognise and 
therefore react to. Typically, it recognises structures that are either not present 
on mammalian cells or characteristic of microbial pathogens. Structures can 
include microbe specific nucleic acids or complex carbohydrates which are 
unique to microbes’ for example LPS in gram negative bacteria. Pattern 
recognition receptors like the toll-like receptors bind such PAMPs (Abbas et al., 
2010). Essentially one of the defining features of the innate immune system is 
its ability to distinguish between self (mammalian) and non self (microbial) 
molecules (Janeway Jr et al., 2002). 
Innate immunity not only recognises microbes, it also helps eliminate injured 
host cells which may have become infected due to stress or trauma. Trauma 
which leads to tissue injury augments T-cell activity as injured host cells often 
express molecules and up regulate co-receptors that are not common in healthy 
cells. The innate immune system will therefore recognise the injured cell 
(Stoecklein et al., 2012). 
While providing the initial defence mechanism the innate immune system is 
also pivotal in stimulating the adaptive immune system. Molecules produced 
during the innate response can determine the nature of the adaptive response 
and thus both systems are interlinked. 
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1.2.2 Adaptive immunity 
In contrast to the innate immune system, the adaptive immune responses are 
triggered by the specific recognition of antigens by lymphocytes. The adaptive 
immune system plays a major role in delayed drug hypersensitivity, and is 
discussed in further detail later in this chapter.  
T- and B-lymphocytes are the major effector cells of the adaptive immune 
system which recognise invading pathogens and in turn mount an immune 
response. Receptors on these cells form antigen binding sites and their great 
diversity allow such a vast range of antigens to be determined. Naive T- and B-
cells reside in secondary lymphoid tissues such as the spleen and lymph nodes. 
Dendritic cells migrate to these tissues and present captured antigens to the 
adaptive immune cells which are recognised via T- and B-cell receptors. This 
leads to clonal expansion and thus a large pool of antigen-specific T- or B-cells. 
Some of these cells can remain dormant and circulate for a lifetime giving rise to 
immunological memory permitting a rapid response following a second 
exposure to the same antigen (Parkin et al., 2001). This is the basis of adaptive 
immunity and indeed of vaccinations. 
Innate and adaptive immunity involve both cellular components and humoral 
immunity. Humoral immunity is distinct due to the involvement of antigen-
specific antibodies formed through the activation of B-cells and their 
subsequent maturation and expansion of antibody-secreting plasma cells and 
memory cells (LeBien et al., 2008).  A cellular response, as the name indicates, 
involves a range of cell-mediated responses with phagocytes, antigen-specific T-
cells and the release of specific cytokines in addition to a range of other 
components all involved. Antibodies are not involved in a cell-mediated 
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response however certain components do overlap between humoral and 
cellular responses. For example, the secretion of specific cytokines from T-cells 
which induce Ig isotype switching (Parkin et al., 2001).    
I have briefly mentioned just a few of the cells involved in the immune system. 
However, these are only a subset of the vast array of cells and tissues involved 
and the next sections gives greater detail of such components.  
1.3 Cells and tissues of the immune system 
Leukocytes (immune cells) are derived from hematopoietic stem cells in the 
bone marrow. Here, depending on a variety of stimuli, the appropriate 
progenitor cells will give rise to all the different cell types of the immune 
system. 
1.3.1 Phagocytic cells 
A major component of the innate immune system, the phagocytes main function 
is to identify and remove microbes. This is achieved by engulfing the pathogen, 
i.e. bacteria, and destroying the ingested pathogen. Phagocytes can be split into 
two major lineages: mononuclear phagocytes or polymorphonuclear 
granulocytes.  
Monocytes, a mononuclear phagocyte, are derived from common myeloid 
progenitor cells and circulate in the peripheral blood (Radtke et al., 2013). 
These can then migrate through blood vessel walls into various tissues and 
organs throughout the body. Here, monocytes mature into macrophages, with 
the location and thus function of the macrophage determining its nomenclature. 
For example, macrophages that reside in the central nervous system are called 
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microglial cells and those located in the liver are known as Kupffer cells. 
Monocytes/macrophages possess many lysosomes that contain enzymes, which 
can digest and break down invading bacteria. They can live for months and are 
widespread throughout the body (Male et al., 2007).  
Neutrophils, polymorphonuclear granulocytes, are short lived, however they 
comprise the majority of circulating leukocytes and 95% of circulating 
granulocytes. They possess acidic lysosomes and intracellular granules which 
contain a variety of specific, often toxic, materials to destroy microbes including 
acidic hydrolases, myeloperoxidase and lactoferrin(Male et al., 2007). Vacuoles 
which contain the ingested microbe (phagosome) fuse together with the 
lysosomes to become phaglysosomes whereupon the killing takes place. 
Neutrophils can also release their granules and cytotoxic molecules 
extracellularly and thus recruit certain cell types to the site of tissue damage. 
Chemokines such as interleukin-8 (IL-8) promote neutrophil migration to 
specific sites (Mitsuyama et al., 1994). Phagocytes also kill ingested microbes 
through a process called an oxidative burst where we see the formation of 
reactive oxygen species (ROS) and nitric oxide (NO) which can damage 
biomolecules and enzymes (Slauch, 2011). 
Mast cells, basophils and eosinophils comprise the remaining 5% of circulating 
granulocytes. Both basophils and mast cells carry histamine, an inflammatory 
mediator. Degranulation, where such a mediator is released, is often stimulated 
by the presence of an allergen or parasite. Both cell types also have numerous 
high affinity Fc receptors for IgE and cross linking of these molecules can cause 
activation and degranulation. Eosinophils hold granules containing major basic 
protein, which can phagocytose and kill microbes directly. They also produce 
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inflammatory mediators such as IL-2, IFN-γ, IL-4, IL-5, IL-10 and can synthesise 
leukotrienes and prostaglandins (Rothenberg et al., 2006). 
Dendritic cells (DCs) are another mononuclear phagocyte with a distinct shape. 
They have long protruding dendrites, which assist in engulfing microbes. DCs 
are a crucial link between the innate and adaptive immune responses due to 
their role as professional antigen presenting cells (APCs). They shall be 
discussed in this context later in section 1.4. 
1.3.2 Lymphocytes 
Lymphocytes are one of the major cell types involved in, and responsible for 
adaptive immune responses. T and B lymphocytes (T and B cells) comprise the 
majority of lymphocytes. An antigen is any substance that can be targeted by 
receptors and which elicit an immune response. The epitope, or antigenic 
determinant is the part of that antigen which is recognised by those receptors 
by either T- or B-cells or even antibodies. They are capable of recognising 
antigenic determinants, and it is this specificity and memory which makes the 
system adaptive. All lymphocytes are derived from haematopoietic stem cells in 
the bone marrow (Male et al., 2007). From there, a number of distinct subsets of 
lymphocytes are generated with differing functions. T-cells mature and develop 
completely in the thymus before entering the circulation whereas B-cells 
partially mature in the bone marrow. 
1.3.3 B-lymphocytes 
B-cells play a critical role in humoral immunity due to their main function: the 
production and secretion of antibodies. Membrane bound antibodies on the 
surface of B-cells are known as immunoglobulins (Ig) and act as antigen 
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receptors. Following antigen exposure, combined with a second signal usually 
from an activated T-cell, B-cells can also be induced to proliferate and 
differentiate into antibody secreting plasma cells. Secreted antibodies reside in 
the circulation and populate the interstitial fluid part of tissues and also 
mucosal secretions. These antibodies halt the harmful effect of pathogens in 
numerous ways. Through binding directly to pathogens, a term called 
neutralization; they can halt toxic effects, inhibit viral components and thus halt 
infections (Abbas et al., 2010). Furthermore, antibodies can activate the 
complement system which consists of distinct plasma proteins that react with 
each other and coat the pathogen. This system can lead easier identification for 
phagocytes, also known as opsonisation, enhancing the immune response. This 
can directly kill bacteria thus aiding phagocytosis.  
Cytokines from helper T-cells can induce Ig isotype switching. Naive and plasma 
B-cells express lower affinity IgD and IgM whereas mature, memory B-cells 
express the secondary isotypes IgA, IgE and IgG. These long lasting memory B-
cells circulate in a resting state, ready to respond rapidly when they encounter 
antigen (Parkin et al., 2001). 
1.3.4 T-lymphocytes 
T-cells, while involved in the humoral immune response, are also major players 
in the cellular immune response. They are distinguished through the variety of 
T-cell antigen receptors (TCRs) of which there are two well defined types: 
either α and β, or γ and δ. Both types of receptors are associated with the CD3 
complex and thus expression of CD3 can identify T-cells in vitro. The vast 
majority of blood T-cells, up to 95%, are αβ T-cells with the remainder 
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consisting of γδ T-cells and natural killer cells (or NKT cells) (Abbas et al., 
2010).  
Each T-cell will only express one subset of TCR, which in turn recognises a small 
proportion of an antigen, or peptide, which is presented by the major 
histocompatability complex (MHC).  It is therefore the TCR that determines the 
antigen specificity. Following recognition of antigenic peptide, the specific T-
cells bearing the appropriate TCR will proliferate and differentiate giving rise to 
a large population of effector T-cells (Teff); thus, resulting in the specific 
immune response. T-cell selection begins in the thymic cortex where cells co-
express CD4 and CD8 giving rise to a double positive CD4+ CD8+ thymocyte 
population which will carry specific TCRs (Bonilla et al., 2010). Thymocytes that 
do not show affinity for the MHC-peptide complex will ultimately die of neglect 
via apoptotic mechanisms (Starr et al., 2003). Those thymocytes that recognise 
the MHC-peptide complex are positively selected, migrate to the thymic medulla 
and as a consequence lose the co-expression of CD4 and CD8. Depending on the 
complex recognised (via MHC class I or II) the double positive T-cells are 
predetermined to become either CD4+ or CD8+ single positive T-cells 
(Romagnani, 2006) (Germain, 2002).  
 
The effector function of T-cell subsets are often generalised with CD4+ T-cells 
considered as helper cells and CD8+ T-cells cytotoxic however the reality is not 
quite so clear cut with some CD4+ T-cells also possessing cytotoxic function 
(Marshall et al., 2011). 
CD4+ T-cells have a central role in the adaptive immune response chiefly in cell 
mediated immunity and are activated by antigen presenting cells (APCs), which 
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present peptides to the TCR via MHC class II. There are two particularly well 
defined subsets of CD4+ T-cell, T-helper cells Th1 and Th2. Understanding of 
the two distinct populations first came about through identification and 
analysis of CD4+ T-cells in mice by Mosmann and Coffman and they termed 
them Th1 and Th2 cells (Mosmann et al., 1986; Zhu et al., 2010). Naive, or Th0 
cells, will differentiate into either Th1 or Th2 cells following activation through 
antigen exposure. The subsequent presence of particular stimuli will go on to 
stimulate Th1/Th2 differentiation. Interleukin-12 (IL-12) and interferon-γ 
(IFN-γ) are critical cytokines for the development of Th1 cells and the presence 
of IL-4 and IL-2 is important in the downstream cascade for the production of 
Th2 cells (Luckheeram et al., 2012). It is also important to note that often Th1 
stimulating cytokines will be inhibitory for Th2 cell differentiation and vice-
versa. For example IL-4 will inhibit Th1 cell development and IFN-γ is 
inhibitory for Th2 cells and thus halts a humoral immune response. Distinct 
immune responses will therefore arise depending on the responsible pathogen.  
Not only does the cytokine environment influence CD4+ T-cell differentiation, 
the subtypes also have specific cytokine secretion profiles, which distinguishes 
their function and can aid in their classification. Th1 cells mainly secrete the 
pro-inflammatory cytokine IFN-γ and IL-2, which promotes CD8+ T-cell 
proliferation (Zhu et al., 2010). Th1 cells and their cytokines promote cell 
mediated immunity through the recognition of microbial antigens. IFN-γ 
activates macrophages for enhanced microbial killing and stimulates IgG 
production by B-cells thus inducing opsonisation (Abbas et al., 2010; 
Luckheeram et al., 2012). Th2 cells mediate the adaptive immune response to 
infection through a humoral immune response. IL-4, IL-5 and IL-13 are the 
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primary Th2 cytokines. IL-4 and IL-13 stimulate the production of specific IgE 
antibodies by B-cells. IgE can thereby form cross links with Fcε receptors on 
mast cells and basophils which induces the secretion and production of active 
mediators like histamine and further cytokines including tumour necrosis 
factor (TNF-α) (Murphy, 2008)  (Abbas et al., 2010). IL-5 activates eosinophils. 
They release granular contents that are able to aid in the destruction of the 
invading extracellular parasite(Zhu et al., 2008).  
 
Naive CD8+ T-cells are activated by APCs which present peptides to the TCR via 
MHC class I. This antigen-dependant stimulation leads to the clonal expansion 
and migration of differentiated cytotoxic T lymphocytes (CTLs) into tissues. 
These are the effector CD8+ T-cells and are particularly important in the 
defence against viruses. CTLs will specifically kill target cells displaying 
peptides from cytosolic pathogens that are presented via the MHC class I 
molecule. Cytotoxic molecules including granzyme-B, perforin and granulysin 
are characteristically produced via CTL as well as IFN-γ (Belz et al., 2010).  
 
CTLs, and effector CD4+ T-cells, are generally short lived but a small portion 
give rise to memory T-cells, which can reside for a lifetime. Following re-
exposure to the offending antigen, memory T-cells (derived from both CD4+ and 
CD8+ T-cells) can respond rapidly, inducing the quick and strong proliferation 
of effector T-cells. Memory T-cells can be further subdivided into central or 
effector memory T-cells; Tcm or Tem. Generally CD4 give rise to Tcm CD8 to 
Tem. Tcm cells home to lymph nodes and express L-selectin and CCR7. They can 
secrete IL-2 but following proliferation will differentiate to effector T-cells for 
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an enhanced immune response. Tem in contrast have an enhanced intrinsic 
effector function producing IFN-γ, IL-4 and IL-5 in a matter of hours following 
antigen recognition (Sallusto et al., 2004).  
 
Regulatory T-cells, Tregs, suppress lymphocyte activity to help control immune 
responses. In vitro they can be identified through their expression of CD4 and 
CD25 and also the transcription factor FoxP3, the classical marker for Tregs 
(Vignali et al., 2008). 
Recently a new Th cell lineage has been discovered, Th17, which does not 
produce the classical Th1/Th2 cytokines. They characteristically produce the 
pro-inflammatory cytokines IL-17, IL-21 and IL-22 and are thought to be 
involved in a variety of immune mediated diseases such as rheumatoid arthritis 
and multiple sclerosis (Waite et al., 2012). 
 
NKT cells comprise a small portion (15%) of lymphocytes and have a large, 
granular morphology. They respond quickly to eliminate infected cells, 
particularly from viruses, and also tumour cells via the secretion of perforin and 
granzyme B. NK cells do not require activation to kill target cells and instead 
rely upon the expression of a variety of inhibitory and activating receptors. 
Inhibitory receptors such as the killer cell Ig-like receptor (KIR) recognise 
different HLA-A, -B and –C alleles on MHC class I molecules which are expressed 
on healthy cells. Activating receptors such as Dap-12 and NKG2D recognise 
ligands on cells that are stressed or infected. The combination of receptors will 
therefore help determine the activation state of the NK cell. In addition, 
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activators such as type I IFN, IL-12, IL-18, IL-15 and IL-2 contribute to cell 
effector function, proliferation and cytotoxicity (Vivier et al., 2008). 
1.3.5 Antigen Presenting Cells (APCs) 
Antigen presenting cells (APCs) are the link between the innate and adaptive 
immune system. These cells capture, process and present antigens to 
lymphocytes to initiate the adaptive T-cell response. Dendritic cells (DCs) are 
the major professional APCs though macrophages and B-cells also possess APC 
functions in cell mediated and humoral responses respectively.  Langerhans 
cells, a specialised subset of DCs are resident in the skin. 
DCs are derived from precursor cells in the bone marrow whereby they migrate 
to the periphery and reside as immature DCs (iDCs) in the epithelium awaiting 
potential pathogens. The spherical morphology of iDCs aid in efficient antigen 
capture and phagocytosis. Following activation by pathogens, a mature 
phenotype will develop, which is essential for the initiation of T-cell responses. 
In contrast to iDCs, mature DCs (mDCs) main function is to presents antigens to 
the TCR. During maturation large cytoplasmic protrusions or dendrites are 
formed. Furthermore, there is a reduced endocytic capacity, an increased 
expression of the costimulatory molecule CCR7 (aids migration to secondary 
lymphoid organs), increased expression of MHC class II molecules for antigen 
presentation and also IL-12 secretion, which aids Th1 development 
(Kapsenberg, 2003). DC maturation is further triggered through contact with 
PAMPs via toll-like receptors and through the release of damage-associated 
molecular patterns (DAMPs) i.e. heat shock proteins, HMGB1 and uric acid (Shi 
et al., 2003). Table 2.1 details the toll-like receptors, the PAMPs that bind them 
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and the DAMPs associated. Drugs can affect DC maturation and antigen 
presentation.  For example, amoxicillin increases the expression of the 
maturation markers HLA-DR, CD80 and CD86 on DCs from hypersensitive 
patients (Rodriguez-Pena et al., 2006). 
 
Table 1.1 Toll-like receptors and their associated PAMPs and DAMPs 
Table is adapted from Essakalli et al and Abbas et al. (Abbas et al., 2010; Essakalli et al., 2009) 
TLR = toll-like receptor, PAMPs = pathogen associated molecular patterns, DAMPs = damage-
associated molecular patterns 
 
TLR PAMP DAMP
TLR1 Bacterial triacylated lipopeptides Human β-defensins
TLR2 Bacterial lipoproteins Heat shock proteins (HSP)
Peptidoglycan HMGB1 (high mobility group box 1)
Lipoteichoic acid
TLR3 Viral double stranded RNA Self double stranded RNA
polyinosinic-polycytidylic acid (poly IC) MRNA, HSP, HMGB1, hyaluronan fragments
TLR4 Lipopolysaccharide (LPS), bacterial (Gram negative bacteria) HMGB1
Mannans fungi Fibrinonectine
Glycoinositolphospholipides parasites A surfactant
Envelope proteins of the virus Lipoproteins
HSP HSP
TLR5 Flagellin flagellated bacteria
TLR6 Lipoproteins mycoplasma Heat shock proteins (HSP)
Lipoteichoic acid HMGB1
Zymozan of Saccharomyces cerevisiae
TLR7&8 Viral single stranded RNA Self single-stranded RNA
TLR9 Bacterial and viral unmethylated CpG DNA Self DNA
TLR10 Unknown Unknown 
TLR11 Profilin
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1.4 Immune Activation 
1.4.1 Antigen presentation 
The presentation of antigens by APCs to T-cells is the bridge between innate 
and adaptive immunity. As mentioned earlier, antigens are recognised by T-
cells via specific TCRs through the context of an MHC molecule. These are cell 
surface molecules encoded by HLA (human leukocyte antigen) genes on 
chromosome 6. There are two distinct pathways in which APCs process and 
present antigens to the T-cell. The route followed is dependent on whether the 
antigen is of an intracellular or extracellular origin.  
Intracellular antigens are often formed due to a viral infection. The virus 
attaches to the host membrane and injects its DNA or RNA into the cells. The 
virus then produces and envelopes itself in a similar membrane to the host cell, 
allowing it to fuse and enter the cell through endocytosis. Once entered, the 
virus replicates and protein products are released into the cell cytosol. These 
proteins are degraded by a nuclear or cytosolic proteasome whereby short 
chains of amino acids, or peptides, are produced. The peptides (8-10 amino 
acids in length) are transported in to the lumen of the endoplasmic reticulum 
(ER) via transporter associated with antigen processing (TAP) and loaded onto 
the MHC I molecule. The peptide-MHC complex can then be released and is 
transported in vesicles to the plasma membrane via the golgi (Pamer et al., 
1998). Now present on the cell surface, intracellular derived peptide-MHC class 
I complex can be recognised by TCRs on CD8+ T-cells (Figure 1.1). 
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Extracellular antigens can only be processed by specialised APCs such as DCs, B-
cells or macrophages due to the need for phagocytosis. Once internalised and 
contained within an endosome, the pathogen is digested by enzymes into 
peptide fragments (Neefjes et al., 2013). In parallel, MHC II molecules are 
transported from the ER in membrane enclosed vesicles. The two are then able 
to fuse, which allows the peptide to be loaded onto the MHC binding groove. 
The peptide-MHC complex then translocates to the cell surface allowing 
recognition by TCRs on CD4+ T-cells and thus initiating immune response 
(Figure 1.1). 
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Figure 1.1 Antigen processing and presentation.  
Intracellular antigens are degraded by proteasomes (1) into peptide fragments and transported 
via TAP to the ER (2) where they are loaded on to MHC I. The peptide-MHC complex is trafficked 
to the golgi (3), loaded onto vesicles and displayed on the cell surface (4) allowing recognition 
by the TCR.  
Extracellular antigens are internalised within an endosome and digested into peptide fragments 
(5).  MHC II molecules meanwhile are transported (6) allowing formation of the peptide-MHC 
complex (7).  This complex then translocates to the cell surface (8) displaying the antigen for 
TCR recognition. 
 
1.4.2 TCR activation 
Following recognition of the peptide-MHC complex, a signalling cascade is 
initiated which ultimately results in the proliferation and differentiation of T 
cells and the release of specific cytokines. Binding of the peptide-MHC complex 
to the TCR is the first signal (signal 1) but in itself is not sufficient to initiate an 
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immune response. Co-stimulatory molecules are involved in the second, signal 
2, which promotes the survival and differentiation of the T-cells. The best 
characterised pathway involves the B7 molecules, B7-1 and B7-2 also known as 
CD80 and CD86 respectively, expressed on APCs and the T-cell receptors CD28 
and CTLA-4 (Murphy, 2008). Engagement between the co-stimulatory receptors 
can either be stimulatory (CD28) or inhibitory (CTLA-4) ensuring a balanced 
and appropriate immune response; positive co-stimulatory signals will promote 
activation while T-cell tolerance will be induced through a negative second 
signal or the absence of co-stimulation.  
Constitutively expressed on the cell surface, CD28 will supplement and sustain 
T-cell responses and survival allowing cytokines to initiate the clonal expansion 
or growth and differentiation of T-cells. The co-stimulatory receptor signal 
transduction enhances T-cell survival through the up regulation of the anti-
apoptotic protein Bcl-xl, aids IL-2 secretion and lowers the T-cell activation 
threshold, which prevents antigen-engaged cells from entering a state of anergy 
(Acuto et al., 2003). Following T-cell activation CTLA-4 expression is up 
regulated and engagement with CD80/CD86 will result in negative regulation of 
the T-cell immune response through inhibition of CD-28 mediated signalling 
(Sharpe et al., 2002).  
Further co-stimulatory molecules include CD40 and its accessory molecule, 
CD40 ligand, CD27 and CD70 and the integrin LFA-1, which play a role 
maintaining T-cell proliferation and TCR interaction (Bachmann et al., 1997; 
Murphy, 2008). Once activated, the secretion of specific cytokines is critical in 
the differentiation from naive CD4/CD8 to mature effector T-cells, which will no 
longer require, or need as much, co-stimulation to exert their immune effects.  
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T-cell activation in turn will trigger further signalling cascades involved in the 
development of the immune response. This includes the phosphorylation of 
immunoreceptor tyrosine based activation motifs (ITAMs) by the Src kinases 
Lck and Fyn (Brownlie et al., 2013). Further downstream this can go on to 
activate MAPK pathways thus activating enzymes (e.g. ERK, JNK), enhancing 
production of transcription factors (e.g. NFAT, STAT3) and facilitating the 
release of signalling molecules (Ca2+ and DAG) (Smith-Garvin et al., 2009). 
 
The above summary of the immune system, its functions and the components 
involved provides a basic insight into this complex network of events that help 
to protect against infection. The immune system is the human bodies’ in built 
safety system to help combat potential threats. Unfortunately it can sometimes 
mistake drugs, which are given to help a patient, as harmful. Indeed, the 
medicine given to patients as treatment can, on occasion, contribute additional 
problems rather than providing relief.  
1.5 Adverse drug reactions 
An adverse drug reaction, or ADR, is defined as “an unwanted or harmful 
reaction following the administration of a drug or combination of drugs under 
normal conditions of use, which is suspected to be related to the drug” (MHRA, 
2014a).  
ADRs are a major clinical problem. A prospective study here in the UK, carried 
out in 2004, looked at over 18,000 patients and found approximately 6.5% of 
hospital admissions were due to an ADR (Pirmohamed et al., 2004). These data 
are consistent with another meta-analysis of prospective studies that attributed 
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the incidence of ADRs as 6.7% (Lazarou et al., 1998) as is the data regarding the 
distribution of age/sex (Martin et al., 1998). Most patients recovered from their 
ADRs; however 2.3% of the reactions were classified as being directly 
responsible for fatality (Pirmohamed et al., 2004). Therefore, when applying the 
results to the cause of death amongst all hospital patients, ADRs are responsible 
for up to 0.2% (Lazarou et al., 1998; Pirmohamed et al., 2004). Lazarou et al. 
therefore propose that ADRs are between the fourth and sixth leading cause of 
death in the USA.  
Not only are ADRs a significant health issue in terms of patient safety they can 
have severe economic consequences.  It is estimated that ADRs cost the NHS in 
the UK £466 million each year (Pirmohamed et al., 2004).  
Furthermore ADRs represent a serious obstacle in the development of new 
therapies and medicines. 10% of all new drugs between 1975 and 1999 
acquired black box warnings or were withdrawn, with 2.9% of new chemical 
entities ultimately being removed from the market. Half of the withdrawals 
transpired within two years drug approval (Lasser et al., 2002). Although 
stringent pre-clinical/clinical testing strategies are in place to limit the chance 
of safety concerns arising after drugs enter the market, as the figures show, 
unanticipated ADRs still arise. In these cases, pharmaceutical companies lose 
significant amounts of money following withdrawal of a compound. The cost of 
bringing a new drug to market is estimated to be between $500 million and 
$2000 million, a significant investment (Adams et al., 2006). 
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1.5.1 Classification of ADRs 
Due to the wide array of drugs that have been reported to cause adverse 
reactions, and the form of reactions that occur a classification system has been 
developed to describe the effects seen. Generally, ADRs are grouped into two 
major categories type A (on-target, augmented) and type B (off-target, bizarre) 
reactions (Park et al., 1998). 
Type A reactions, the most common ADR, are dose dependent and a result of the 
exaggeration of a drugs’ pharmacological effect. Drug metabolism, transporters 
and the effects of co-administered treatments can all contribute to the 
development of Type A reactions. This type of reaction can be controlled by an 
adjustment of the dose and careful monitoring. For example, hypotension that 
arises from the use of anti-hypertensive drugs can be resolved through dose 
reduction. 
Type B reactions are less frequent, affecting a small subset of individuals. 
However, due to their unpredictable and often severe nature, they are a leading 
cause of drug withdrawal. Type B drug reactions are thus often termed as 
idiosyncratic. Effects are not related to the drugs’ pharmacological action and so 
it can be difficult to determine the underlying mechanisms involved. Therefore, 
complete removal of the offending drug is often required. Examples include the 
development of Stevens-Johnson syndrome, a severe skin reaction that 
develops when patients are exposed to several oral drug classes including the 
aromatic anticonvulsants. 
Less common ADRs may also occur in a small number of individuals whereby 
the above classifications are not appropriate (Edwards et al., 2000): 
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Type C, chronic, reactions arise with the use of a drug for a prolonged period of 
time e.g. iatrogenic Cushing’s syndrome due to high glucocorticoid levels 
following prednisolone treatment. 
Type D, delayed, reactions can occur many years after drug treatment had 
ceased e.g. the development of tumours following treatment with alkylating 
agents. Type D reactions can also be used to describe the adverse effects of 
teratogenic drugs on the children of mothers taking these drugs while pregnant. 
Thalidomide is one such drug associated with birth defects. 
Type E, end of use, reactions occur after drug withdrawal e.g. the sudden 
cessation of β-blockers can result in angina and following termination of 
phenytoin (anticonvulsant) withdrawal seizures can occur. Re-introducing the 
drug and gradually withdrawing it can avoid this type of reaction.    
 
A greater understanding of the mechanisms involved the development of ADRs 
is essential. By noticing potential risk areas early on and with improved drug 
screening we can hope to reduce the number of unsafe drugs that reach the 
market. 
1.5.2 Drug-induced liver injury (DILI) 
With incidences between 1 in 10,000 and 1 in 100,000 new drug exposures, 
drug-induced liver injury (DILI) is a rare but serious health condition, 
associated with high morbidity and mortality (Holt et al., 2006). Due to its low 
frequency this idiosyncratic adverse drug reaction is often missed in 
development and trials of new drug treatments. Adverse effects only become 
apparent after its distribution to the wider population, meaning DILI is the most 
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common cause of drug attrition, withdrawal and post-marketing regulatory 
action (Watkins, 2005). The lack of pre-clinical predictive and diagnostic tools 
or suitable animal models makes it difficult to identify hepatotoxic drugs during 
the developmental phases of new chemical entities (Kaplowitz, 2005). 
Measurements of serum liver enzymes such as alanine aminotransferases 
(ALTs), which are released from dying hepatocytes, are taken during clinical 
trials. Mild elevations, 2-5 x the upper limit of normal (ULN) requires more 
frequent monitoring with severe elevations of 10 x ULN necessitating the 
immediate withdrawal of the drug and termination of the trial (Abboud et al., 
2007). High bilirubin levels indicate the metabolism of haem has been 
compromised and so levels of bilirubin are also measured alongside ALTs which 
together help diagnose hepatocellular injury (Antoine et al., 2008). The 
combination of jaundice (bilirubin at over 2 x ULN) and hepatocellular injury 
(ALT levels at more than 3 x ULN) is the foundation of Hy’s law. Hy’s law cases 
have a 10% - 50% mortality rate (Björnsson, 2006).  
Though a panel of liver tests are conducted, diagnosis of DILI is complicated. It 
can be difficult to determine if the drug in question is actually responsible, a 
term known as “guilt by association” and so other aetiologies such as 
underlying disease states must be correctly excluded. The use of certain 
hallmarks of DILI can help in diagnosis including the time for onset, a 
diminished reaction following removal of drug or indeed a severe and rapid 
reaction following drug rechallenge (Lee et al., 2005). Confounding factors 
including polypharmacy, hepatitis infection, congestive heart failure and 
patients’ medical history can all lead to incorrect diagnosis.  
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DILI diagnosis and research becomes even more complicated when you 
consider the involvement of the immune system. In recent years more and more 
evidence has come to light regarding the role of the immune system in the 
pathogenesis of idiosyncratic DILI (Uetrecht, 2013). Key components of the 
innate immune system including natural killer cells (NK cells), NK cells with T-
cell receptors (NK T-cells) and kupffer cell (liver resident macrophages) are all 
enriched in the liver allowing immune mediation (Yano et al., 2014). The 
adaptive immune system is also implicated as a promoter of DILI as many drugs 
including halothane, diclofenac and carbamazepine which are known to cause 
DILI, also result in hypersensitivity and immune reactions (Ju et al., 2012). 
Furthermore, certain drugs associated with liver injury, including flucloxacillin 
and lumiracoxib have known HLA associations (Daly et al., 2009a; Singer et al., 
2010). Several immune mediators have been implicated in the induction of 
hepatotoxicity via an excessive inflammatory response. TNF-α, IL-1β, high-
mobility group box 1 (HMGB1) and IL-17 have all been suggested as mediators 
which induce hepatocyte cell death (Yano et al., 2014; Zhu et al., 2013). Though 
more and more information comes to light, mechanisms of DILI remain poorly 
understood and innovative research methods to study and understand DILI are 
required. 
1.6 Drug hypersensitivity 
ADRs that have an immunological aetiology are defined as drug hypersensitivity 
reactions. They account for up to a third of all ADRs. Also referred to as drug 
allergies, they affect between 10 and 20% of hospital patients and are also 
common within the general population affecting up to 7% (Gomes et al., 2005). 
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Immune-mediated reactions to otherwise safe and effective drugs occur at 
therapeutic doses and are therefore sometimes referred to as Type B reactions. 
Since the immune system is involved in the pathogenesis and as they are only 
observed in a small percentage of the population, reactions are almost 
impossible to predict. However, scientific advances continue to enhance our 
understanding of these complex cases, and it is this area on which my thesis 
hopes to contribute knowledge.   
Antibiotics, namely penicillins, are the most common causative drug in drug 
hypersensitivity accounting for almost 56% of cutaneous drug eruptions 
(Fiszenson-Albala et al., 2003). However, a wide range of agents are implicated 
in the development of drug hypersensitivity (Table 1.2). Moreover, the range of 
clinical manifestation observed differ not only in severity but also with regards 
to the cytokine profiles and the lymphocytes involves. CD4+ T-cells are 
implicated in MPE and AGEP while CD8+ T-cells are known to play an important 
role in SJS and TEN (Nassif et al., 2004; Pichler et al., 2002). 
 
 
Table 1.2 Drugs commonly associated with hypersensitivity reactions 
DRESS AGEP SJS/TEN
Abacavir
Allopurinol
Carbamazepine
Dapsone
Lamotrigine
Minocyclin
Phenytoin
Sulfamethoxazole
Sulfasalazine
Vancomycin
Aminopenicillins
Cephalosporins
Celexoxib
Dilitiazem
Macrolides
Quinolones
Allopurinol
Β-lactams
Carbamazepine
Lamotrigine
Nevirapine
Oxicam NSAIDs 
Phenytoin
Sulfonamides
Tramadol
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1.6.1 Clinical manifestations 
Though drug hypersensitivity reactions can target a number of organs in the 
human body including the liver, kidney, heart and lungs the most commonly 
affected organ is the skin. This is unsurprising owing to its large surface area, 
the network of blood vessels involved and therefore the potential for the 
recruitment of vast numbers of immune cells. 
1.6.2 MPE 
The majority of cutaneous drug reactions present as maculopapular exanthema 
(MPE) accounting for up to 95% of drug-induced skin reactions (Bigby, 2001; 
Hunziker et al., 1997). Reactions  consist of diffuse cutaneous erythema and can 
range from mild rashes to more severe manifestations where pustules develop, 
with itching and fever also adding to the list of symptoms. CD4+ T-cells are the 
major cell type involved in the induction of MPE, alongside a variety of secreted 
molecules including granzyme B, perforin, IL-5 and eotaxin which are also 
known to mediate the development of the disease (Blanca et al., 2009; 
Fernandez et al., 2009). Furthermore, the cocktail of cytokines released 
promotes the recruitment of further cells, such as eosinophils, to the affected 
site (Yawalkar, 2005). Though reactions can be seen 1-2 days after the start of 
drug treatment, more commonly MPE is seen between 4 and 14 days following 
drug administration. 
1.6.3 DRESS 
DRESS, also known as drug hypersensitivity syndrome, affects skin and multiple 
internal organs including the lungs, kidney and most commonly the liver. The 
recruitment of eosinophils mediated by activated T-cells and subsequent IL-5 
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secretion is a major part of the pathophysiology of DRESS (Choquet-Kastylevsky 
et al., 1998). Further symptoms include high fever and skin rash. The mortality 
rate is around 10%, however administration of corticosteroids when organ 
involvement is apparent can dramatically improve prognosis (Bocquet et al., 
1996). Reactivation of herpes virus 6 and 7 (HHV-6 and HHV-7) is often 
observed in DRESS, and measurements of increased specific IgG and viral DNA 
reactivation can be used as a tool for diagnosis (Kano et al., 2004; Suzuki et al., 
1998). However, these are often not detected until 3 – 5 weeks after symptoms 
develop and so viral reactivation may occur as a consequence of T-cell 
activation (Shiohara et al., 2006). Reactivation of further virus has also been 
implicated including the rise of immunoglobulins against Epstein-Barr virus 
(EBV) and cytomegalovirus (CMV) (Kano et al., 2004; Picard et al., 2010). Picard 
et al. found activated CD8+ T-cells in all DRESS patients and viral reactivation in 
around 76%. Furthermore, approximately half of the CD8+ T-cells involved 
responded to at least one EBV epitope. However, the role of drug and viral 
specific T-cells in the disease pathogenesis is still to be fully determined. 
Anticonvulsants are more often than not the culprit drug involved in DRESS, in 
so much that anticonvulsant hypersensitivity syndrome (AHS) was originally 
used to describe DRESS symptoms.  
Other drug classes including sulphonamides, allopurinol and anti-retroviral 
drug such as abacavir are also known to cause DRESS (Walsh et al., 2013). 
1.6.4 Acute generalised exanthematous pustulosis (AGEP) 
An uncommon cutaneous reaction mediated by IL-8 secreting T-lymphocytes, 
AGEP is characterised by the vast number of very small, non follicular sterile 
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pustules that form mainly in the folds of the skin (Britschgi et al., 2001; Sidoroff 
et al., 2001). Fever and neutrophilia with/without eosinophilia are also seen. 
(Roujeau et al., 1991). Antibiotics are the leading causative drug involved in 
AGEP, with aminopenicillins, macrolides, quinolones and sulphonamides all 
implicated (Sidoroff et al., 2007). Without clinical intervention, mortality from 
AGEP is around 5% (Roujeau, 2005). 
1.6.5 Fixed drug eruptions 
Fixed drug eruptions (FDE) are a distinct type of cutaneous reaction where 
eruptions recur at the same site often following sensitization to a particular 
drug. Characteristically, after healing a residual hyperpigmentation can remain 
on the skin (Lee, 2000). An influx of intraepidermal CD8+ T-cells which reside 
within the lesions of FDE are thought to contribute to local tissue damage 
(Shiohara, 2009).  
1.6.6 Stevens-Johnson syndrome/ toxic epidermal necrolysis 
(SJS/TEN) 
SJS/TEN is the most severe cutaneous hypersensitivity reaction. Both are 
diseases (SJS and TEN) which affect the skin and mucous membrane causing 
blistering skin lesions with the separation of the epidermis from the dermis, 
accompanied with the death of keratinocytes (the predominant cell type in the 
epidermis). SJS and TEN are now commonly referred to as two parts or 
spectrums of the same disease with the extent of epidermal separation used as 
the major clinical diagnostic feature (Mockenhaupt, 2011). Skin detachment 
from the body’s surface area at a rate of 10% or less is classed as SJS, 
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detachment of 10-30% is the overlap between SJS and TEN and so classed as 
SJS/TEN and over 30% is the most severe – TEN (Bastujigarin et al., 1993). 
The apoptotic death of keratinocytes in the epidermis is thought to eventually 
lead to necrosis and skin detachment, which is characteristically seen in 
patients (Paul et al., 1996). NK T-cells and cytotoxic T-cells are implicated as the 
effector cells particularly as skin lesions contain high numbers of these cells 
(Chung et al., 2008). Blister fluid is also found to contain up to 4 times the 
expression of granulysin compared to perforin, Fas ligand and granzyme-B. 
These recent findings suggesting granulysin is a key mediator for the death of 
keratinocytes and development of SJS and TEN (Chung et al., 2008). 
Furthermore, granulysin may even be an important diagnostic tool as levels 
correlate with clinical severity (Gerull et al., 2011). 
SJS/TEN has high rates of mortality, between 20 and 25%, which may be due to 
the idiosyncratic nature of the disease, limited information regarding its 
pathogenesis and lack of treatment options (Mockenhaupt et al., 2008). 
Fortunately cases of SJS/TEN are rare – up to 6 cases per million people per 
year for SJS and an incidence of up to 1.2 cases per million people per year for 
TEN (Roujeau et al., 1994). 
1.6.7 Time course  
The time between initial drug exposure and development of clinical features of 
a reaction are important for the treatment and diagnosis. Many drug 
hypersensitivity reactions take between one and 11 days for clinical 
manifestations to appear and these reactions are known as delayed-type 
(Pichler et al., 2010). 
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The activation of T-cells and the molecular changes that subsequently occur are 
a key feature of delayed type hypersensitivity and helps explain the lag in 
presentation of clinical manifestations. Moreover, the production of functional 
cytotoxic molecules including perforin and granzyme B can take up to 7 days 
following drug exposure and antigen stimulation (Ortiz et al., 1997). 
At the other end of the scale immediate hypersensitivity reactions, as the name 
suggests, occur immediately with symptoms generally manifesting within 
minutes (Gould et al., 2003). In these reactions antigen cross links IgE 
antibodies with their high affinity Fc receptors on mast cells leading to the rapid 
release of cytotoxic molecules (Corry et al., 1999).  
With the vast range of clinical manifestations that can arise with 
hypersensitivity reactions, classification is essential to help separate the 
different clinical features seen and ultimately aid in the treatment and research 
of these adverse drug reactions.  
1.6.8 Classification of immune reactions 
In 1963 Gell and Coombs first categorised hypersensitivity reactions into four 
major groups, determined by the time to clinical manifestation and according to 
the type of immune response and the mechanisms involved. Type I, Type II and 
Type III reactions are antibody-mediated whilst Type IV reactions are T-cell 
mediated. Though this classification system is still relevant and widely used, 
more recently further sub divisions of Type IV reactions have been introduced 
(Pichler, 2003). Table 1.3 highlights the key features of each type of reaction.  
Type I reactions are mostly immediate, IgE-mediated which result from the 
cross-linking of receptors on mast cells and basophils leading to the quick 
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release of histamine and leukotrienes. Broncho-constriction and anaphylaxis 
are common clinical manifestions. 
Type II, or cytotoxic reactions are mediated by IgG and IgM antibodies which 
bind to cells. This leads on to binding of complement proteins and the rupture 
of cells. 
Type III reactions are IgG or IgM mediated reactions which can occur due to the 
presence of high antigen concentrations in the circulation. Serum sickness and 
vasculitis are type III reactions. 
Type IV reactions are mediated by T-cells and are mainly delayed-type 
hypersensitivity reactions. The wide range of delayed type IV reactions can be 
divided further into four classes depending on cell involvement; monocytes, 
eosinophils, cytotoxic T-cells and neutrophils are characteristically involved in 
Type IVa, IVb, IVc and IVd respectively.  Many of the clinical symptoms of drug 
hypersensitivity detailed earlier including MPE, DRESS and SJS/TEN, are a 
result of a type IV reaction and it is these type IV delayed hypersensitivity 
reactions in which this thesis focuses on. 
Although these immune reactions have been grouped it is important to note 
that, as is to be expected with such a complicated system involved, there is often 
crossovers between the different categories. This is especially true with regard 
to specific mediators that are released. 
1.6.9 Sensitisation and Elicitation 
The first exposure to an antigen is known as sensitisation. Here the antigen 
binds to proteins and is taken up by antigen presenting cells (APCs) and 
proceed to the draining lymph node. Antigen derived peptides are presented to 
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CD4+ and CD8+ T-cells which then enter the lymphatic system and general 
circulation. This in effect is the priming of naive T-cells. When the body is re-
introduced to the same antigen, again protein binding occurs yet now antigen 
specific CD4+ and CD8+ T-cells from the draining lymph node travel to the site 
where the antigen is bound (Weber et al., 2015). This is the elicitation phase 
where responses, including T-cell mediated tissue damage, are seen quickly. 
While priming of cells is seen across the board in hypersensitivity, this 
mechanism of sensitization and elicitation has been studied extensively and is 
characteristic of contact hypersensitivity (an inflammatory skin disease 
triggered by repeated exposure to allergens).    
Table 1.3 Classification of immune mediated drug reactions. 
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1.7 T-cell activation by drugs 
Traditionally, peptides are main activators of a cellular immune response, 
combating potential threats to the host. Unfortunately, small molecules i.e. 
drugs, can also activate the immune system to a detrimental effect as seen in 
drug hypersensitivity. In this thesis I shall be focussing on delayed, Type IV 
hypersensitivity reactions in the hope of furthering the understanding of this 
adverse reaction. 
 In order to describe the molecular mechanisms and immunological basis of 
drug-specific activation of T-cells, a number of specific terms are used 
(Uetrecht, 2013); 
Hapten – these are any low molecular weight compounds that are able to bind 
and modify macromolecules such as proteins in an irreversible manner. Binding 
almost always involves the formation of a covalent bond between the 
compound and protein. 
Antigen – a molecule that is able to bind with immunological receptors. 
Immunogen – these are molecules that are able to trigger an immune response. 
Co-stimulatory molecule – these substances interact with DCs to stimulate or 
polarise an immune response. 
1.7.1 Drug protein binding 
Owing to their low molecular weight and small size, drugs are not likely to act 
as traditional antigens. Instead it is suggested they bind to host proteins 
forming a hapten which becomes immunogenic. The work of Landsteiner and 
Jacobs who first described drug-protein binding and the formation of haptens, 
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has since been expanded significantly with detailed information now available 
for the binding sites of a number of drugs. 
It is now well known that the penicillin class of β-lactam antibiotics typically 
become immunogenic following covalent, non reversible, binding to a carrier 
protein. As the most abundant serum protein, human serum albumin (HSA) is 
commonly used to characterise drug-protein binding. The work of Levine et al 
established that the formation of a stable, covalent bond between penicillin and 
lysine residues on proteins is an essential step to sensitisation, furthermore 
they found that the benzylpenicilloyl group is the major haptenic determinant 
(Levine et al., 1961b; Levine et al., 1969). In recent years advanced mass 
spectrometers coupled with an improvement in methods, techniques and 
expertise, particularly here at the University of Liverpool, has allowed the 
relationship between the chemistry of drug-protein binding not only to be 
characterised but for this to be related back to stimulation of drug-specific T-
cells. Indeed HSA binding has been characterised for a number of β-lactam 
antibiotics. Benzylpenicillin binds to 14 lysine residues whilst 18 penicilloylated 
lysine residues were dectected with the rearrangement product benzylpenicillic 
acid with selectivity at positions 199 and 525 respectively (Meng et al., 2011a). 
Flucloxacillin-HSA binding has also been characterised with modified lysine 
residues detected, furthermore modification has been shown in vivo (Jenkins et 
al., 2009a). The sulphonamide, sulfamethoxazole (SMX) forms a nitroso 
metabolite SMX-NO following oxidative metabolism which is able to bind and 
modify intracellular proteins. Callan et al were able to chemically define SMX-
NO modification with HSA, glutathione S-transferase π and a synthetic peptide 
(DS3) using mass spectrometry. Selective binding occurred at cysteine residue 
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47 with glutathione S-transferase π and with HSA at Cys34 which formed only 
the N-hydroxysulfinamide adduct (Callan et al., 2009). A stable sulfenic acid 
form of Cys34 in HSA exists in vivo, however the biological consequences of this 
or the modifications described above have not yet been defined. Abacavir 
research has finely defined the great selectivity of abacavir to HLA-B*57:01, 
with the interaction of abacavir with MHC mapped to the antigen-binding F 
pocket and the importance of serine at position 116 and aspartate at position 
114 highlighted for drug antigen presentation (Chessman et al., 2008). A change 
in these specific residues was able to alter structure of the F pocket in such a 
way as to change the repertoire of peptides bound to HLA-B*57:01. The 
formation of haemoglobin-abacavir aldehyde (ABCA) adducts in patients 
however suggest that parallel hapten mechanism may be involved in the 
activation of T-cells.  Using mass spectrometric methods ABCA modifications of 
HSA have beed defined in patients taking abacavir. Modifications were not 
exclusive to one amino acid; adducts were detected on Lys159, Lys190, His146 
and Cys34.  
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Figure 1.2 HSA ribbon structures with sites of modification 
Model HSA structures highlighting amino acid modification sites for benzylpenicillin, 
sulfamethoxazole and abacavir in vitro. Structures taken from (Diaz et al., 2001), (Callan et al., 
2009) and (Meng et al., 2014). 
 
 
Antigenicity and in turn immunogenicity is integral for the initiation of an 
immune response       
A number of mechanisms have been proposed by which T-cells are activated 
following interactions with small molecules/drugs. These are outlined below. 
1.7.2 Hapten hypothesis 
Early research in the 1930s provided the basis for the hapten hypothesis. 
Landsteiner and Jacobs were looking to understand the mechanisms by which 
small molecules activate T-cells. They were able to sensitise guinea pigs to the 
low molecular weight, chemically reactive compound, dinitrochlorobenzene 
(DNCB). They went on to report protein modification and formation of 
conjugated antigens in the animal leading to the hypothesis that protein 
haptenation by DNCB may play an important role in the immune response 
observed (Landsteiner et al., 1935; Landsteiner et al., 1936). 
Lys199
Benzylpenicillin SMX-NO Abacavir
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Owing to the small size of low molecular weight compounds such as drugs it is 
unlikely they are able to act as antigens directly. These compounds or their 
metabolites might therefore act as haptens, inducing immune responses 
through the covalent binding of proteins in the host. The hapten hypothesis is 
outlined in a schematic in Figure 1.3. 
Figure 1.3 The hapten hypothesis.  
Drug/reactive metabolites bind and covalently modify host proteins which are 
processed (see Figure 1.2) and the subsequent peptide fragments displayed via MHC 
molecule for recognition by the TCR on T-cells. Presentation via MHC I will elicit a 
CD8+ T-cell response and via MHC II the immune response will be mediated by CD4+ 
T-cells. The drug or reactive metabolite my also modify the MHC-peptide complex 
directly for presentation to T-cells. 
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Interactions between the nucleophilic sites on proteins and the electrophilic 
sites of low molecular weight compounds form the basis for the hapten 
hypothesis. Binding to specific lysine or cysteine amino acid residues has been 
seen with the β-lactam antibiotics piperacillin and flucloxacillin and the 
sulphonamide sulfamethoxazole (SMX) (Callan et al., 2009; El-Ghaiesh et al., 
2012; Jenkins et al., 2009a). Indeed, penicillin is one drug where the chemical 
and molecular basis of hypersensitivity seems to be well defined by the hapten 
hypothesis.  
Many drugs however are not able to react with proteins directly. For example, 
SMX requires bioactivation through drug metabolising enzymes to form SMX 
hydroxylamine, and the reactive nitroso metabolites (Castrejon et al., 2010a; 
Elsheikh et al., 2011). Using T-cells isolated from sensitised mice and T-cell 
clones form allergic patients Elsheikh et al were able to show the need for 
processing for T-cell stimulation to occur. APCs were also shown to metabolise 
SMX in this study, subsequently forming a T-cell antigen from the resultant 
protein binding (Elsheikh et al., 2011). In further experiments, nitroso 
derivatives of SMX including SMX-NO (the reactive metabolite which 
irreversibly binds to protein) were synthesised and administered to mice for 2 
weeks. The splenocytes of sensitised mice proliferated and secreted a number 
of Th2 cytokines following stimulation with the nitroso metabolite and not SMX, 
the parent compound illustrating importance of metabolism (Castrejon et al., 
2010b). Similar results were also observed in T-cell clones generated from 
allergic patients (Castrejon et al., 2010a) 
Continuing with the hapten hypothesis, once protein modification has been 
achieved, these proteins are processed and cleaved into peptide fragments that 
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associate with MHC molecules. From there the peptide is presented to, and 
recognised by specific TCRs. Peptides presented via MHC class I molecules 
initiate a CD8+ T-cell response, whilst CD4+ responses are a result of MHC class 
II presentation.   
It is also possible for the formation of novel or neo-antigens whereby following 
modification of the protein by the offending drug, newly synthesized 
determinants i.e. peptides are able to bind and stimulate an immune response 
in the absence of the drug. Indeed it is difficult to determine exactly which 
peptide fragment will elicit the hypersensitivity reaction as a number of drug-
modified peptides whilst antigenic are not immunogenic.  
The importance of peptides in the development of an immune reaction has been 
investigated. Using synthetic TNP-peptides, the work of Weltzien and Martin 
have described specific differences in the MHC binding sites for peptides with 
the haptens bound in different positions. Two functionally different TNP 
epitopes were defined. The major epitope for class I MHC-restricted T-cells is 
peptides with TNP-Lys substitutions at positions 4 and anchor residues at 
positions 5 and 8. A highly unique set of peptides with lysine modification by 
TNP at position 7 were able to induce specific, position 7 T-cells, but not other 
TNP-specific T-cell clones highlighting the importance of the hapten binding site 
(Martin et al., 1992; Martin et al., 1993; Von Bonin et al., 1992). 
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1.7.3 Pharmacological Interaction of drugs with immune receptors 
(PI concept) 
Some drug-specific T-cells have been found to become activated via an MHC 
restricted but processing-independent manner. The hapten theory fails to 
explain the ability of otherwise non-reactive compounds to stimulate an 
immune response and so another mechanism has been proposed – the p-i 
concept (Figure 1.4). The p-i hypothesis suggests that direct, non-covalent 
interactions occur between the drug, TCR and MHC molecule, which are labile 
and reversible, but sufficient to activate T-cells (Pichler, 2002). A number of 
drugs have been found to activate T-cells via the p-i mechanism including 
carbamazepine (Wu et al., 2006), lamotrigine (Naisbitt et al., 2003b) and SMX 
(Schnyder et al., 1997). T-cells activated in this manner respond rapidly to drug 
with Ca2+ influx seen almost immediately (Zanni et al., 1998). Following 
interaction between the T-cell and APC there is a rapid redistribution of certain 
organelles and following TCR engagement a rapid intracellular Ca2+ 
endoplasmic reticulum store is released. Indeed the intracellular concentration 
of Ca2+ can increase from 50-100nM to around 1µM following engagement of 
the TCR (Joseph et al., 2014). This pattern of activation is incompatible with the 
hapten hypothesis as the time involved is not sufficient for processing, 
suggesting these pathways are bypassed. Furthermore, it has been observed 
that certain drugs activated T-cells via MHC molecules expressed on 
gluteraldehyde fixed APCs, thus preventing antigen processing but not 
presentation (Schnyder et al., 1997). The p-i theory states that there is no de 
novo antigen formation and T-cell priming; drugs may be able to stimulate 
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memory and effector cells directly via TCR as these have a much lower 
threshold for activation  (Adam et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The p-i concept. 
Drug/reactive metabolites bind directly to the TCR and/or MHC molecule in a non-covalent 
manner, thus eliciting an immune response. Hydrogen bonds, Van der Waals forces and 
hydrophobic interactions may be involved. A peptide may or may not be present. 
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1.7.4 Altered self-peptide repertoire hypothesis 
MHC genes encode for an array of cell surface glycoproteins, which in humans 
are known as HLAs. These are either class I or II genes (MHC I, MHC II) and 
initiate specific immune responses through the presentation of peptides to the 
TCR as previously detailed. In certain cases of drug hypersensitivity strong links 
have been found between the offending drug and specific HLA alleles. I will 
discuss these associations in further detail in later sections.   
The nucleoside reverse transcriptase inhibitor (NRTI) abacavir in particular, 
has a strong association with the HLA-B*57:01 allele (Chessman et al., 2008; 
Mallal et al., 2002) in so much that genetic testing for the risk allele (HLA-
B*57:01) is highly recommended before commencing therapy (Hughes et al., 
2004; Rauch et al., 2006). It is possible that abacavir hypersensitivity reactions 
occur via the hapten hypothesis; HSA adducts with the aldehyde metabolite 
have been characterised and could possibly play a role in abacavir toxicity 
(Charneira et al., 2011). Conversely the PI concept has also been suggested as a 
possible pathway (Adam et al., 2011). More recently however the altered 
peptide hypothesis has been introduced. The altered self-peptide repertoire 
hypothesis seems to most accurately describe the chemical basis of abacavir 
hypersensitivity. This model, illustrated in Figure 1.5, proposes that the drug 
settles in a particular site within the antigen binding cleft which leads to a 
change in the repertoire of self-peptides that can interact with the MHC 
molecule i.e. specific HLA (Bharadwaj et al., 2012; Ostrov et al., 2012). These 
peptides are subsequently presented to the TCR and thus immune response is 
initiated. Abacavir interacts specifically with the F pocket of HLA-B*57:01 in a 
non-covalent manner and so there are changes in the configuration of the 
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antigen binding cleft (Illing et al., 2012; Norcross et al., 2012). The repertoire of 
self-peptides that are able to be presented is thus changed and this is the basis 
for the hypersensitivity reaction. 
 
 
Figure 1.5 The altered peptide repertoire hypothesis. 
A. Normal interaction of peptide 1 with HLA molecule and TCR. B. Presence of drug within the 
peptide binding groove of the HLA molecule alters the repertoire of peptides (peptide 2) 
presented by the HLA to the TCR which goes on to initiate the immune 
response/hypersensitivity. 
 
 
Whilst this hypothesis and previous work has allowed abacavir binding to be 
elucidated we still have not determined how this translates to T-cell activation. 
Furthermore, we are yet to determine the time frame in which this hypothesis 
acts highlighting the need for further research in drug hypersensitivity 
reactions to fill the gaps in knowledge. 
Recently Bell et al were able to describe two pathways in which T-cells were 
activated by abacavir. In one set of abacavir specific CD8+ T-cell clones 
abacavir-pulsed APCs were able to stimulate T-cells, in addition responses were 
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blocked when the processing capacity of APCs was blocked. Other T-cell clones 
however were activated by abacavir in the absence of APCs, forgoing the need 
for processing suggesting that T-cells can be activated by abacavir through 
direct interaction between T-cell and MHC (Bell et al., 2013).  
It is important to note that the mechanisms proposed for drug hypersensitivity 
reactions are not mutually exclusive and indeed parts of each may be involved 
in the development of an immune response to a drug. 
1.7.5 Danger hypothesis 
Matzinger proposed the danger model in 1994 stating the body does distinguish 
between self and non-self and instead immune responses are determined 
according to the context in which an antigen is presented (Anderson et al., 
2000; Matzinger, 1994). Danger signals initiate and activate immunity whereas 
in the absence of such signals, tolerance is induced.  
Three signals are thought to be required to fully complete an immune response 
with two needed for activation of the immune system (Curtsinger et al., 1999). 
Specificity of the immune response is provided by the first signal – interaction 
between the TCR and the MHC-peptide complex (Danese et al., 2004). 
Activation occurs following a second signal whereby co-stimulatory molecules 
such as CD40 and CD80 present on APCs, interact with those on T-cells (CD40L, 
CD28). This signal 2 is essential for the proliferation and clonal expansion of T-
cells, for the release of cytokines and for T-cell effector function. Without a 
second signal however, tolerance to the antigen in question will be observed. 
Pro-inflammatory cytokines, such as IFN-γ can up regulate co-stimulatory 
molecules and receptors on APCs further inducing/driving immune responses.  
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A wide array of co-stimulatory and inhibitory receptors have been reviewed in 
detail quite recently (Chen et al., 2013).  
Modulation of signal 2 can occur through exogenous PAMPS (LPS, 
peptidoglycan) and endogenous DAMPs released from dead/damaged cells 
(heat shock proteins, HMGB1). These can contribute to danger signals which are 
the basis for the danger hypothesis. 
Numerous drugs have been found to induce danger signalling and thus immune 
activation. SMX-NO, the metabolite of SMX, increases the expression of CD40 on 
DCs (Sanderson et al., 2007), abacavir induces redistribution of heat shock 
protein in APCs (Martin et al., 2007)and amoxicillin has been found to drive DCs 
to a mature phenotypes (Rodriguez-Pena et al., 2006).  
Viruses including herpes virus 6 (HHV6), human immunodeficiency virus (HIV) 
and Epstein Barr virus (EBV), have all been implicated in DRESS yet their role in 
providing danger signals is not fully understood and can complicate diagnosis 
(Descamps et al., 1997; Descamps et al., 2003; Phillips et al., 2007). 
Tissues have the potential to act as a source of further danger signals which 
may help explain the localised release of such signals and why some reactions 
are confined to a particular organ. 
The third signal is derived from polarising cytokines which act on T-cells and 
lead to an either Th1 or Th2 immune response (Pirmohamed et al., 2002).  
Chemically reactive drug metabolites can act as antigens as part of signal 1 and 
may also induce cell damage, promoting signal 2 and 3 and thus initiating a full 
immune response as seen in drug hypersensitivity (Li et al., 2010; Park et al., 
2001). 
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1.8 Factors that predispose drug hypersensitivity 
As previously mentioned, ADRs are a major health concern, and a vast range of 
reactions can develop (Davies et al., 2009). A number of risk factors are known 
to predispose certain populations to the development of adverse reactions. 
Large numbers of associations have been found linking particular HLA alleles to 
reactions caused by certain drugs as detailed in Table 1.3. In addition to genetic 
variation in MHC, polymorphisms in drug metabolism enzymes can also play a 
role in the development of ADRs. Mutations in the genes that encode these 
enzymes can lead to alterations in their activity; an increase, decrease of even 
complete lack of activity may be observed resulting in a wide variation of 
toxicities seen in individuals (Meyer et al., 1997). N-acetyltransferases are 
involved in acetylation and ultimately in the detoxification of a number of drugs 
including isoniazid, sulphonamides, dapsone and even caffeine (Vatsis, 1995). 
Polymorphisms in the NAT1 and NAT2 genes, which code for N-
acetyltransferase can result in an either fast or slow acetylator phenotype. Fast 
acetylators often have low concentrations of the parent drug remaining 
whereas the opposite is true for slow acetylators and so the risk of a reaction 
may differ between these 2 groups (Shenfield, 2004). Indeed, slow acetylators 
have a higher risk of developing certain ADRs (Kosseifi et al., 2006) however, it 
is not always so clear cut. For example, fast acetylators of isoniazid are not 
necessarily more likely to avoid hepatotoxicity (Gardiner et al., 2006) whilst a 
slow acetylator phenotype or genotype is not like to be a risk factor for the 
development of SMX hypersensitivity in HIV-positive patients (Alfirevic et al., 
2003). Highly polymorphic cytochrome P450 enzymes such as CYP2C9, 
CYP2C19 and CYP2D6 are also implicated in toxic adverse drug reactions 
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(Johansson et al., 2011). Though many drug metabolising enzymes and their 
genetic variations are involved in the development of an array of adverse 
reactions, there is currently no strong link to the development of immune 
reactions (Gardiner et al., 2006). 
Other risk factors include gender, with females reported to have a higher 
predisposition for ADRs, viral infections particularly HIV, and polypharmacy 
(Fattinger et al., 2000; Saiag et al., 1992).  
1.8.1 Major Histocompatability Complex (MHC) molecule 
Recently, genes within the MHC region have been linked to the development of 
an ADR. The MHC region, on the short arm of chromosome 6, is the most 
polymorphic region within the human genome and this high rate of 
heterogeneity results in wide inter-individual variation within the population 
(Parham et al., 1988). Evolutionarily, maintenance of such high rates of 
polymorphisms in this region implies it is advantageous to possess a 
heterozygote genotype (Doherty et al., 1975). In humans, MHC class I and MHC 
class II genes are known as human leukocyte antigen, HLA, I and II. 
 
MHC Class I 
Nearly all nucleated cells express MHC I molecules. The MHC molecule consists 
of the polymorphic transmembrane α heavy chain, encoded by the HLA-A, HLA-
B and HLA-C loci, and a light chain called β2 microglobulin (β2m) (Johnson, 
2000) as detailed in Figure 1.5. The β2m is not membrane bound and is thought 
to play a key role in the transportation of new MHC molecules. The folded α1 
and α2 domains form the peptide binding groove whereby the peptide (9 – 11 
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amino acids in length) can settle and bind through a combination of hydrogen 
bonds and Van der Waals forces (York et al., 1996). 
 
MHC Class II 
MHC II molecules are only expressed on professional antigen presenting cells 
such as DCs, B-cells and macrophages. The HLA-DR, HLA-DQ and HLA-DP loci 
encode for MHC II (Lienert et al., 1996). The structure of MHC II differs from 
MHC II as the β chain is anchored (Figure 1.6). Furthermore, longer peptides 
(14 – 20 amino acids) are able to accommodate the peptide binding groove due 
to its more open and flexible structure (Nojima et al., 2003). 
 
 
Figure 1.6 Structure of major histocompatability complex molecule, Class I and Class II. 
 
Not only do these genes encode for the MHC molecules, they also include genes 
relating to the complement cascade, heat shock proteins, cytokines and other 
inflammatory mediators (Horton et al., 2004). 
Chapter 1 
51 
 
1.8.2 HLA nomenclature 
MHCs were first discovered in mice after tissue transplant experiments and 
soon after, work in the 1950’s by Dausset and colleagues, revealed the existence 
of HLAs (Kelley et al., 2005). When first discovered, the huge diversity of HLA 
alleles was unlikely to have been expected and so over the years it has been 
necessary for the naming system to evolve (Albert et al., 1978; Marsh et al., 
2010). Indeed regular meetings take place to discuss and revise the ever 
expanding HLA allele classification. The current method for the nomenclature of 
HLA alleles is detailed in Figure 1.7.   
 
Figure 1.7 Nomenclature of HLA alleles. 
 
 
The letter after HLA identifies the particular gene locus i.e. A, B, C etc. and the 
asterix indicates molecular typing techniques have been utilised to assign this 
allele. Each HLA allele then has up to four sets of unique, specific numbers 
separated by colons. The first two numbers correspond to the allele type 
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usually assigned by serology. The next two digits represent the subtype and 
specific HLA allele and signify differences in amino acid sequences. Numbers 
are assigned sequentially as new DNA sequences/alleles are discovered. The 
third set of digits represents alleles that differ through synonymous nucleotide 
substitutions i.e. polymorphisms that do not alter the peptide sequence. The 
fourth set of numbers can also identify polymorphisms in the non-coding 
region. Letters at the end of the series of numbers provide information on allele 
expression: 
N – Null allele (not expressed on cell surface) 
L – Low expression 
S – Expressed as a soluble product 
C – Expressed in the cytosol (not on cell membrane) 
A – Aberrant expression 
Q – Questionable expression (expression effected by mutation) (Tait, 2011) 
 
Over recent years, genome wide association studies have highlighted links 
between HLA genetics and the development of a hypersensitivity reaction. 
Table 1.4 lists a number of drugs with known HLA associations which 
predispose certain populations for the development of a reaction. 
Chapter 1 
53 
 
Table 1.4 Drug reactions with HLA associations.   
 
For a number of drugs, upon discovering a HLA association, research has led to 
a link between the drug and the immune response that is observed. Abacavir is 
a key example whereby binding sites to HLA-B*57:01 has been characterized in 
the development of hypersensitivity. HLA allele associations for flucloxacillin 
and carbamazepine have also been investigated (Lichtenfels et al., 2014; Monshi 
et al., 2013). For other drugs however it has been difficult to relate the HLA 
association and its involvement to the reaction observed in clinic. Despite 
extensive investigations with the use of in vitro models, a mechanism for the 
development of ximelagatran induced liver injury is yet to be defined (Keisu et 
al., 2010). With such a complex system it can be difficult for researches to 
elucidate mechanisms involved, develop appropriate models and to relate in 
vitro findings to the clinic.  
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1.9 Drug hypersensitivity reactions – diagnosis and 
experimental approaches 
In the clinic, skin tests are the only diagnostic tool routinely used for 
hypersensitivity reactions with numerous publications providing guidelines for 
carrying out these skin tests (Barbaud et al., 2001; Barbaud et al., 1998; 
Brockow et al., 2002). There are three classic methods of skin tests; skin prick, 
intradermal and patch tests.  Skin prick tests, whereby a needle with the 
suspected allergen pricks the skin, is followed up with intradermal testing 
(injection of up to 50µl of drug solution) if results are negative (Torres et al., 
2003). Skin prick and intradermal test are normally carried out where the 
reaction is thought to be IgE mediated/immediate hypersensitivity, whereas 
patch tests are normally performed in cases of delayed hypersensitivity 
(Demoly et al., 2005). Suspect chemical entities are applied to the upper back 
with the use of adhesive tape with reactions noted (Barbaud et al., 1998). 
However these traditional skin test often give false-negative results, have low 
sensitivity and in the case of intradermal tests, are invasive (Barbaud et al., 
2001; Strauss et al., 2001). Re-challenging patients in provocation tests are 
useful for the confirmation of culprit drug following inconclusive results after 
skin testing. This must be carried out under careful medical observation due to 
the risk of re-activation of symptoms and so in severe reaction i.e. in SJS, these 
test are discouraged (Romano et al., 2004).   
 
The diagnosis of delayed hypersensitivity, particularly T-cell mediated 
reactions, can be complemented by the use of in vitro techniques which help 
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characterise clinical symptoms and highlight the drug responsible for such a 
reaction.  These tests are not widely used in the clinic due to various reasons 
including the availability of freshly isolated peripheral blood mononuclear cells, 
the expertise required to conduct such assays/training researchers to carry out 
the tests and the lack of high throughput methods. The use of patient cells ex 
vivo is however at the centre of drug hypersensitivity research. The in vitro 
techniques described below can offer a safe alternative to often invasive skin 
tests and importantly in research, allow a better understanding of the molecular 
mechanisms of the reactions seen in the clinic.  
1.9.1 Lymphocyte transformation test (LTT) 
The lymphocyte transformation test (LTT) is used to detect drug-specific T-cell 
responses and the most commonly utilised in vitro assay for patients with 
suspected drug allergies (Nyfeler et al., 1997). Peripheral blood mononuclear 
cells (PBMCs) are isolated from hypersensitive patients, exposed to the culprit 
drug and the proliferation of memory T-cells previously sensitised are 
measured (Luque et al., 2001; Nyfeler et al., 1997; Pichler et al., 2004). 
Sensitized lymphocytes generate cytokines including IL-2, undertake 
blastogenesis and the subsequent proliferative response is measured and 
quantified through the incorporation of 3H-thydmidine during the synthesis of 
DNA (Merk, 2005). The stimulation index (SI), the ratio of antigenic 
proliferation in comparison to proliferation in the absence of antigen i.e. cell 
culture medium, is used to express lymphocyte proliferation. An SI of 2 or more 
is considered a positive response.  
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The LTT can be used in delayed and also immediate hypersensitivity reactions 
though particular drugs have higher specificity including the β-lactam 
antibiotics, sulphonamides and anticonvulsants (Luque et al., 2001; Merk, 
2005). Tolerant or naive individuals would not display positive responses. 
Studies have shown the usefulness of LTTs in diagnosing penicillin allergy in 
delayed hypersensitivity, with sensitivities between 60% and 75% (Rozieres et 
al., 2009). Although non-invasive, the length of the assay (six days) and the 
requirement of radioactive isotopes do not translate well clinically. 
1.9.2 Enzyme-linked immunospot (ELISpot)  
The enzyme-linked immunospot (ELISpot) assay has a shorter duration than 
the LTT (four days), is sensitive and allows the detection and characterization 
of drug-specific cytokine secreting T-cells (Czerkinsky et al., 1988). T-cells 
secrete an array of cytokines following activation. Pro-inflammatory (generally 
Th1) cytokines such as IFN-γ, TNF-α, IL-2, IL-6 and IL-12, Th2 anti-
inflammatory cytokines such as IL-4, IL-5, IL-10, IL-13and TGF-β and other 
secreted molecules such as granzyme B, perforin and Fas ligand can be 
investigated (Lehmann et al., 2012; Lochmatter et al., 2009; Romagnani, 1992; 
Romagnani, 2006). This assay provides more detailed information on the 
biological function of the T-cells that mediate the hypersensitivity reaction.  
IFN-γ is one of the major cytokines implicated in numerous delayed 
hypersensitivity reactions and drug-induced exanthemas. Drug-specific IFN-γ 
secreting T-cells have been detected and quantified (Naisbitt et al., 2005; Teraki 
et al., 2003; Yoshimura et al., 2004). While playing an important role in Th1 
responses and serving as a cytotoxicity marker, IFN-γ can also contribute to the 
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Th2 response through its ability to upregulate MHC II molecules on the surface 
of CD4+ T-cells (Beeler et al., 2006). Sensitivity from PBMC cultures in the IFN-γ 
ELISpot can reach 90% and up to 100% specificity can be seen in penicillin-
induced MPE (Porebski et al., 2011; Rozieres et al., 2009). 
Multiplex, or Luminex, assays also quantify drug-specific cytokine secretion by 
T-cells (Beeler et al., 2006; Chen et al., 2009). Capture antibodies directed at 
each target molecule/cytokine are bound to colour-coded beads and are 
detected and quantified by a fluorescently labelled reporter. As each antibody is 
coupled with a specific bead, multiple beads can be added and therefore 
multiple cytokines can be examined in a single sample. 
1.9.3 Flow cytometry 
Flow cytometry allows for the identification of multiple cell surface markers 
and subsequently the phenotypic analysis and characterisation of cells involved 
in drug hypersensitivity. Cell surface markers on activated T-cells can be used 
to detect drug-specific T-cell populations and thus can be utilised in the 
diagnosis of hypersensitivity (Hari et al., 2001). The surface molecule CD69 is 
one such marker that has been used as a marker of delayed drug 
hypersensitivity and is comparable to LTT in terms of sensitivity and specificity 
(Beeler et al., 2008). Other cell surface markers of drug-specific T-cell activation 
include CD25, CD40L CD71 and HLA-DR which are upregulated in sensitized 
individuals (Beeler et al., 2006; Porebski et al., 2011).  
As with the LTT, flow cytometry can also be used to measure the proliferative 
response of previously sensitised memory T-cells. Drug-specific T-cells are 
stained with the fluorescent dye carboxyfluoescein succinimidyl ester (CFSE), 
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which binds to amino groups of intracellular proteins and becomes integrated 
within the lipid membrane. During a drug-specific proliferative response, the 
intensity of CFSE fluorescence will decrease by half with each cell division and 
so the the number of divisions can be determined and evaluated (Beeler et al., 
2006). 
Following stimulation by a drug or antigen Th1, IFN-γ secreting cells and Th2, 
IL-4 secreting cells play an important role in the development and nature of the 
immune response (Del Prete et al., 1993; Mosmann et al., 1996). Intracellular 
cytokine staining, ICS, uses flow cytometry to evaluate such cytokine secretion 
as these two subsets of cells do not possess cell surface markers. Fluorescent 
antibodies for cytokines, including IFN-γ and IL-4, form the basis of ICS and 
with flow cytometry we can determine their involvement in drug induced 
immune response. 
1.9.4 T-cell cloning 
In some individuals it can be difficult to detect drug-specific T-cells as part of a 
PBMC culture using the above described methods. The use of T-cell clones in 
assays adapted from those previously described provides an alternative 
allowing research to focus specifically on antigen-specific cells. Using the well-
established method of serial or limiting dilution, long lived drug-specific T-cells 
can be isolated from allergic individuals and expanded to generate drug-specific 
T-cell clones (Mauri-Hellweg et al., 1995; Staszewski, 1984). Figure 1.8 provides 
further details of the processes involved in the generation of drug-specific T-cell 
clones. T-cell clones can then be fully characterised in terms of phenotype, for 
the expression of specific markers, proliferative capacity and their cytokine 
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secretion prolife determined. This allows the pathomechanism of drug 
hypersensitivity to be investigated.  
 
Figure 1.8 T-cell cloning 
Timeframe and process involved in the generation of antigen-specific T-cell clones 
 
1.10 Cystic fibrosis and drug hypersensitivity 
Cystic fibrosis (CF) is one of the most common lethal recessive genetic diseases 
in the Caucasian population with over 8,500 sufferers and 2 million carriers in 
the UK (cftrust.org.uk, 2012). Faulty or absent chloride channels in the airways 
and digestive tract are caused by mutations in the cystic fibrosis 
transmembrane regulator (CFTR) gene. Cells are therefore unable to release 
chloride and sodium reabsorption increases, leading to the accumulation of 
thick, mucous secretions in the airways. This environment is exploited be 
bacteria meaning CF patients frequently develop infective pulmonary 
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exacerbations, destruction of airways and bronchiectasis (Turcios, 2005). 
Though great improvements have been made in treatment and quality of life, as 
patients age pseudomonal infections reach up to 80% prevalence with a strong 
correlation between lung disease and patient morbidity and mortality (Kirkby 
et al., 2009; Parmar et al., 2005). Antibiotics are therefore prescribed both for 
treatment and prophylactically.  
Unfortunately, allergy to β-lactam antibiotics is a major health concern in 
patients with CF. Sufferers are three times more likely to develop 
hypersensitivity reactions compared to the general population with a 
prevalence of up to 50% (Burrows et al., 2007; Parmar et al., 2005). Delayed 
type hypersensitivity is most commonly observed in CF patients with a mean 
time of onset around 9 days after β-lactam administration (Whitaker et al., 
2011b; Wills et al., 1998). MPE is the most common manifestation with 
reactions also consisting of fever, nausea and flu-like symptoms.   Less 
frequently seen, immediate hypersensitivity reaction accounted for 6% of β-
lactam reactions with no severe skin reactions and systemic involvement 
reported (Whitaker et al., 2012).  
A number of factors may be responsible for the higher rates of hypersensitivity 
reactions observed in patients with CF namely the high doses of intravenous 
antibiotics delivered on a frequent basis increasing risk for sensitisation. With 
multiple exposures, there is likely to be increased sensitisation and ultimately 
elicitation of an immune response. Where a bacterial illness occurs, the 
inflammatory response in lung of CF patient consists of a chronic acute 
response. High concentrations of neutrophils are observed and as a result, high 
levels of circulating IL-8, IL-6, IL-17 and in particular the cytokines IL-1β and 
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TNF-α provide danger signals which could also increase risk of sensitisation 
(Whitaker et al., 2012). Although the CFTR mutation is still to be fully 
investigated for its influence on inflammatory state, CFTR knockout mice have 
been observed mounting an exaggerated cytokine response to bacteria 
(Heeckeren et al., 1997). An inflated Th2 response in CFTR deficient 
lymphocytes compared to controls has been described suggesting that the CFTR 
mutation may contribute to an increased risk of hypersensitivity (Mueller et al., 
2011).   
1.11 Piperacillin 
Patients with CF are prescribed a range of drugs throughout treatment 
including the anti-pseudomonal antibiotic piperacillin. Part of the penicillin 
class of antibiotics, the broad-spectrum piperacillin contains a β-lactam ring 
and is often given in combination with the β-lactamase inhibitor, tazobactam 
improving its activity against β-lactamase producing resistant bacteria (Speich 
et al., 1998). Biliary excretion of piperacillin is around 15% in rats and 
approximately 37% in rabbits whereas in humans, it is negligible (Brogard et 
al., 1994; Calhoun et al., 1987; Ghibellini et al., 2006). Studies using human liver 
microsomes and in vivo duodenal samples showed metabolism of piperacillin 
into desethyl-piperacillin through N-dealkylation. Furthermore a glucuronide 
conjugate of the desethyl metabolite has been detected (Ghibellini et al., 2007; 
Komuro et al., 1997; Minami et al., 1991). As with all patients with CF, 
piperacillin is given intravenously for rapid absorption, often at relatively high 
doses and alongside an aminoglycoside. Piperacillin and its desethyl metabolite 
is able to bind to proteins in plasma (between 20% and 30%) and the formation 
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of these drug-protein adducts may represent functional antigens which are able 
to cause hypersensitivity reactions (Sorgel et al., 1993; Whitaker et al., 2011b). 
Hypersensitivity to piperacillin is most commonly delayed cutaneous reactions 
consisting of MPE and whilst piperacillin metabolites have been identified liver 
reactions have not been reported. Research on piperacillin hypersensitivity has 
allowed T-cell responses to piperacillin to be characterised and piperacillin 
adducts to be identified. Indeed piperacillin-specific lymphocytes have been 
identified and isolated in allergic patients and with the generation of 
piperacillin-specific T-cell clones a predominantly Th2 cytokine secretion 
profile has been determined (El-Ghaiesh et al., 2012; Whitaker et al., 2011b).  
1.12 Flucloxacillin 
The β-lactam antibiotic flucloxacillin is used to treat staphylococcal infection. It 
inhibits peptidoglycan synthesis and so inhibits bacterial cell-wall synthesis 
(Van Langevelde et al., 1998). Commonly prescribed to the general population, 
flucloxacillin is generally well tolerated although it is allied with the 
manifestation of cholestatic liver disease, which affects bile flow. This is seen at 
a frequency of between 7 and 8.5 in every 100,000 first-time users (Russmann 
et al., 2005). Metabolism of flucloxacillin via the CYP3A4 enzyme forms a 5-
hydroxymethyl metabolite, which has been implicated in biliary epithelial cell 
cytotoxicity though hepatocyte toxicity was not observed (Lakehal et al., 2001). 
It has been also been shown that flucloxacillin is able to bind to liver proteins in 
rat hepatocytes with drug modified albumin detected (Carey et al., 2005).  
Susceptibility to flucloxacillin-induced liver injury is strongly associated with 
the expression of HLA-B*57:01. A genome-wide association study (GWAS) 
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showed 84% of patients with flucloxacillin-induced liver injury carried the risk 
allele compared to 5% in the control population (Daly et al., 2009b). 
Hypersensitivity reactions to the NRTI abacavir, used as part of combination 
therapy for HIV, is also associated with HLA-B*57:01 indicating possible T-cell 
involvement, though it is unclear why the liver is targeted in the case of 
flucloxacillin. Metabolism may play a role as both flucloxacillin and the 5-
hydroxymethyl metabolite have been found to bind to human serum albumin 
(HSA) and at similar residues both in vitro and in vivo with modified peptides 
detected in patient plasma (Jenkins et al., 2009a). Hapten formation may 
therefore play a role in adverse reaction to flucloxacillin. 
Recently Monshi et al. highlighted the immune basis for flucloxacillin-induced 
liver injury through the characterisation of flucloxacillin-specific T-cell clones 
isolated from patients with liver injury. T-cell activation was processing 
dependent with the level of flucloxacillin binding to albumin correlating with 
activation of T-cells. Interestingly, other β-lactam antibiotics stimulated 
flucloxacillin-responsive T-cell clones whereas abacavir, which is also 
associated with HLA-B*57:01 restricted hypersensitivity, did not induce 
stimulation in flucloxacillin-responsive clones. Using a panel of APCs expressing 
a range of HLA-B alleles, HLA specificity was investigated. Flucloxacillin 
activation of clones was restricted by the risk allele HLA-B*57:01 and the 
structurally similar HLA-B*57:01 (Monshi et al., 2013). 
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Figure 1.9 Drug structures 
Core structure of the penicillin class of antibiotics is shown. The chemical structures of 
piperacillin (a penicillin), aztreonam (a monobactam), meropenem (a carbapenem) and 
flucloxacillin (a penicillin) are also shown. 
 
1.13 Aims and objectives of thesis 
The aim of this thesis was to investigate T-cells and their role in delayed 
hypersensitivity particularly in patients with skin and liver reactions to β-
lactam antibiotics. Through an array of in vitro techniques I aimed to 
characterise drug antigen formation and further our understanding of the 
relationship between drug-protein binding and the initiation of an immune 
response that results ultimately in tissue injury in susceptible patients. 
Specific aims of this thesis were: 
 To investigate multiple drug hypersensitivity and T-cell cross reactivity 
between different classes of β-lactam antibiotic (piperacillin, aztreonam 
and meropenem). 
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 To explore T-cell responses to drugs and drug haptens in human patients 
expressing HLA risk alleles. 
 Develop methods to quantify drug-protein adducts in vitro and in patient 
plasma. 
 To explore the relationship between adduct formation and the activation 
of patient T-cells.
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2.1 Materials and reagents 
Cell culture flasks and multi-well plates were purchased from Thermo Scientific 
(UK). LymphoprepTM was purchased from Axis-Shield (Dundee, UK). Human AB 
serum was purchased from Innovative Research (Michigan, USA). Foetal bovine 
serum (FBS) was purchased from Invitrogen (Paisley, UK). Cyclosporin-A was 
bought from Fluka Analytical (Gillingham, Dorset, UK). Multisort bead 
separation kits were purchased from Miltenyi Biotec (Surrey, UK). Purified 
tetanus toxoid was bought from Statens seruminstitut (Copenhagen, Denmark). 
Recombinant human interleukin-2 (rhIL-2) was purchased from Peprotech 
(London, UK). Printed glass fibre filter mats, meltilex melt on scintillator sheets 
and sample bags for microbeta trilux were from Perkin Elmer Life Sciences 
(Waltham MA, USA). Tritiated [3H]-methyl thymidine was purchased from 
Moravek (California, USA).  
MultiscreenHTS filter plates for ELISpot were purchased from Millipore 
(Watford, UK). Interferon-γ, interleukin-13, interleukin-5, granzyme-B and 
perforin ELISpot kits including antibodies and substrate solution were 
purchased from Mabtech (Stockholm, Sweden). Fas ligand ELISpot kit was 
purchased from Abcam (Cambridge, UK).  
HPLC grade methanol, analytical grade acetonitrile and all LC/MS grade 
solvents were purchased from Fisher Scientific (Loughborough, UK).  
Reducing Laemmli sample buffer. Precision plus protein standards and 
Bradford reagent was purchased from Bio-Rad (Hertfordshire, UK). 
Chemiluminescent substrate was purchased from Thermo Scientific (UK). 
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Nitrocellulose membrane and Hyperfilm ECL was obtained from GE Healthcare 
Life Sciences (Buckinghamshire, UK). Developer and fixer solution were from 
Kodak.  
CD4-APC, CD8-PE and purified anti-human HLA-ABC-PE and FITC mouse anti-
human HLA-DR, DP and DQ monoclonal antibodies were purchased from BD 
Biosciences (Oxford, UK). Mouse anti-penicillin antibody was bought from AbD 
Serotec (Oxford, UK). Polyclonal goat anti-mouse immunoglobulins/HRP was 
purchased from Dako cytomation (Glostrup, Denmark). Anti-flucloxacillin 
antibody was a gift from Frank Van Pelt (University College Cork, Ireland). Anti-
rabbit IgG peroxidise secondary antibody produced in mouse was from -Aldrich 
(Dorset, UK) 
Collagenase A or IV was purchased from Roche (Basel, Switzerland) or Sigma 
Aldrich (St. Louis, MO). Collagen-I coated plates were from BD Beckinson (San 
Jose, CA). 
Meropenem, aztreonam and flucloxacillin was purchased from AstraZeneca 
(Luton, UK), Bristol-Myers Squibb Pharmaceuticals (Dublin, Ireland) and 
Wockhardt UK Ltd (Wrexham, UK) respectively.  Insulin-transferrin-selenium 
was from Life Technologies (Carlsbad, CA). 
All other solvents, chemicals and reagents were of analytical grade purchased 
from Sigma-Aldrich (Dorset, UK) unless otherwise stated.  
2.2 Devices, lab-ware and instrumentation 
MS and LS columns were purchased from Miltenyi Biotec (Surrey, UK). The 
liquid scintillation counter used in proliferation assays was the MicroBeta 
Trilux counter (PerkinElmer, Cambridge, UK). AID ELISpot reader was from 
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Cadama Madical (Stourbridge, UK). FACs analysis was acquired on BD 
FACSCanto II flow cytometer (BD Biosciences, Oxford, UK) and post acquisition 
analysis of flow cytometry data (FCS) files were done using Cyflogic software 
(CyFlo Ltd). Protein concentration was determined using MRX plate reader 
from Dynex (Lincoln, UK). C18 ZipTips were purchased from Millipore UK Ltd. 
Amicon Ultra-4ml centrifugal filter units were bought from Merk Millipore Ltd 
(Carrigtwohill, Ireland). Mean values and standard deviations were calculated 
and statistical analysis (paired T tests, Mann-Whitney, one-way ANOVA) was 
performed using GraphPad Prism (GraphPad Software).   
2.3 Patient and volunteer recruitment 
CF patients involved in piperacillin, meropenem and aztreonam work attended 
the Regional Adult Cystic Fibrosis Unit, St James’s University Hospital, Leeds, 
UK. A tolerant CF group consisted of CF patients who had not previously had an 
adverse reaction to repeated antibiotic therapy. Naive controls were healthy 
volunteers who had never received the antibiotic in question. Written informed 
consent was obtained from all patients and the study was approved by the 
Leeds East Ethics Committee.  
For DILI patients and healthy volunteers of the HLA-typed cohort, approval for 
the study was obtained from the Liverpool Local Research Ethics Committee. 
Informed written consent was obtained from all patients and participants 
involved.  
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2.4 Cell culture medium  
Culture medium for T-lymphocytes comprised of RPMI 1640 supplemented 
with 10% human AB serum, HEPES (25mM), penicillin (1000 U/ml), 
streptomycin (0.1 mg/ml), L-glutamine (2mM) and transferrin (25µg/ml). 
Flucloxacillin-specific T-cells were generated and cultured in medium free from 
penicillin and streptomycin. Assays were conducted using penicillin-free media. 
 
Antigen presenting cells (APC, EBV-transformed B-cells) were maintained in 
medium comprised of RPMI 1640 supplemented with 10% foetal bovine serum, 
HEPES (25mM), penicillin (1000 U/ml), streptomycin (0.1 mg/ml) and L-
glutamine (2mM) 
 
Media for use with hepatocytes comprised of Williams E supplemented with 1% 
insulin-transferrin-selenium, 2mM L-glutamine, 10-7M dexamethasone and 
streptomycin (100µg/ml).  
2.5 Methods  
2.5.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of 
patients and volunteers which were collected into heparinised vacutainer tubes. 
Blood (25ml) was delicately layered on top of lymphoprep (25ml) and the 
erethrocytes sedimented by density centrifugation (400g, 25mins at room 
temperature). The buffy coat layer containing the PBMCs was then carefully 
aspirated using a Pasteur pipette. PBMCs were washed twice in Hanks balanced 
salt solution (HBSS) to remove any remaining lymphoprep and resuspended in 
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10ml HBSS. A 10µl aliquot was added to an equal volume of trypan blue (0.2% 
w/v) and a 10µl aliquot of the stained cells counted using a Neubauer 
haemacytometer under a Lecia DME microscope (Leica Microsystems, Milton 
Keynes, UK). Cells for subsequent assays were also counted using Neubauer 
haemacytometer. Cell viability was assessed by trypan blue exclusion and 
calculated using the following equation: percentage viability = viable cells ÷ total 
cells x 100. Percentage viability was typically >95%.  
PBMCs were again spun down and resuspended in FBS containing 10% DMSO 
at a density of 1 x 107 cells/ml for 24 hours in a Mr Frosty at -80°C. Cells were 
then frozen in liquid nitrogen or at -150°C for long term storage until required. 
Alternatively PBMCs were transferred to appropriate media for immediate use 
in experiments.  
2.5.2 T-cell cloning  
2.5.2.1 Generation of autologous antigen-presenting cell lines 
Epstein-Barr virus (EBV) transformed B-cell lines were used as APCs in all T-
cell clone assays. These were created from PBMCs by transformation with the 
supernatant from the virus-producing cell line B9.58. 5ml of supernatant was 
filtered through a 0.45µm syringe filter onto a PBMC pellet containing 5 x 106 
cells. Cyclosporin A (CSA) was added to inhibit the proliferation of T-
lymphocytes. After incubation overnight at 37°C under an atmosphere of 95% 
O2/5% CO2, cells were washed and resuspended in APC medium supplemented 
with CSA (1µg/ml) and transferred to a 24-well plate for cell culture. Fresh APC 
cell culture medium was added twice a week to maintain cells. CSA was omitted 
from the culture medium after two weeks to enhance B-cell proliferation. Cells 
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were transferred to a tissue culture flask when confluent and were maintained 
with fresh APC culture media twice a week.  
2.5.2.2 Generation of antigen-specific T-cell clones 
Through T-cell cloning we aim to generate antigen-specific cultures derived 
from a single cell. PBMCs from patients and volunteers (1x 106; 500µl) were 
cultured with 500µl of the drug in T-cell media in three wells of a 48-well cell 
culture plate. For piperacillin a concentration of 2mM was used, and for 
meropenem, aztreonam and flucloxacillin 0.5-1mM drug was used. On days 6 
and 9 cell cultures were supplemented with IL-2 (200IU/ml) to expand the 
number of antigen-specific T-cells. 
For the generation of flucloxacillin-specific T-cell clones, CD4+ and CD8+ cells 
were first separated on day 14 using a CD8 Multisort kit. Cells were harvested 
and resuspended in PBS containing 0.5% BSA and 2mM EDTA. Magnetic CD8 
microbeads were added to the cells and incubated for 15 minutes at 4°C. Cells 
were then washed twice and added to an MS column held in a magnet. Negative 
unlabelled cells are able to pass through the column and collected as the CD4+ 
fraction. The column is then removed from the magnet and CD8+ cells flushed 
out. 
The separated cells and, for piperacillin, meropenem and aztreonam, the un-
separated bulk cells were then cloned (on day 14) using an established serial 
dilution method (Wu et al., 2006). Cells were seeded in 96-well (u-bottom) 
plates at densities of 0.3, 1 and 3 cells/well and re-stimulated with allogenic 
irradiated PBMCs (feeder cells, 5 x 104 cells/well, PHA (1µg/ml) and IL-2 (60 
U/ml). Well growing clones were transferred to new plates and split as 
required. Antigen specificity was assessed by proliferation assay (see 2.5.4 ). T-
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cell clones were re-stimulated every 14 days as described above in order to 
maintain T-cell proliferation. 
2.5.3 Lymphocyte transformation test (LTT) 
LTT assays were performed on PBMCs isolated from the peripheral blood of 
hypersensitive patients to detect the presence of drug-specific memory T-cells  
using an established protocol (Nyfeler et al., 1997) provided an overall view of 
the nature of the immune response. Briefly PBMCs (0.15 x 106, 100µl) were 
cultured with 100 µl drug (0.125 – 8 mM) in 96-well u-bottomed cell culture 
plates in triplicate. Tetanus toxoid (0.5µg/ml) was used as the positive control 
and T-cell culture medium for the negative. Plates were incubated at 37°C under 
an atmosphere of 95% O2/5% CO2 for 6 days with tritiated [3H]-thymidine 
(0.5µl per well) added in the last 16 hours. Plates were harvested on day 6 and 
radioactive transmission from each well was read using a MicroBeta Trilux 
counter. Dividing cells incorporate the radiolabelled thymidine into newly 
synthesised DNA. Data is expressed as counts per minute for each well (cpm) 
with lymphocyte proliferation quantified using the stimulation index (SI), (cpm 
in drug treated culture/cpm in non treated control culture). Those with an SI of 
2 or more are considered positive (Pichler et al., 2004).  
2.5.4 Proliferation assay 
Similar in principle to the LTT assay proliferation assays allow us to determine 
proliferative activity and in doing so gives us information on the extent of the 
extent of the immune reaction. Using this assay we are able to get a measure of 
the T-cell response and can confirm antigen specificity.  T-cell clones are 
primarily used in proliferation experiments.  
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Penicillin and streptomycin-free T-cell media is used throughout. T-cell clones 
(5 x 104, 50µl) are cultured in 96-well u-bottomed plate alongside irradiated 
autologous APCs (1 x 104, 50µl) and 100µl of the drug which is being 
investigated. Drug concentrations are made up at twice that required to account 
for 1:2 dilution in cell culture plate. Cells are cultured for 72 hours at 37°C 
under an atmosphere of 95% O2/5% CO2. Tritiated [3H]-thymidine (0.5µl per 
well) is added in the last 16 hours and proliferation measured by scintillation 
counting (MicroBeta Trilux counter). An SI ≥ 2 is considered a positive result.  
2.5.5 Enzyme-linked immunospot (ELISpot) assay 
 The ELISpot assay is a quick and effective assay that allows for the detection 
and characterisation of low frequency drug-specific cytokine secreting T-cells 
(Czerkinsky et al., 1988).  ELISpot kits with the appropriate antibodies are 
widely available for a vast range of cytokines. The majority of assays conducted 
as part of this thesis were for the detection of IFN-γ.  MultiscreenHTS ELISpot 
filter plates are coated overnight at 4°C with 100µl capture antibody (15ug/ml 
for IFN-γ, 10µg/ml for IL-13). The following day wells are washed five times 
with sterile PBS and blocked with 200µl T-cell culture media (penicillin and 
streptomycin-free media used throughout) at room temperature for 30 
minutes. Drug-specific T-cell clones (5 x 104, 50µl) are cultured in the ELISpot 
plate alongside irradiated autologous APCs (1 x 104, 50µl) and 100µl of the drug 
which is being investigated. Drug concentrations are made up at twice that 
required to account for 1:2 dilution within the plate. Plates are incubated for 48 
hours at 37°C under an atmosphere of 95% O2/5% CO2. After 48 hours cells are 
discarded and the wells washed five times with 200µl PBS. Biotin labelled 
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detection antibody (specific for each cytokine) is diluted to 1µg/ml in PBS 
containing 0.5% FBS and 100µl added to the wells. The plate was incubated at 
room temperature for 2 hours before wells were washed five times with PBS 
(200µl). Streptavadin-ALP was diluted 1:1000 in PBS containing 0.5% FBS and 
100µl added to wells and left to incubate at room temperature for 1 hour. Wells 
were then washed five times with PBS (200µl) and BCIP/NBT substrate added 
(100µl, 15mins) for spot visualisation. Wells were the washed under slow 
running tap water. A schematic of the ELISpot assay is illustrated in Figure 2.1. 
Wells were left to dry completely and spots were visualised and counted on an 
AID ELISpot reader.   
When PBMCs are used 5 x 105 cells (in 100µl) are added to each well and APCs 
omitted from the assay. 
 
Figure 2.1 Schematic representation of the ELISpot assay to detect cytokine secretion 
Wells are coated with a capture antibody for the cytokine of interest. Cells are co-cultured with 
drug for 48hours at 37°C. The molecule of interest, if secreted by cells, is captured. Cells are 
removed and a biotin labelled detection antibody (specific for each cytokine) is added. 
Strepdavidin-conjugated alkaline phosphatase is added which binds to the secondary 
biotinylated antibody. Upon addition of BCIP/NBT substrate solution alkaline phosphatase 
catalyses a reaction which results in a colour change and the formation of distinct dark spots. 
Capture Antibody
T-cells
Secreted molecule of interest
Biotinylated detection antibody
Streptavidin-ALP
1. 2. 3.
4. 5.
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2.5.6 Liquid chromatography/Tandem mass spectrometry  
Over the past two decades advances in mass spectrometry methods has allowed 
the field of proteomics to emerge and improved protein characterisation. This 
sensitive technique is used to detect, identify and quantify molecules based on 
their weight (mass, m) and charge (z). The samples, or analytes, in our case will 
consist of small peptides/fragments. All mass spectrometers have three main 
components; an ion source, a mass analyser and an ion detector. The first step is 
ionisation; at least one electron is removed to provide a positively charged ion. 
The ions are accelerated through the machine and deflected with lighter and 
more positively charged ions deflected more. The beam of ions is detected and 
recorded.   
With tandem mass spectrometry (MS/MS) following a first round of MS, distinct 
ions of interest are selected according to their mass to charge ratio (m/z) and 
fragmented further. In the second round of MS the fragments are further 
separated based on individual m/z. 
Liquid chromatography (LC-MS/MS) is used to pre-fractionate peptides by in-
line reversed phase chromatography meaning the MS instrument analyses a 
fewer species in a chromatographic timescale. Each multiply-charged peptide 
ion is bombarded with nitrogen which provides a known fragmentation profile 
at the peptide bond between amino acid residues. The mass analyser detects 
the series of ions as a mass ladder, with the mass difference between each step 
equivalent to the mass of one of twenty common amino acids. The peptide 
sequence can therefore be derived.  
Multiple Reaction Monitoring MS (MRM-MS) provides further sensitivity and 
specificity for the detection and quantification of peptides in complex mixtures. 
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A triple quadripole instrument (a QTRAP 5500 hybrid quadripole-linear ion 
trap mass spectrometer was used) is able to select ions of specific a mass to 
charge ratio (m/z) in the first and third quadrupoles using different voltage 
settings across the four rods which make up the quads. The precursor ion of 
interest is preselected in Quadrupole 1 (Q1) while Q2 acts as a collision 
chamber wherein the peptides are fragmented into partial sequences. A small 
number of sequence-specific fragment ions are therefore analysed in Q3 rather 
than a full MS/MS scan. Thus the parent ion is selected in Q1 and fragmented in 
Q2 whilst a characteristic fragment in may be selected in Q3 (Gillette et al., 
2013). The transition (combination of parent ion mass and fragment ion mass) 
is designed to be diagnostic for the peptide of interest, but must also be 
detected with good sensitivity. The selection of MRM transitions is therefore 
critical for sensitive and specific peptide quantification. 
2.5.7 LC-MS analysis of drugs 
Meropenem and aztreonam were dissolved in 50% methanol/0.1% formic acid 
to concentrations of 0.25 µM and 2.5 µM, respectively, and infused at 5 µl/min 
directly into a QTRAP 5500 hybrid quadrupole-linear ion trap mass 
spectrometer (AB Sciex, Foster City, CA, USA) fitted with a turboion source. The 
ionspray potential was set to 5500 V and the interface heater was turned off. 
For meropenem, an ion of m/z 384 was selected manually for fragmentation to 
generate a full product ion scan, plus the resulting fragment ions of m/z 254 and 
340 were further fragmented.  For aztreonam, an ion of m/z 436 was 
fragmented to generate a full product ion scan, and the fragment ion of m/z 356 
was further fragmented. The MS3 scans were acquired to aid identification and 
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reveal potential diagnostic fragment ions to aid in the detection of covalently 
bound drug in studies of modified protein. 
2.5.8 Time- and concentration-dependent modification of human 
serum albumin by meropenem, aztreonam and piperacillin 
Human serum albumin (66 mg/ml, 1 mM) was incubated with piperacillin, 
meropenem and aztreonam (0.1mM, 1 mM, 10 mM, 20 mM or 50 mM) in 200 µL 
phosphate buffer, pH 7.4 at 37°C for 24h. In separate experiments the drugs 
were incubated at a molar ratio of drug to protein of 20:1 for 24, 48, 72 and 96 h 
under the same experimental conditions. Drug was removed by precipitation of 
the protein with 9 volumes of ice-cold methanol followed by centrifugation at 
14000xg and 4°C for 10min. This was repeated once more, and the protein 
pellet reconstituted in 50 µL phosphate buffer. The protein was reduced by 
incubation with 10 mM DTT (w/v) at room temperature for 15 min, and 
alkylated by incubation with 55 mM iodoacetamide (w/v) for a further 15 min 
at room temperature. The samples were again subjected to methanol 
precipitation and were reconstituted in 50 mM ammonium bicarbonate buffer 
and the concentration was determined by Bradford assay (Bradford, 1976). The 
modified albumin was diluted to 1.6 mg/ml in 50 µl ammonium bicarbonate 
buffer.  Trypsin (2 µg) was added, and the samples were incubated overnight at 
37°C. The digestions were desalted using C18 Zip-Tips (Millipore) and dried 
prior to LC-MS/MS analysis. 
2.5.9 LC-MS analysis of drug-modified peptides 
For multiple reaction monitoring (MRM) detection of modified peptides, 
samples were reconstituted in 2% ACN/0.1% formic acid (v/v), and aliquots of 
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2.4-5 pmole were delivered into a QTRAP 5500 (AB Sciex) fitted with a 
NanoSpray II source by automated in-line liquid chromatography (U3000 HPLC 
System, 5 mm C18 nano-precolumn and 75 µm x 15cm C18 PepMap column 
[Dionex, California, USA]) via a 10 µm inner diameter PicoTip (New Objective, 
Massachusetts, USA). A gradient from 2% ACN/0.1% FA (v/v) to 50% 
ACN/0.1% FA (v/v) in 60mins was applied at a flow rate of 280 nL/min. The 
ionspray potential was set to 2,200-3,500V, the nebuliser gas to 19 and the 
interface heater to 150oC.  
In order to acquire unequivocal MS/MS characterisation of modified peptides, 
samples were also analysed using a Q-TOF instrument. Samples were delivered 
into a Triple TOF 5600 mass spectrometer (AB Sciex) by automated in-line 
reversed phase liquid chromatography, using an Eksigent NanoUltra cHiPLC 
System (AB Sciex) mounted with microfluidic trap and analytical column 
(15cm×75μm) packed with ChromXP C18-CL 3μm. A NanoSpray III source was 
fitted with a 10 μm inner diameter PicoTip emitter (New Objective). Samples 
were loaded in 0.1% formic acid onto the trap which was then washed with 2% 
ACN/0.1% FA for 10mins at 2 µL/min before switching in-line with the 
analytical column.  A gradient of 2-50 % (v/v) ACN/0.1 % (v/v) FA over 90 min 
was applied to the column at a flow rate of 300 nL/min. Spectra were acquired 
automatically in positive ion mode using information-dependent acquisition 
powered by Analyst TF 1.5.1. software, using mass ranges of 400-1600 amu in 
MS and 100-1400 amu in MS/MS. Up to 25 MS/MS spectra were acquired per 
cycle (approximately 10Hz) using a threshold of 100 counts per sec, with 
dynamic exclusion for 12secs and rolling collision energy. Sequence coverage 
was determined using ProteinPilot software v4.0 with the ParagonTM algorithm 
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(Shilov et al., 2007) and the most recent version of the SwissProt database. 
Modified peptides were identified by filtering for specific fragment ions in 
PeakView 1.1.1 (AB Sciex) and manual inspection of the spectra.  
 
To detect drug haptens, raw LC-MS/MS data were perused in order to identify 
peptides known to be modified with other β-lactam antibiotics (Jenkins et al., 
2009b; Meng et al., 2011b; Whitaker et al., 2011b) which were present with 
unexplained mass additions in samples exposed to meropenem or aztreonam. 
These data were used to design transitions specific for drug modified peptides. 
For meropenem, the m/z values were calculated for all possible peptides with a 
missed cleavage at a lysine residue. To these were added the masses of the 
proposed haptens (339, 384, 397 and 440 amu) and the parent ion masses were 
then paired with the proposed fragment masses of 175, 205 and/or 232 amu. 
For aztreonam, the mass of the proposed hapten (435 amu) was added to the 
peptide masses and paired with the proposed fragment ion mass of 237 amu. 
MRM transitions were acquired at unit resolution in both the Q1 and Q3 
quadrupoles to maximize specificity, they were optimised for collision energy 
and collision cell exit potential, and dwell time was 20ms. MRM survey scans 
were used to trigger enhanced product ion MS/MS scans of drug-modified 
peptides, with Q1 set to unit resolution, dynamic fill selected and dynamic 
exclusion for 20s. Total ion counts were determined from a second aliquot of 
each sample analysed on the same instrument by conventional LC-MS/MS. Drug 
peak areas were determined by MultiQuant 1.2 software (AB Sciex). Epitope 
profiles were constructed by comparing the relative intensity of drug peaks for 
each of the modified peptides within a sample and normalisation of those 
Chapter 2 
77 
 
signals across samples using the total ion counts. In order to confirm the 
identity of the fragment ions used in the MRM transitions, MS3 experiments 
were performed on selected peptides modified with each of the proposed 
haptens: MRM-triggered enhanced product ion MS/MS scans of drug-modified 
peptide were in turn used to trigger information-dependent MS3 scans, with 
two MS/MS scans and four MS3 scans per cycle. Piperacillin modified peptides 
were analysed as described previously (Whitaker et al., 2011b). 
2.5.10 Flow cytometry for T-cell phenotyping 
T-cell clones were examined for CD4 and CD8 cell surface expression using flow 
cytometry. T-cell suspensions (100µl) were stained with fluorescent antibodies; 
CD4-APC (3µl) and CD8-PE (3µl) and incubated in the dark for 20 minutes at 
4°C). Cells were then washed and resuspended in 200µl FACs buffer. Cells were 
acquired using FACS Canto and analysis conducted using Cyflogic. A minimum 
of 50,000 lymphocytes were acquired using forward and side scatter 
characteristics.  
2.5.11 Antigen pulsing assays 
Pulsing assays allows us to investigate drug-protein binding and presentation. 
APCs are incubated or pulsed with the drug overnight (16-24 hours). Cells are 
then washed extensively with HBSS to exclude free drug. These cells are then 
used in place of the regular non-pulsed APCs in our standard proliferation and 
ELISpot assays with T-cell clones (see 2.5.4.). T-cell clones (5 x 104, 50µl) are 
cultured with irradiated autologous drug-pulsed APCs (1 x 104, 50µl) and 100µl 
of the T-cell media. Soluble drug (100µl) is used as positive control. 
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2.5.12 Fixation of APCs 
The fixation assay is used to determine the role of intracellular processing in 
APCs as part of the T-cell immune response. APCs (2 x 106 cell/ml) were 
washed twice with HBSS to exclude FBS and resuspended in 1ml HBSS. 
Glutaraldehyde (25%, 1µl) was then added to the cell suspension mixed gently 
for 30 seconds. Glycine (1M, 1ml) was quickly added and the cells agitated for a 
further 45 seconds. Cells were washed three times to remove glutaraldehyde 
and resuspended in T-cell media. T-cell clones were T-cell clones (5 x 104, 50µl) 
are co-cultured with irradiated glutaraldehyde-fixed APCs (1 x 104, 50µl) and 
100µl of drug. Cells are incubated for 3 days at 37°C under an atmosphere of 
95% O2/5% CO2 with tritiated [3H]-thymidine (0.5µl per well) added in the last 
16 hours. Proliferation is measured through scintillation counting with an SI ≥ 2 
is considered positive.  
2.5.13 Absolute quantification 
2.5.13.1 Reagents 
The following products were purchased from Sigma-Aldrich (Gillingham, UK): 
HSA (97-99%), Fmoc-L-amino acids, trifluoroacetic acid (TFA), N,N'-
Dicyclohexylcarbodiimide  (DCC), 1-hydroxybenzotriazole (HOBt) , N-
methylmorpholine (NMM), dimethylformamide (DMF) , piperidine, and 
dichloromethane(DCM). Invitrogen (Paisley, UK) provided fetal bovine serum. 
Radiolabeled thymidine was obtained from Moravek International Limited (CA, 
USA). Trypsin was obtained from Promega (Madison, WI, USA). Piperacillin was 
kindly provided by Dr Whitaker from Regional Adult Cystic Fibrosis Unit, St. 
James’s Hospital, Leeds. 
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2.5.13.2 Synthesis of penicillin modified peptides 
The synthesis of penicillin modified peptides was achieved by Fmoc chemistry 
in solution phase. Amino acid side chain protection was effected by the 
following: triphenilmethyl (Trt) for glutamine; tert-butyl (tBu) for aspartic acid, 
glutamic acid, and threonine; and benzyloxycarbonyl (Z) for C-terminus lysine. 
The synthesis was initiated with lys(Z)-OBn salt as shown in Scheme 1. The 
coupling reactions were activated by means of addition of N,N'-
Dicyclohexylcarbodiimide  (DCC), in the presence of 1-hydroxybenzotriazole 
(HOBt) and a base such as N-methylmorpholine (NMM). The Fmoc deprotection 
step was accomplished twice with 20% piperidine in chloroform for 10 min. 
The efficiency of these reactions was evaluated by the ninhydrin colorimetric 
reaction. Once the synthesis was complete, the deprotection processes were 
carried out following a series of sequential steps: firstly to remove benzyl or Z 
groups by catalytic transfer hydrogenation; secondly to remove Fmoc with 50% 
diethylamine in acetonitrile; thirdly to precipitate the peptides with cold diethyl 
ether. The crude peptides were purified by semi-preparative HPLC on a C18 
column (details) with a linear gradient of 95-50% solvent A (0.05% TFA in 
water) in solvent B (0.05% TFA in acetonitrile) over 30 min at a flow rate of 
5mL/min.  The purity of peptides was determined by UV spectroscopy and the 
structure of the peptides were characterised by MS/MS analysis. The 1H NMR 
spectra were recorded in CDCl3 or MeOD at 400 MHz on a Bruker Advance NMR 
spectrometer. This was conducted by Dr Xiaoli Meng, University of Liverpool. 
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2.5.13.3 Isolation of HSA from plasma 
HSA was isolated by affinity chromatography. In brief, a POROS anti-HSA 
affinity cartridge (Applied Biosystems, Foster City, CA, USA) attached to a Vision 
Workstation (Applied Biosystems) was used to affinity capture HSA which was 
then eluted with 12 mM HCl. Protein was methanol precipitated, processed as 
described previously, and analysed by reversed phase LC-MS. 
2.5.13.4 Mass spectrometric analysis of Pip modified HSA 
Analyses were performed on a 5500 QTRAP® hybrid triple-quadrupole/linear 
ion trap instrument with Nanospray® II source (AB SCIEX, Foster City, CA, 
USA). MRM transitions specific for drug modified peptides were selected as 
follows: the m/z values for all possible modified peptides with a missed 
cleavage at the modified lysine residue were used together with a fragment 
mass of 160 corresponding to the cleaved thiazolidine ring of the drug. 
Notwithstanding the disparity in the ionisation efficiency of the peptides, 
relative MRM peak heights for each of the modified peptides were determined 
by MultiQuant software version 2.0 (AB SCIEX) to achieve the absolute quantity 
of the modified peptides. The total ion count for the whole digest for each 
sample was normalised to an internal synthetic peptide: in this way, the MRM 
signals were adjusted for differences in sample loading on-column. Further 
details of MS method are provided in supplementary methods. Calibration 
Curves for the synthetic standards were constructed by synthetic peptides (30, 
75, 150, 225, 375, 750 fmol). 
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2.5.14 Generation of synthetic piperacillin-HSA conjugates 
Human serum albumin (66 mg/ml, 1 mM) was incubated with piperacillin (at 
ratios of 50:1, 250:1 and 500:1) in phosphate buffer, pH 7.4 at 37°C for 24h. 
Conjugates were then processed used two methods as described below. 
 Conjugate 1 
Following 24 hours incubation piperacillin-HSA conjugates were transferred to 
Amicon Ultra 4ml and 15ml Filter spin columns for removal of free drug. 
Conjugates were washed 5-6 times with phosphate buffer (5000g, 10mins at 
4°C). Conjugates generated through this method with spin columns are referred 
to as S-conjugates. 
 Conjugate 2 
Piperacillin-HSA incubations are transferred to 15 or 50ml tubes for removal of 
free drug by MeOH precipitation. 9 x volume of ice-cold methanol is added to 
the culture followed by centrifugation at 4000RPM at 4°C for 15 minutes. 
Protein pellets are then washed three times with equal an equal volume of ice-
cold methanol before being reconstituted in phosphate buffer. Conjugates 
generated through methanol precipitation are referred to as M-conjugates. 
 
LC-MS/MS analysis was used to confirm drug modification of HSA in both sets 
of conjugates. The protein was reduced by incubation with 10 mM DTT (w/v) at 
room temperature for 15 min, and alkylated by incubation with 55 mM 
iodoacetamide (w/v) for a further 15 min at room temperature. The samples 
were subjected to methanol precipitation and reconstituted in 50 mM 
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ammonium bicarbonate buffer. Concentration was determined by Bradford 
assay (Bradford, 1976). The modified albumin was diluted to 1.6 mg/ml in 50 µl 
ammonium bicarbonate buffer.  Trypsin (2 µg) was added, and the samples 
were incubated overnight at 37°C. The digestions were desalted using C18 Zip-
Tips and dried prior to LC-MS/MS analysis. 
All conjugates were diluted in RPMI 1640 to appropriate concentrations for use 
in T-cell assays. 
2.5.15 Western blotting 
Protein samples (conjugates or cell lysates) were treated with reducing 
Laemmli buffer for western blot analysis at a ratio of 70 to 30% sample buffer 
to reducing agent. Samples were boiled for 10 minutes in preparation for 
western blot analysis. Aliquots of protein samples (5µg, 10µl) were loaded onto 
10% SDS-polyacrylamide gel for separation by electrophoresis (300V, 60mA, 1 
hour). Separated proteins were transferred from gel onto nitrocellulose 
membrane (300V, 250mA, 1 hour). Non-specific binding was blocked in 2.5% 
non-fat dry milk prepared in Tris/saline/Tween buffer (TST; 150mM NaCl, 
10mM Tris-HCL, 0.05%Tween 20 [pH 8]) for 2 hours at room temperature. 
Immunodetection of drug protein adducts was performed by incubating the blot 
with primary antibody diluted in 2.5% milk/TST at 4°C overnight. Unbound 
antibody was removed by washing with PBS-Tween. This was followed by 
incubation with secondary antibody diluted in 2.5% milk/TST for 2 hours at 
room temperature. Unbound antibody was removed by washing with PBS-
Tween.  Signals from the membrane were detected by ECL and developed in 
dark room using autoradiography film before scanning.  
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Table 2.1 Antibodies and concentrations used for western blot analysis 
 
 
2.5.16 Hepatocyte culture and flucloxacillin modification 
Primary human hepatocytes were isolated using a previously described 2-step 
collagenase method (Berry et al., 1969; LeCluyse et al., 2005; Seglen, 1976). 
Briefly, liver resections were received as surgical waste (Aintree hospital, 
Liverpool, United Kingdom) with full patient consent and ethical approval. The 
resections were perfused with HEPES-buffered saline (HBS; 10mM Hepes, 5mM 
KCl, 136mM NaCl, 5g/l glucose), followed by digestion with Collagenase A or IV 
in HBS containing 700µM CaCl2. The capsule was then opened and the digested 
cells separated using gauze. The suspension was centrifuged twice at 80xg for 5 
minutes at 4°C, and resuspended in Williams E medium. Cells were plated onto 
Collagen-I coated 6-well plates at 1 x 105 cells/ml, 2mls per well, in hepatocyte 
media. After 3 hours incubation at 37°C under an atmosphere of 95% O2/5% 
CO2, non-adherent cells were washed away and the culture medium replaced. 
Cell media was changed the next day and replaced with either hepatocyte media 
or RPMI 1640 supplemented with 10% human AB serum, HEPES (25mM), 
streptomycin (100µg mg/ml), L-glutamine (2mM) and transferrin (25µg/ml). 
Cells were treated with flucloxacillin (0 – 4mM) for 24 or 48 hours after which 
cells were harvested. The dry cell pellets and supernatants were recovered and 
Piperacillin Flucloxacillin
Primary Antibody Dilution Antibody Dilution
Mouse anti-
penicillin
1:20,000
Rabbit anti-
flucloxacillin
1:2,000
Secondary Antibody Dilution Antibody Dilution
Goat anti-mouse 
HRP
1:1,000 Anti-rabbit IgG 1:1,000
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stored at -80°C for immunoblot and LC/MS analysis. Protein concentrations 
were determined by Bradford assay.  
2.5.17 MHC restriction assay 
Anti-human HLA-A, -B, -C (MHC I) and anti-human HLA-DP, -DQ, -DR (MHC II) 
antibodies were used to determine if drug presentation to T-cell clones were 
restricted by MHC I or MHC II. APCs (1 x 104, 50µl) were pre-incubated with 
either MHC I or MHC II blocking antibodies (5µg/ml) at 37°C under an 
atmosphere of 95% O2/5% CO2 for 30 minutes. The APCs were then co-cultured 
with drug-specific T-cell clones (5 x 104, 50µl) with or without soluble drug for 
72 hours. Tritiated [3H]-thymidine (0.5µCi per well) was added in the last 16 
hours and proliferation of T-cells measured through scintillation counting. 
2.5.18 APC mismatch assay 
Flucloxacillin-specific T-cell clones (5 x 104, 50µl) were co-cultured in 96-well 
u-bottom plates with either autologous or heterologous EBV-transformed B-
cells which were used as APCs. Cells were exposed to flucloxacillin, or medium 
as a negative control, for 72 hours. A selection of heterologous APCs were 
chosen based on the expression of MHC class II molecules specifically HLA-B 
expression. EBV-transformed B-cells were generated from HLA-B*57:01 
positive volunteers and a vast range of other HLA-B alleles were selected to 
enhance variety of allelic expressions available for tests. Cells were incubated at 
37°C under an atmosphere of 95% O2/5% CO2 with tritiated [3H]-thymidine 
(0.5µCi per well) added in the last 16 hours and T-cell proliferation measured 
through scintillation counting. Cytokine secretion was determined using IFN-γ 
ELISpot.
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3.1 Introduction 
Cystic fibrosis (CF) is a fatal inherited disorder, of particular prevalence within 
the Caucasian population, with over 10,000 affected by the disease in the UK 
and 1 in 25 carriers of the faulty gene responsible for the condition 
(www.cysticfibrosis.org.uk, 2014). The development of CF is linked withthe 
long arm of chromosome 7 particularly the gene sequence that encodes cystic 
fibrosis transmembrane conductance regulator (CFTR) protein (Riordan et al., 
1989; Tsui et al., 1985; Wainwright et al., 1985). CF is an autosomal recessive 
disease arising due to mutations in the highly polymorphic region of DNA which 
codes for the CFTR protein (Gibson et al., 2003; Knowlton et al., 1985).  
A single mutation, whereby a single phenylalanine residue at position 508 
(ΔF508) has been deleted in the CFTR sequence, is accountable for the majority 
(68%) of CF causative mutations (Kerem et al., 1989). However, great 
mutational heterogeneity exists in the remaining third of CF alleles. Over 1700 
mutations have been identified and implicated in CF with varying frequencies 
and distribution (Bobadilla et al., 2002; Cuthbert, 2011). CFTR is a cAMP-
activated ATP-gated anion channel that  transports chloride across epithelial 
cell membranes, and mutations in the region encoding CFTR can lead to an 
absent, faulty or defective CFTR protein function, particularly the ability to 
transport chloride across cell membranes (Rowe et al., 2005). Chloride 
secretion across the apical airway epithelial cell membrane is reduced and 
sodium absorption is increased basolaterally. As a result, the transport of fluids 
and electrolytes is disrupted, airway surface liquid is reduced and ciliary 
function becomes defective (Matsui et al., 1998; Rowe et al., 2005). The 
environment provided by the thick viscid secretions formed in the airways and 
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gastrointestinal system of CF patients is prone to bacterial infection and 
colonization. Pulmonary exacerbations, airway inflammation and 
bronchiectasis are a frequent occurrence and unfortunately the chronic 
bacterial infections and concomitant airway destruction experienced by CF 
patients, will prove fatal in 80 to 95% of patients (Lyczak et al., 2002; Turcios, 
2005).    
Intravenous drug therapy usually comprising an aminoglycoside and a β-lactam 
antibiotic is the foundation for the treatment of respiratory infections in 
patients with CF. Unfortunately, a high frequency of hypersensitivity reactions 
can restrict the therapeutic choices available. A number of studies have 
reported the development of an allergic reaction to be around 26% - 50% in CF 
patients which is in stark contrast to reaction prevalence of 1% - 10% in the 
general population (Burrows et al., 2007; Parmar et al., 2005; Pleasants et al., 
1994; Whitaker et al., 2011c).  
At the Leeds Adult Cystic Fibrosis Unit, only 6% of reactions induced by β-
lactam antibiotics are classified as immediate reactions, and no severe skin 
reactions or systemic involvement was encountered (Whitaker et al., 2012). 
Allergy to β-lactam antibiotics is normally a non-immediate or delayed-type IV 
hypersensitivity reaction with a mean time of onset around 9 days after drug 
exposure, with rashes, fever, nausea and flu-like symptoms most commonly 
observed (Whitaker et al., 2011b).   
 If an allergic reaction to one β-lactam antibiotic is encountered, another drug 
often from a different class of antibiotic is given in replacement. It is 
unfortunate however, that up to 20% of CF patients develop allergic reactions 
to multiple antibiotics thus limiting treatment options (Whitaker et al., 2011c).  
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The development of multiple drug hypersensitivity (MDH) syndrome whereby 
hypersensitive reactions are seen with at least 2 drugs can lead to further 
difficulties in patient cases where, for example, a lung transplant becomes the 
next step in their treatment. The condition of the lungs is critically dependent 
on the sustained use of antibiotics due to the nature of CF. Furthermore 
sufferers are usually restricted to one lung transplant and so it is vital to ensure 
functional lungs for as long as possible (Whitaker et al., 2012). Patients with 
MDH may be excluded from the transplant program and so the appearance of a 
mild rash can therefore lead to serious consequences in a patient’s prognosis. 
Clinical data suggest the extent of cross-reactivity between the different classes 
of β-lactam antibiotics is low. Moss et al. reported that 19 of 20 patients with 
previous penicillin or cephalosporin reactions safely tolerated aztreonam (Moss 
et al., 1991) and rates of cross-reactivity between penicillin and meropenem in 
patients with immediate reactions are estimated at less than 1%. However, 
many patients become sensitized to the replacement drug following repeated 
exposure and still experience Type IV hypersensitivity at a later 
date.(Atanasković-Marković et al., 2008; Frumin et al., 2009; Moss, 1991). The 
factors that lead to multiple delayed reactions in β-lactam allergic patients have 
not been fully elucidated and there is need for a clearer understanding of the 
drug-specific-immune response to inform drug selection and use.  
Previous work in the department has focused on one particular commonly used 
β-lactam antibiotic, piperacillin. Using piperacillin-specific T-cell clones isolated 
from piperacillin-allergic CF patients, mechanistic studies could be conducted to 
further our understanding of the immune pathogenesis in this subset of 
patients. These studies revealed high drug specificity, both for proliferative 
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responses of lymphocytes, and with regards to cytokine secretion. Not only was 
the secretion of classic Th1 cytokine IFN-γ detected, Th2 cytokines (IL-4, IL-5 
and IL-13) were also secreted at high levels (El-Ghaiesh et al., 2012). 
Furthermore, using pulsing assays, whereby free drug is excluded and instead 
bound to APCs before culture with T-cells, show evidence of time dependant 
antigen formation for the stimulation of an immune response. A minimum of 
four hours incubation time (piperacillin and APC) is required to elicit a positive 
T-cell proliferative response. In addition, using novel mass spectrometric 
methods we have been able to identify the lysine residues that piperacillin 
modifies on the model protein human serum albumin (HSA) and thus 
characterise the hapten formed both in vitro and in vivo. Modifications were 
most commonly seen at positions Lys 190, Lys 432 and Lys 541 and indeed 
levels of modification coincided with the intensity of lymphocyte proliferative 
response. As drug incubation time and drug concentration increased so too did 
modification of HSA and T-cell response. Analysis suggested peptide sequences 
around these lysine positions could be the principal functional epitopes and are 
likely to be antigenic (Whitaker et al., 2011b).      
3.2 Aims and Hypothesis 
In our department, work has previously focussed on piperacillin in order to 
define the mechanisms of T-cell activation using PBMCs from hypersensitive 
patients. Aztreonam and meropenem from the monobactam and carbapenem 
classes of β-lactam antibiotics respectively, are further drugs used in the 
treatment of lung infections in patients with CF. This chapter is focussed on 
these antibiotics in order to determine if it possible to detect individual T-cell 
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responses to the three drugs. Through the generation of drug-specific clones, 
we hope to address the question of cross reactivity and further our knowledge 
of the immune response in hypersensitive individuals.  
We aim to characterize the haptenic structures that piperacillin, meropenem 
and aztreonam form with lysine residues on human serum albumin (HSA). 
Furthermore, through the isolation of antigen-specific T-cell clones from 
patients with multiple allergies to β-lactam antibiotics we aim to present a 
biological read-out to analyse cross-reactivity of these drugs.  
From previous literature, with such high rates of hypersensitivity and the 
structural similarities of the three drugs I propose the following hypothesis: 
Drug specific T-cell clones will cross react with each of the three drugs and similar 
patterns of HSA modification will be observed. 
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3.3 Methods 
The methods used are described fully in Material and Methods, Chapter 2. A 
brief experimental outline is detailed below. 
 
 
Scheme 3.1 Experimental plan and methods used in this chapter 
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3.4 Results 
A close collaboration with the Leeds Adult Cystic Fibrosis Unit has allowed the 
recruitment of patients with allergies to multiple β-lactam antibiotics. We were 
therefore able to utilise PBMCs isolated from patients to examine T-cell 
responses to piperacillin, meropenem and aztreonam and further understand 
the immune responses in patients with MDH.  
3.4.1 Piperacillin, Meropenem and Aztreonam stimulates PBMCs 
from allergic patients 
PBMCs were isolated from four patients with cystic fibrosis and allergies to the 
following β-lactam antibiotics; piperacillin, meropenem and aztreonam. Table 
3.1 provides a summary of patient information including the clinical features of 
reactions.  
PBMCs from these patients with MDH were stimulated in vitro to proliferate 
with graded concentrations of each drug (0.5 – 2mM). We observed that the 
proliferative responses were dependent on drug concentrations (Figure 3.1). 
Furthermore, PBMC cytokine secretion (IFN-γ) and/or IL-13) is observed 
following drug treatment.  
With the exception of patient 3, the strongest responses were seen following 
piperacillin exposure often differing greatly to the SI’s recorded with the other 
two drugs. This is demonstrated clearly in the case of patient 4 where 
piperacillin yields an SI of over 60 whilst much weaker responses are seen 
following exposure to aztreonam and meropenem, <2 and 4 respectively. 
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Table 3.1 Clinical details of allergic patients 
MPE = maculopapular drug eruption, LTT = lymphocyte transformation test, SI = stimulation index. 
 
Figure 3.1Drug-specific stimulation of PBMCs from allergic patients 
(A) PBMCs from 4 patients with MDH were cultured in the presence of piperacillin, meropenem 
or aztreonam for 6 days. Proliferation of lymphocytes was measured with the addition of [3H]-
thymidine in the last 16 hours. Results are shown as mean CPM of triplicate cultures, CPM = 
counts per minute. Coefficient of variation was consistently less than 20%. (B) The drug specific 
secretion of IFN-γ and IL-13 was determined and visualised by ELISpot assay. Well images from 
patient PBMCs which were cultured with drug for 48 hours. Plates were developed for spot 
visualisation according to manufacturer’s instructions. 
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1 21/M
Piperacillin
Aztreonam
Meropenem
MPE, fever
MPE
MPE
9
4
5
7
5
5
3
2
3
13.3
<2
8
2 26/M
Piperacillin
Aztreonam
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MPE
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MPE
5
2
3
2
1
3
3
4
5
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Flu-like symptoms, vomiting
9
6
6
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4
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1
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4
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Four drug-exposed tolerant patients were also recruited. These patients had 
previously been exposed to several courses of the three drugs with no reported 
allergies. In contrast to MDH patients, PBMCs from tolerant individuals were 
not stimulated to proliferate or secrete cytokines (Table 3.2). In the LTT, an SI 
greater than two is considered a positive response. Tolerant patient PBMCs did 
not yield positive LTTs with any of the three drugs investigated.    
 
Patient 
ID 
Age/sex Drug reaction Drug exposure 
LTT 
(maximum 
SI) 
1 28/M None 
Exposed to piperacillin, aztreonam and meropenem in the last 
three years. One year prior to his death, he required 73 days of 
antibiotic treatment. 
<2 
2 24/F None 
Exposed to piperacillin, aztreonam and meropenem in the last 
three years. In the last 12 months, the patient received 33 days of 
antibiotic treatment. 
<2 
3 21/M None 
Exposed to piperacillin, aztreonam and meropenem in the last 
three years. Averaged 81 days of antibiotic treatment per year. 
<2 
4 29/M None 
Exposed to piperacillin, aztreonam and meropenem in the last 
three years. Averaged 14 days antibiotic treatment per year. 
<2 
Table 3.2 Clinical details of tolerant patients 
LTT = lymphocyte transformation test, assay conducted with each drug (0.1 – 2mM). SI = stimulation 
index. 
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3.4.2 Generation of piperacillin, meropenem and aztreonam-
responsive T-cell clones 
To further investigate antigen-specificity of T-lymphocytes and the nature of 
the immune response in patients with MDH we generated drug-specific T-cell 
clones. One thousand six hundred and sixty-three T-cell clones were generated 
from the four allergic patients following PBMC stimulation with piperacillin, 
meropenem or aztreonam. Clones were tested for drug specificity with a total of 
one hundred and twenty-two found to display reactivity against piperacillin (n 
= 89), meropenem (n = 14), or aztreonam (n = 22). Figure 3.2 shows the 
proliferative response of representative clones.  
 
Figure 3.2 Activation of T-cell clones with piperacillin, meropenem and aztreonam 
Clones were co-cultured with antigen presenting cells and drug (2mM) for 72 hours. 
Proliferation was measured with the addition of [3H]-thymidine in the last 16 hours. 
Proliferative responses of representative clones are shown; piperacillin (n = 10), meropenem (n 
= 6) and aztreonam (n = 10). 
 
The majority of drug-responsive clones were CD4+, however CD8+ and dual 
positive CD4+/CD8+ clones were also generated from the allergic patients. The 
dual positive T-cell clones expressed high levels of both CD4 and CD8 proteins. 
The number of piperacillin, meropenem and aztreonam-responsive clones 
generated from each patient and their phenotypic qualities are summarised in 
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Table 3.3. Average CPMs for all specific clones for the drug in question are 
detailed alongside the standard deviations of all the specific clones. Due to the 
large range of responses seen (some clones were only just positive with an SI of 
2 -3, while others had SI’s greater than 20), when grouped together standard 
deviations were extremely large. If greater number of clones were used it may 
have been possible to group clones as weak, average and strong responders. 
However, no previous literature offers advice as to what SI/CPM constitutes a 
weak or strong response and would therefore be a matter of individual 
preference. I therefore looked at responses by individual clones rather than 
solely looking at grouped data. 
Fifty-five well growing CD4+ and CD8+ clones were selected from all four 
allergic patients and utilised in further assays. This pool of T-cell clones were 
used to characterise concentration-dependent proliferation, cytokine release 
and cross-reactivity. 
Table 3.3 Origin, phenotype and specificity of T-cell clones from allergic patients 
CPM = counts per minute.  
 
 
 
Patient
ID
Drug Clones 
tested (n)
Specific 
clones (n)
Proliferation (CPM)
Control                Drug (2mM)
Phenotype (%)
CD4 +                  CD8+           CD4+/CD8+
1 Piperacillin
Aztreonam
Meropenem
58
111
111
2
2
5
1422 ± 365
2043 ± 788
4340 ± 3988
10512 ± 7907
6683 ± 2042
11744 ± 11173
100
100
80
-
-
20
-
-
-
2 Piperacillin
Aztreonam
Meropenem
67
160
100
23
6
4
5477 ± 4137
3529 ± 1761
1046 ± 441
36004 ± 23732
15711 ± 19623
2399 ± 938
78
65
100
9
17
-
13
17
-
3 Piperacillin
Aztreonam
Meropenem
144
216
72
16
13
1
8133 ± 4353
8984 ± 5963
3504
53954 ± 18612
23323 ± 12356
9550
50
84
100
50
8
-
-
8
-
4 Piperacillin
Aztreonam
Meropenem
216
208
200
48
1
5
2134 ± 2412
6867
3795 ± 2827
24461 ± 18542
33942
11493 ± 9648
88
100
100
6
-
-
6
-
-
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3.4.3 Drug-antigen specificity of T-cell clones 
Piperacillin, meropenem and aztreonam-responsive CD4+ and CD8+ T-cell 
clones were co-cultured with drug and EBV-transformed B-cells used as APCs. 
Clones proliferated in a drug-concentration dependent manner with maximal 
responses detected between 0.5 and 2mM (Figure 3.3). Fifty-five clones were 
tested for reactivity against piperacillin, meropenem and aztreonam and 
responses to each drug were found to be highly drug specific. Clones were 
stimulated to proliferate (Figure 3.3A) and release IFN-γ (Figure 3.3B) in the 
presence of the drug to which the PBMC was originally cultured to generate the 
T-cell clone, but not to the other β-lactam antibiotics. Essentially, a piperacillin-
responsive clone, generated via PBMC culture with piperacillin and subsequent 
serial dilution is piperacillin-specific and will not be stimulated by the other 
drugs investigated; meropenem and aztreonam. This specificity was also 
observed in meropenem and aztreonam-responsive T-cell clones. 
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Figure 3.3 Cross reactivity of piperacillin, meropenem and aztreonam-responsive T-cell clones 
T-cell clones were co-cultured with APCs and drug (0.1 – 2mM) with culture medium serving as 
negative control. (A) Proliferative responses were determined by [3H]-thymidine incorporation 
which was added in the last 16 hours of the experiment. Results are shown as mean CPM of 
triplicate cultures. Six representative clones are shown. Coefficient of variation was consistently 
less than 20%. CPM = counts per minute. (B) The drug specific secretion of IFN-γ was 
determined and visualised by ELISpot assay. Well images from patient PBMCs which were 
cultured with drug for 48 hours. Plates were developed for spot visualisation according to 
manufacturer’s instructions. 
 
 
 
 
0 10000 20000 30000 40000
1
3
5
7
9
11
13
0 10000 20000 30000 40000
1
3
5
7
9
11
13
0 5000 10000 15000 20000
1
3
5
7
9
11
13
0 2000 4000 6000 8000 10000
1
3
5
7
9
11
13
0 5000 10000 15000 20000 25000
1
3
5
7
9
11
13
0 20000 40000 60000
1
3
5
7
9
11
13
Piperacillin Meropenem Aztreonam
Proliferation (cpm x 103)
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
0
.1
.5
1
2
.5
1
2
.5
1
2
0
1
2
1
2
1
2
0
1
2
1
2
1
2
.1
.5
.1
.5
0
1
2
1
2
1
2
.1
.5
0
1
2
1
2
1
2
.1
.5
0
1
2
1
2
1
2
.1
.5
Piperacillin clone
0
Piperacillin 
0.5 mM
Piperacillin 
1 mM
Piperacillin 
2 mM
Aztreonam
1 mM
Meropenem
1 mM
Aztreonam clone
0
Aztreonam
0.5 mM
Aztreonam
1 mM
Aztreonam
2 mM
Piperacillin
1 mM
Meropenem
1 mM
Meropenem clone 
0
Meropenem
0.5 mM
Meropenem
1 mM
Meropenem
2 mM
Aztreonam
1 mM
Piperacillin
1 mM
B
A
Piperacillin clones Meropenem clones Aztreonam clones
.5
.5
.5
.5
.5
Chapter 3 
99 
 
3.4.4 Elucidation of haptenic structures by mass spectrometric 
analysis of modified peptides 
Previous work in our department was performed to fully characterisee the 
haptens formed from piperacillin binding to HSA and for comparative purposes 
the MS/MS spectrum of the 182LDELRDEGKASSAK195 peptide modified at 
Lys190 with the cyclised form of piperacillin has been included in Figure 3.4A 
(Whitaker et al., 2011b). The chemical structure of cyclised piperacillin is 
shown in Chapter 4, Figure 4.8. We wanted to utilise these techniques to 
characterise meropenem and aztreonam derived haptens. HSA was exposed to 
meropenem in vitro at a molar ratio of 20:1 (drug to protein) to characterize 
drug haptens. Careful examination of raw MS/MS data revealed the additions of 
four different masses (339,383, 396 and 440 amu) to tryptic peptides exhibiting 
a missed cleavage at lysine residues. Peptide 182LDELRDEGKASSAK195 with a 
mass increase of 383 amu is shown in Figure 3.4B as an example. The retention 
times of the four different peptide species were identical however suggesting all 
four had been derived from in-source fragmentation of peptide plus 440 amu.  
Mass addition of 339 and 383 amu were associated with drug-specific fragment 
ions of m/z 175 and 205, whereas mass additions of 396 and 440 were 
associated with fragment ions of m/z 205 and 232. These data together with the 
MS3 spectra for the three fragment ions (Figure 3.5) were interpreted as 
follows. The drug hapten of 440 amu corresponded to the covalent binding of 
the parent meropenem iodoacetylated on the nitrogen at the 1’ position (Figure 
3.6). This gave rise to the immonium ion of Lysine modified with the 3-methyl-
3H-pyrrole ring of meropenem (m/z 205) and the fragment ion of m/z 175 plus 
acetamide (232 amu; S-(5-(dimethylcarbamoyl)-pyrrolidin-2-yl) 
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carbamothioate). In-source cleavage of the acetamide group from the drug 
resulted in the drug hapten of 383 amu (440 minus 57 amu). In-source cleavage 
of the propanol at position 6, the carboxylic acid at position 2, or the 
trimethylyamine group at position 9’ from the iodoacetylated drug hapten gave 
rise to the observed mass addition of 396 amu (440 minus 44) and the same 
fragment ions as observed for the hapten of 440 amu. Finally the mass addition 
of 339 amu was derived from the cleavage of both the acetamide group and the 
propanol, carboxylic acid, or trimethylamine group from the hapten of 440 amu 
(440 minus 57 minus 44) and the same fragment ions as observed for the 
hapten of 383 amu. 
Chapter 3 
101 
 
Figure 3.4 Mass spectrometric characterisation of piperacillin, meropenem and aztreonam 
haptens formed on HSA 
Representative MS/MS spectra of peptide 182LDELRDEGKASSAK195 modified on LYS190 with 
(A) piperacillin (B) meropenem and (C) aztreonam.  
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Due to cleaving by trypsin, the same peptides do not appear in the MS analysis 
of unmodified HSA, so it can be difficult to compare to drug-modified protein. 
Instead of LDELRDEGKASSAK there will be shorter peptide fragments seen, for 
example; LDELR, DEG and ASSAK. These are too small to be seen with our 
standard MS methods. However, the MS/MS spectra of the longer peptide can 
be seen 182LDELRDEGK190 is shown in Figure 3.4.1. 
 
 
Figure 3.4.1 MS/MS spectra of peptide 182LDELRDEGK190from unmodified HSA 
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Figure 3.5 Mass spectrometric characterisation of meropenem haptens formed on HSA 
Representative MS3 spectra of characteristic fragment ions from meropenem-modified peptides. 
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Figure 3.6 Scheme detailing structure of proposed haptens formed via covalent binding of 
meropenem to HSA 
Meropenem forms a hapten by the opening of the β-lactam ring and nucleophilic attack by 
protein lysine residues, resulting in a mass increase of 383 amu for each modified lysine 
residue. In-source fragmentation of this hapten results in the loss of the propanol at position 6, 
the carboxylic acid at position 2, or the trimethylamine group at the 9’ position (loss of 44 amu; 
mass increase of 339 amu). The chemistry is complicated by the methods conventionally used 
to process proteins for mass spectrometry analysis, namely iodoacetylation of cysteine. The 
drug itself was shown to be iodoacetylated, resulting in two further haptens of 440 and 396 
amu.  
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HSA was modified with aztreonam in vitro at a molar ratio of 50:1 (drug to 
protein) to characterise potential haptenic structures. This higher ratio 
provided higher levels of HSA modification necessary for our experiments. 
Nucleophilic attack by the protein lysine residues and opening of the β-lactam 
ring was the pathway predicted for the covalent binding of aztreonam. This 
would lead to a mass increase on the peptides of 435 amu (Figure 3.8). The 
MS/MS spectrum of the peptide 182LDELRDEGKASSAK195 modified with 
aztreonam confirms this (Figure 3.4C), with a mass addition of 435 amu to the 
peptide plus the presence of partial drug hapten of 338 and 236 amu illustrated 
in Figure 3.7. We propose the former is formed following the loss of the sulfonic 
acid and amino groups from position 1’’’ (Figure 3.8, a → b) and that the latter is 
formed following the further loss of 2-hydroxy-2methylpropanoic acid (Figure 
3.8, c → d). The MS3 spectrum of characteristic fragment ion from aztreonam-
modified peptides is shown in Figure 3.7 below. 
 
 
Figure 3.7 Mass spectrometric characterisation of aztreonam haptens formed on HSA 
Representative MS3 spectra of characteristic fragment ions from aztreonam-modified peptides. 
 
 
m/z 237
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Figure 3.8 Scheme detailing structure of proposed haptens formed via covalent binding of 
aztreonam to HSA 
Aztreonam forms a hapten by opening of the β-lactam ring, resulting in a mass increase of 435 
amu for each modified Lysine residue. The hapten is labile in the mass spectrometer leading to 
the detection of partial haptens in the MS/MS spectra of modified peptides of 338 and 236 amu. 
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3.4.5 Time and concentration dependency of HSA modification with 
piperacillin, meropenem and aztreonam 
Using LC-MRM-MS we have previously characterised the time and 
concentration dependency of the modification of HSA with piperacillin 
(Whitaker et al., 2011b). After normalisation for total ion count, the MRM peak 
areas for the modified peptides were determined in order to assess changes in 
the relative abundance of those peptides; this is the epitope profile. This 
revealed that the levels of covalent binding increased with an increased molar 
ratio of drug to protein and with incubation time up to 72 hours (Figure 3.9C 
and 3.9D). Piperacillin consistently bound to Lysine at positions 190, 432 and 
541 in vitro and in vivo and drug modifications were detected at an additional 
10 out of the 59 Lysine residues in HSA in vitro (Figure 3.9B). These are 
nucleophillic addition reactions, and whilst other nucleophiles exist on HSA (i.e. 
cysteine and histidine), only lysine forms stable adducts with β-lactams.  
A similar approach was adopted to characterise the HSA binding profiles of 
meropenem and aztreonam. Beginning with meropenem, the MRM peak areas 
for all four hapten signals were summed for each of the modified peptides. Up to 
7 of the 59 Lysine residues in HSA were modified with meropenem after 24 
hours (Figure 3.9B). The stability of meropenem in aqueous solution at 37°C is 
limited so after 8 hours little active drug will be present in the drug HSA 
incubations (Berthoin et al., 2010; Keel et al., 2011). Similarly, increasing the 
molar ratio of drug to protein up to a ratio of 20:1 resulted in an increase in 
signal for each modified peptide. However, no further increase in covalent 
binding could be detected at molar ratios exceeding 20:1 (Figure 3.9C). 
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Meropenem is sparingly soluble in water, limiting the maximal drug 
concentration available for reaction with the protein in aqueous solution.  
Figure 3.9 Chemical characterisation of piperacillin, meropenem and aztreonam-HSA covalent 
binding profiles 
A. Hapten structures of the three drugs as bound to protein (prot). B. Epitope profiles showing 
the lysine residues in HSA which had been covalently modified by the three drugs in vitro, as 
determined by LC-MRM-MS/MS. C. Concentration dependency of total drug modification of HSA, 
as determined by LC-MRM-MS/MS. D. Time dependency of total drug modification of HSA, as 
determined by LC-MRM-MS/MS. 
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The modification of HSA by aztreonam was detected at 11 Lysine residues after 
24 hours at a drug to protein ratio of 20:1. The levels of modification increased 
progressively with time and increasing drug concentrations (Figure 3.9C and 
3.9D).  
Whilst the same subset of Lysine residues are targeted by all of the β-lactam 
drugs investigated here, the relative abundance of modification at each Lysine 
differs between the three drugs. Lys190 was a primary target for modification 
with piperacillin, meropenem and aztreonam: the high signal observed was 
probably not due to the innate greater ionization efficiency of the peptide. We 
have reached this conclusion as observations from other work in the 
department has seen the same peptide modified with benzylpenicillin or 
ampicillin, further β-lactam antibiotics, detected at low relative signal.  
3.5 Discussion 
It is hypothesised that β-lactam antibiotics form covalent bonds with lysine 
residues on proteins in drug-exposed patients leading to the generation of 
antigenic determinants (Batchelor et al., 1965; Jenkins et al., 2009a; Whitaker et 
al., 2011b). Several studies have shown that processing of β-lactam HSA 
conjugates liberates peptide sequences that stimulate T-cells, although it must 
be noted that naturally occurring drug-modified peptides eluted from MHC have 
yet to be characterised (Brander et al., 1995a; Padovan et al., 1997; Whitaker et 
al., 2011b). In vitro, β-lactam antibiotics can bypass the requirement for protein 
processing by binding directly to MHC-associated peptides (Brander et al., 
1995a; Padovan et al., 1996). Cross-reactivity studies using PBMCs and T-cell 
clones from penicillin allergic patients have revealed a plethora of drug 
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response profiles (Mauri-Hellweg et al., 1996; Rozieres et al., 2009; Sachs et al., 
2004). In most allergic patients, the peptide-bound penicilloyl ring structure is 
thought to represent the main structural determinant for T-cells, as β-lactams 
that contain a different core structure do not stimulate a response. However, 
individual T-cells can display a range of side-chain reactivity as penicillin, 
piperacillin and flucloxacillin specific T-cell clones have previously been shown 
to be cross reactive.  
 
Figure 3.10 Penicillin derivatives including the penicilloyl ring structure 
 
Indeed, cross-reactive clones can be stimulated with several penicillins, some of 
which the allergic patient will not previously have been exposed to. In contrast, 
other clones are incredibly drug antigen-specific. Our recent studies with mono-
allergic patients revealed that piperacillin-responsive PBMCs and clones 
proliferated and secreted a mixed panel of cytokines including IFN-γ and IL-13 
following drug stimulation. Interestingly, piperacillin-responsive clones were 
not stimulated with other penicillins, whereas several penicillins stimulated 
flucloxacillin-responsive T-cells (El-Ghaiesh et al., 2012; Monshi et al., 2013; 
Nucleophilic 
attack opens up 
β-lactam ring
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Whitaker et al., 2011b). Collectively, these data suggest that different antigenic 
determinants derived from penicillins can be accommodated within the MHC 
binding cleft without interfering with the T-cell receptor binding interaction. 
However, the degree of cross-reactivity observed is drug and patient-specific 
and might be influenced by previous drug exposure. Unfortunately this 
information was not available to us at the time, although it may be possible to 
retrieve in the future as part of an ongoing prospective study currently 
underway at the University of Liverpool. Thus, there is a need to further 
delineate the structural features that determine T-cell receptor cross-reactivity.  
Our investigation focussed on patients with a history of allergic reactions to 
piperacillin, meropenem and aztreonam. Piperacillin is a member of the 
penicillin class of antibiotics, which contains β-lactam and thiazolidine ring 
structures. Meropenem, a carbapenem licensed by the FDA in 1996, contains 
similar ring structures but the sulphur in the thiazolidine ring has been 
replaced with a carbon atom, and unsaturation has been introduced. Finally, the 
monobactam aztreonam is unusual in that the β-lactam ring is not fused to 
another ring structure. Superficially, the free drugs would appear to show some 
structural similarities, most notably the presence of the β-lactam ring, and these 
have been used previously to explain the observed immunological cross-
reactivity within this class of antibiotics (Kishiyama et al., 1994; Padovan et al., 
1996; Pham et al., 1996; Zhao et al., 2002). However, characterisation of the 
piperacillin, meropenem and aztreonam haptens formed following ring opening 
and binding to protein lysine residues reveals markedly different structures 
(Figure 3.9A) which it would be difficult to argue could drive a cross-reactive 
response. The chemical differences are further highlighted by the fact that the 
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drugs favour different covalent binding sites in our model protein, HSA (Figure 
3.9B). This suggests that an alternative explanation is required for the multiple 
drug allergies observed in these patients.  
 
To this end, T-cells from patients with MDH were used as a biological read-out 
of chemical cross-reactivity. Our objectives were to determine whether it was 
possible to detect lymphocyte responses to each drug in the allergic patients 
and to analyse T-cell receptor cross-reactivity through the generation of T-cell 
clones. Symptoms of the drug-induced immune reactions were classified 
according to patient’s medical records. Patients 1, 2 and 4 developed 
maculopapular exanthema and/or non-immediate urticarial eruptions against 
the 3 drugs (Table 3.1). Patient 3 developed less-classical symptoms of drug 
allergy (arthralgia, nausea and vomiting). Reactions were relatively mild, but in 
every case treatment had to be discontinued. Each patient received and 
tolerated several courses of the individual drugs prior to the allergic reaction.  
The LTT and IFN-γ ELISpot are the biological assays most commonly applied to 
diagnose drug allergy in vitro (Pichler et al., 2004; Rozieres et al., 2009). 
Previous studies with piperacillin (mono) allergic patients revealed almost all 
drug-responsive T-cells proliferate and secrete IFN-γ following drug 
stimulation (El-Ghaiesh et al., 2012). Utilising both approaches we have shown 
that piperacillin, meropenem and aztreonam stimulate PBMC from allergic 
patients, but not drug-exposed tolerant controls, to proliferate and secrete 
cytokines. These data confirm our previous findings with piperacillin allergic 
patients and demonstrate that T-cell responses are also readily detectable with 
meropenem and aztreonam. The drug-specific response was dose-dependent 
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and in the case of one patient, who was recalled, LTT data was reproducible. 
PBMCs were stimulated with similar concentrations of the drugs. For three of 
the patients, piperacillin stimulated the strongest proliferative response and the 
highest levels of IFN-γ secretion, in comparison to the other drugs (Table 3.1 
and Figure 3.1). The number of patients examined was limited due to time, 
however it is interesting to speculate that this may relate to intrinsic chemical 
reactivity and differences in the epitope profile of drug protein conjugates 
formed in vitro (Figure 3.2B). Although the absolute level of binding of each of 
the drugs to protein cannot be defined from the experiments presented here, 
the data show that piperacillin is more promiscuous in its binding profile 
suggesting a higher epitope density may be achieved (Figure 3.2B).  
Here we have established the range of piperacillin concentrations necessary to 
elicit a positive T-cell proliferative responses and characterised the hapten 
formed in vitro. However, we are yet to elucidate the threshold of piperacillin 
haptenation required to trigger an immune response. Quantification of 
piperacillin modified HSA and subsequent peptides would help relate this to 
functional T-cell activation. Quantifying levels of piperacillin hapten in patients 
will aid in determining the minimum quantity of piperacillin antigen required to 
provoke T-cell activation and immune responses. Using novel mass 
spectrometric methods we addressed this gap of knowledge in chapter 5. 
CD4+, CD8+ and CD4+/CD8+ T-cell clones were isolated from piperacillin, 
meropenem and aztreonam-stimulated PBMCs to explore T-cell receptor cross-
reactivity. CD4+/CD8+ clones expressed high levels of both proteins indicating 
they somehow evaded thymic deletion. Interestingly, the number of 
CD4+/CD8+  T-cells is known to increase in certain pathogenic conditions 
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including certain auto-immune disease and chronic inflammatory disorders 
such as atopic dermatitis (Bang et al., 2001). Using T-cell clones generated from 
the PBMCs of patients with MDH we measured antigen-specificity of the T-
lymphocytes using proliferation and cytokine release as readouts. No cross-
reactivity was observed in over 50 clones that were analysed (Figure 3.3). It 
may be possible that during the process of generating T-cell clones in vitro the 
clones were driven to become more specific to one particular drug; however 
this phenomenon had not been noted previously. Indeed, T-cells are more likely 
to cross-react with other drugs of related structures through epitope spreading. 
These data clearly demonstrate that non-immediate hypersensitivity reactions 
to different classes of β-lactam antibiotics in patients with cystic fibrosis are 
instigated not by cross-reactive T-cells, but through priming of naive T-cells 
against the different drug antigens. Daubner et al. have recently demonstrated 
that drug-responsive T-cells in certain patients with a history of multiple drug 
allergy reside in an in vivo activated (CD4+CD25dim, with elevated CD38 and 
PD-1) T-cell fraction (Daubner et al., 2012). It would be interesting to explore 
whether a similar phenotype of drug-responsive T-cells exist in patients with CF 
and multiple drug allergies, and whether increased numbers of such T-cells 
explains why multiple drug allergy is such a common occurrence in CF patients.    
Data from this chapter has shown that piperacillin, meropenem and aztreonam-
specific T-cell responses are detectable in CF patients with MDH and reactions 
are likely due to a primary immune response rather that T-cell cross-reactivity. 
Furthermore this has led to the characterisation of the complex haptenic 
structures on distinct lysine residues on HSA which provides a chemical basis 
for the drug specific T-cell response. 
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4.1 Introduction 
Antibiotic hypersensitivity is a major health concern for patients with CF. 
Hypersensitivity to β-lactam antibiotics occurs in up to 50% of patients with CF 
compared to an incidence of 0.5-10% in the general population (Burrows et al., 
2007; Parmar et al., 2005; Pleasants et al., 1994). Piperacillin, commonly used 
as part of a treatment regimen for patients with CF, is one such culprit drug 
implicated in drug hypersensitivity. Symptoms of hypersensitivity include MPE, 
fixed drug eruptions, fever and flu-like symptoms.  Despite the high rates of 
hypersensitivity, continuation of β-lactam therapy is vital for these patients. The 
nature of CF means that mucus can quickly accumulate in the airways, an 
environment which bacteria exploit leading to frequent chronic infections. The 
condition of the lungs is therefore critically dependent on the sustained use of 
antibiotics.  
Antibiotics are most commonly delivered to patients with CF via an intravenous 
injection resulting in rapid accumulation of the drug. In the case of piperacillin, 
patients are typically given 4.5g every 6-8 hours for 2 weeks 
(CysticFibrosisTrust, 2009). This regimen is in stark contrast to the lower oral 
dose given to the general population where for acute bronchitis 500mg 
amoxicillin, three times a day for 5 days is recommended (NICE, 2014). The 
increased incidence of β-lactam hypersensitivity in patients with CF provides a 
pool of individuals whereby the mechanisms of drug antigenicity and 
immunogenicity can be investigated.  
The hapten hypothesis is one widely accepted theory for the development of 
hypersensitivity reactions. It proposes that small molecules form novel 
antigenic determinants through covalent binding to host proteins and that this 
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binding interaction determines whether exposure will result in an aberrant 
immune response (Weltzien et al., 1996b).  Drugs, including the β-lactam 
antibiotics, are thought to activate immune cells through covalent modification 
of proteins (Padovan et al., 1997; Weltzien et al., 1996b). β-lactam antibiotics 
form covalent bonds with lysine residues on proteins (Brander et al., 1995a; 
Padovan et al., 1997). The nature of the binding interaction is well established 
with binding sites identified in model proteins with numerous drugs including 
penicillin G, piperacillin, amoxicillin and flucloxacillin (Batchelor et al., 1965; 
Jenkins et al., 2009a; Levine et al., 1961b; Meng et al., 2011a; Yvon et al., 1990). 
The β-lactam ring is targeted by nucleophilic lysine residues on proteins. 
Subsequently, the ring opens allowing the binding of the penicilloyl group and 
the formation of a drug-protein conjugate with the potential to act as an antigen 
and activate specific T-cells (Batchelor et al., 1965; Levine et al., 1961b).  
Recent advances in mass spectrometry methods have allowed the detailed 
characterisation of drug modified amino acid residues on proteins, both in vivo 
in plasma samples of  hypersensitive patients and in vitro (Whitaker et al., 
2011b). Penicillin and piperacillin albumin adducts have been shown to 
stimulate immune cells (Brander et al., 1995a; El-Ghaiesh et al., 2012). 
Furthermore, El-Ghaiesh et al have shown that the activation of T-cells with 
piperacillin-HSA conjugates is dependent on antigen processing within the 
antigen presenting cell. The use of solvents including methanol or acetone to 
precipitate drug-bound proteins, dialysis or chromatography to remove free 
drug are traditional methods in the generation of drug-protein conjugates. New 
methods continue to emerge though, specifically the use of centrifugal filters or 
“spin column” has assisted in the generation of protein adducts that are 
Chapter 4 
117 
 
“essentially” free of parent drug. With this method there is an absence of solvent 
in the purification process which has the potential to alter protein structure. In 
this chapter, in addition to using a previously employed method within the 
department for the generation of a synthetic piperacillin-HSA conjugate, we 
used a new method involving centrifugal filters to generate a second synthetic 
conjugate to investigate further the role of covalent binding in the development 
of drug hypersensitivity. 
The human plasma proteome is complex (over 10,000 proteins - 
www.plasmaproteomedatabase.org/) so that there is the potential for large 
numbers of drug-protein adducts and drug modified peptides to be generated. 
However, HSA is considered as a potential candidate of an endogenous protein 
carrier for a number of reasons. Primarily,  HSA is the most abundant protein in 
human plasma accounting for 57-71% w/w of total protein (Greenough et al., 
2004). 16-22% of an intravenous dose of piperacillin is non-covalently bound to 
plasma proteins and the majority of covalently bound penicilloyl groups in 
plasma are bound to HSA (El-Ghaiesh et al., 2012). Furthermore, human serum 
is also commonly used as a supplement to cell culture media and has been 
shown to be modified by β-lactams including piperacillin in situ (Bertucci et al., 
2002; Nerli et al., 1997; Whitaker et al., 2011b).  
Though derivatives of the penicillin class of β-lactam antibiotics can form 
antigenic determinants through binding to cellular proteins, the rate at which 
this binding occurs is much slower in comparison to serum proteins (Warbrick 
et al., 1995). Indeed previous work in the department found no evidence for the 
formation of cellular adducts with piperacillin, albumin was the primary drug 
target (El-Ghaiesh et al., 2012). Nevertheless, we cannot disregard binding to 
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cellular proteins as traditional methods for the detection of modified proteins 
may not be sufficiently sensitive, or indeed inappropriate cells/proteins may 
have been studied. Recently, using confocal fluorescence microscopy and 
biotinylated amoxicillin, the higher sensitivity of detection revealed 
intracellular protein adducts and modified proteins in a range of cell lines 
(Ariza et al., 2014). However, as the main target protein for penicillins, HSA was 
used as a model protein to explore the role of piperacillin-protein conjugation 
in the activation of piperacillin-specific T-cells.  
4.2 Aims and Hypothesis 
There are limited studies that characterise the chemistry of drug-protein 
binding and the pathways which link antigen formation to the immune 
response seen in patients. This chapter aims to begin to bridge this gap of 
knowledge through: 
(1) Generation and characterisation of piperacillin specific T-cell clones from 
hypersensitive patients to investigate the mechanisms involved in piperacillin 
protein binding, antigen presentation and T-cell stimulation.  
 (2) Generation of synthetic piperacillin albumin conjugates using new and 
established techniques and assessment of their ability to activate T-cells. 
From work previously conducted in this department, and by other groups 
looking at drug-protein binding I propose that: 
(1) Protein binding is an essential part of the mechanism for piperacillin 
hypersensitivity  
(2) Synthetic protein conjugates (made by either method) will stimulate 
piperacillin specific T-cell clones   
Chapter 4 
119 
 
4.3 Methods 
The methods used are described fully in Material and Methods, Chapter 2. A 
brief experimental outline is detailed below. 
 
Scheme 4.1 Experimental plan and methods used in this chapter 
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4.4 Results  
4.4.1 Piperacillin specific T-cell clones  
PBMCs from piperacillin hypersensitive patients (patient details shown in Table 
4.1) were used to generate 1,699 T-cell clones of which over 1,000 were specific 
to piperacillin (Table 4.2). A pool of 123 antigen-specific T-cell clones were 
expanded for use in assays to assess function and to investigate piperacillin 
antigenicity and immunogenicity. These experiments took place over the course 
of a year and clones from each patient used, was dependent on availability at 
the time. Owing to the large number of clones generated from patient H3 only a 
small subset were expanded and their phenotype determined. Those not 
phenotyped were frozen and stored. The majority of the T-cell clones, 91%, 
were CD4+ with 7% found to be CD8+ and 2% double positive. CD4+ T-cell 
clones were used in subsequent experiments. Clones proliferated in response to 
piperacillin in a dose dependent manner and secreted significant amounts of 
the Th1 cytokine IFN-γ when exposed to the drug. A sample of piperacillin 
specific clones highlighting proliferative responses, cytokine secretion and 
characteristic phenotypes are shown in Figures 4.1 and 4.2. 
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Table 4.1 Patient characteristics  
Clinical details of piperacillin-hypersensitive CF patients. Tazocin = medicine made up of the 
antibiotic piperacillin and the β-lactamase inhibitor tazobactam, MPE = maculopapular 
exanthema.   
 
 
Table 4.2 Number and phenotype of T-cell clones generated 
T-cell clones were generated from 6 piperacillin-hypersensitive patients with CF. a specific 
clones generated by colleagues within the department and kindly donated for experimental 
work. Flow cytometry was used to determine phenotype of T-cells.  
 
 
 
 
Patient Age/ 
Gender
Drug Reaction Time from treatment 
to reaction (days)
Time since reaction 
(years)
Number of courses 
prior to reaction
H1 18/M Tazocin MPE/Fevers 9 7 3
H2 17/M Piperacillin Flu-like illness 2 5 5
H3 19/M Tazocin MPE/Fever 2 0.5 4
H4 23/M Tazocin MPE 11 4 9
H5 26/M Tazocin MPE 5 2 3
H6 28/F Tazocin Fever/Arthralgia 9 6 7
Patient ID
Clones tested 
(n)
Specific clones
(n)
Phenotype
CD4 +                  CD8+           CD4+/CD8+
H1 7a 2 2 - -
H2 58a 12 12 - -
H3 1632
1412 
(100 expanded, 
50 phenotyped)
48 2 -
H4 21a 12 12 - -
H5 67 21 19 1 1
H6 208a 26 19 5 2
Total 1993 1485 112 (91%) 8 (7%) 3 (2%)
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Figure 4.1 Antigen specific proliferation and phenotype of T-cell clones  
(A) T-cell clones were co-cultured with antigen presenting cells and piperacillin (0 – 4mM) for 
96 hours. Proliferation was measured with the addition [3H]-thymidine in the last 16 hours. 
Each data point represents mean [3H] incorporation from 43 piperacillin specific clones with 
mean cpm and range shown in (B) *** = P value < 0.001 
(C) Flow cytometry showing phenotype of T-cells. CD4+ phenotype was observed for majority 
of T-cell clones. Representative traces for CD4+ and CD8+ T-cell clones are shown here. 
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Figure 4.2 T-cell clones secrete IFN-γ in a dose-dependent manner  
Piperacillin specific secretion of IFN-γ was determined and visualised by ELISpot assay. Plates 
were pre coated with human IFN-γ antibody overnight. T-cell clones were co-cultured with 
APCs and piperacillin (0 – 2mM) for 48 hours at 37°C. The plates were then developed 
according to manufacturer’s instructions. Once dry spots were visualised (B) and counted (A) 
using AID ELISpot reader. 7 representative clones shown. SFU = spot forming units.  
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4.4.2 T-cell clones are stimulated by piperacillin pulsed antigen 
presenting cells 
To investigate the relationship between time-dependent piperacillin protein 
binding and the T-cell response, antigen presenting cells (APCs) were pre-
incubated, i.e. pulsed, with piperacillin for 1 – 48hrs to allow antigen formation 
and processing to occur before use in T-cell proliferation assays. Drug-exposed 
EBV-transformed B-cells were washed three times to remove unbound 
piperacillin prior to incubation with piperacillin-specific T-cell clones. T-cell 
clones were then incubated with pulsed APCs in the absence of soluble drug for 
72 hours with [3H] thymidine (0.5µCi) added in the last 16 hours of the 
incubation to assess lymphocyte proliferation. Clones were activated to 
proliferate with APCs pulsed with piperacillin for 24 and 48 hours. In contrast, 
little proliferation was detected at the earlier time points of 1 and 4 hours. The 
stimulatory response observed after a 24 hour APC pulse was reproducible and 
comparable to that with soluble drug (Figure 4.3B). This pattern of was 
observed with multiple clones generated from two piperacillin allergic patients 
(Figure 4.3A). Representative data from two clones are shown in Figure 4.3B.     
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Figure 4.3 T-cell clones are stimulated by piperacillin pulsed antigen presenting cells  
EBV-transformed B-cells were pulsed with piperacillin (2mM) and culture medium as a control 
for 1, 4, 24 and 48 hours. Cells were washed three times to remove unbound drug before co-
culture with T-cell clones for 72 hours with [3H]-thymidine added in the last 16 hours to assess 
proliferation.  (A) 4 clones from two hypersensitive patients were cultured with piperacillin 
pulsed APCs and proliferation quantified by [3H]-thymidine incorporation. (B) Individual data 
from 2 representative clones with soluble drug included as a comparator are shown (CPM = 
counts per minute).  
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4.4.3 Processing is required to activate piperacillin specific T-cell 
clones 
In order to investigate the role of antigen processing in the activation of 
piperacillin-specific clones, APCs were fixed with 0.025% glutaraldehyde to 
inactivate protease activity prior to co-incubation with piperacillin-specific T-
cell clones and soluble drug. T-cell clones were not stimulated to proliferate 
when cultured with piperacillin (Figure 4.4).  
 
Figure 4.4 Processing is required for the activation of T-cell clones  
T-cell clones (n = 9) were incubated with piperacillin (0 - 2mM) and with either irradiated 
autologous APCs (control APCs, light blue boxes) or APCs which had undergone glutaraldehyde 
fixation (fixed APCs, dark blue bars). Proliferation was determined by [3H]-thymidine 
incorporation, CPM = counts per minute. ** P < 0.01, ***P < 0.001 
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A minority of clones (approximately 20%) were activated with piperacillin in 
the absence of APCs (Figure 4.5). These clones were excluded from mechanistic 
analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Certain T-cell clones are activated in the absence of APCs. 
A small proportion of clones (~ 20%) were activated with piperacillin alone. Their proliferative 
capacity in the absence of APCs is shown here alongside control conditions with APCs for 
comparative purposes. T-cell clones were cultured with 2mM piperacillin and autologous 
irradiated APCs (standard proliferation assay) or without APCs for 72 hours. [3H]-thymidine 
was added in the last 16 hours to determine cell proliferation. CPM = counts per minute. 
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4.4.4 Conjugates 
The data presented in Figures 4.3 – 4.5, show T-cell proliferative responses are 
antigen processing dependent and involve the formation of a drug protein 
adduct. To explore whether a synthetic model drug protein adduct activates 
clones, piperacillin-modified HSA was synthesised off-line and added to the T-
cell assays as a source of antigen in the absence of free drug. Synthetic albumin 
conjugates modified with piperacillin have previously been shown to stimulate 
piperacillin specific T-cell clones (El-Ghaiesh et al., 2012). New methods for the 
purification of conjugates have since been developed in which the level of free 
drug is more stringently controlled and measured. With these more defined 
conjugates, it was possible to investigate mechanisms of T-cell activation in 
greater detail.   
4.4.4.1 Conjugate generation 
Two methods for the generation of synthetic piperacillin-HSA conjugates were 
used and applied for experiments in this chapter. Piperacillin was incubated 
with HSA at 37°C for 24 hours in phosphate buffer to generate synthetic drug-
protein conjugates. Conjugates were then transferred to 15ml spin columns and 
washed to remove free drug. Hereafter the synthetic piperacillin-HSA 
conjugates and HSA control conjugates (incubated with phosphate buffer alone) 
generated via this method shall be referred to as conjugate 1. Conjugate 
generated and purified via MeOH precipitation is referred to as conjugate 2. 
Detailed methods are described in Material and Methods Chapter 2 2.5.14. 
Figure 4.7 briefly summarises methods and profile of conjugates and the 3-D 
model illustrating sites of modification by piperacillin are shown in Figure 4.6.  
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Figure 4.6 Model of HSA with major piperacillin binding sites at specific lysine residues 
 
Figure 4.7 Generation of synthetic piperacillin-HSA conjugates 
Brief outline of conjugate generation is detailed in the scheme above. The epitope profile of each 
conjugate detailing drug modification sites is also shown. 
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Analysis by mass spectrometry confirmed modification of HSA by piperacillin in 
both sets of conjugates generated. Extrapolating the known chemistry of β-
lactam antibiotics, protein modification would be predicted to occur through 
nucleophilic attack of the β-lactam ring, ring opening and covalent binding to 
protein lysine residues. A hapten with the predicted mass of 517 amu, formed 
from the direct adduction of piperacillin, was identified (cyclised hapten [1], 
Figure 4.8). A second hapten of mass 535 amu was also detected. This is thought 
to have been formed through hydrolysis of the 2,3-dioxopiperazine ring 
(hydrolysed hapten [2] Figure 4.8) 
 
 
 
 
 
 
 
 
 
Figure 4.8 Chemical structures of piperacillin and the resultant cyclised and hydrolysed forms of 
haptens. The dominant fragmentation sites induced by MS are also detailed. 
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The tandem MS spectra of the tryptic peptide 182LDELRDEGK*ASSAK195 
modified with the cyclised hapten is shown is shown in Figure 4.9A. A triply 
charged ion at m/z 679.25 was observed, corresponding to the peptide mass 
with a mass addition of 517 amu; (peptide mass =679.25X3-3=2034.75, 
Δm=2034.75-1517.77=517). The most characteristic fragmentation ions at m/z 
160 and 143 (circled) indicate the incorporation of piperacillin with this 
peptide.  The presence of the abundant ion at m/z 868 which corresponds to 
the doubly charged peptide mass plus 216 (hapten mass after loss of 
thiazolidine ring (minus 159) and dioxopiperazine ring (minus 142)) provides 
further evidence the hapten of mass 517 amu was formed by addition to the β-
lactam ring rather than the dioxopiperazine ring.  
The mass spectrum of the peptide modified with the hydrolysed hapten which 
has a mass shift of 535 is shown in Figure 4.9B. It highlights the most 
characteristic fragment ions were detected at m/z of 106 and 160. In a similar 
manner to the cyclised hapten, the ion at m/z 867.8 confirmed that nucleophilic 
addition took place at the β-lactam ring, whilst hydrolysis occurred at the 2,3-
dioxopiperazine ring.  
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Figure 4.9 Mass spectrometric characterization of piperacillin haptens formed with HSA in vitro. 
Representative MS/MS spectrum of the albumin peptide 182LDELRDEGK*ASSAK195 modified at 
Lys190 by the cyclised and hydrolysed haptens, (A) and (B) respectively.  
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Time and concentration dependent piperacillin-modified HSA was also detected 
by western blot (Figure 4.10A). The anti-penicillin antibody, bound to the 
protein, is detectable at the band corresponding to a molecular mass of 66 kDA 
(albumin), This was confirmed by MRM-MS (Figure 4.10B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Piperacillin-HSA binding is time and concentration dependent. 
(A) Western blot with anti-drug antibody confirmed piperacillin modification and showed time 
and concentration dependency. (B) MS analysis of time and concentration dependent 
piperacillin binding. Combined signal for cyclised and hydrolysed adducts are shown. Conjugate 
at 50:1 ratio was used to investigate time dependency. 
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The epitope profiles of conjugate 1 and conjugate 2 were strikingly similar 
(Figure 4.11). Modification of HSA by piperacillin at the Lysine at positions 190, 
432 and 542 produced the strongest MRM signals. The hapten was detected at 
13 out of 59 lysine residues in HSA for both the hydrolysed and cyclised forms 
of piperacillin. Table 4.3 details the HSA derived tryptic peptides which contain 
lysine residues modified by piperacillin. 
 
 
Figure 4.11 Epitope profile of piperacillin-HSA conjugates.  
Epitope profile of the lysine residues of piperacillin-modified HSA is shown. Normalised AUC of 
cyclised and hydrolysed haptens.   
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Lysine residue Peptide 
Cyclised  
hapten 
Hydrolysed 
hapten 
4 DAHK*SEVAHR   
12 FK*DLGEENFK   
137 K*YLYEIAR   
162 YK*AAFTECCQAADK   
190 LDELRDEGK*ASSAK   
195 ASSAK*QR   
199 LK*CASLQK   
212 AFK*AWAVAR   
351 LAK*TYETTLEK   
432 NLGK*VGSK   
525 K*QTALVELVK   
541 ATK*EQLK   
545 EQLK*AVMDDFAAFVEK   
 
Table 4.3 HSA derived tryptic peptides containing piperacillin modified lysine residues in 2 
conjugates. 
Piperacillin:albumin ratio of 50:1, incubation time was 24 hours. The * indicates site of 
piperacillin modification.  
 
4.4.4.2 Synthetic piperacillin-HSA conjugates purified using centrifugal filters 
(conjugate 1) do not stimulate piperacillin-specific T-cell clones. 
Conjugate 1 was added to co-cultures with piperacillin specific clones and EBV-
transformed B-cell lines in a standard proliferation assay. [3H] thymidine was 
added to the cultures for the last 16 hours of incubation to assess proliferative 
activity. Piperacillin-specific T-cell clones were not stimulated by conjugate 1 
prepared at molar ratios of drug to HSA of 50:1, 250:1 or 500:1 (Figure 4.12).   
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Figure 4.12 Conjugate 1 does not stimulate piperacillin-specific T-cell clones.  
(A) Piperacillin was incubated with HSA at 50:1, 250:1 and 500:1 molar ratios for 24hrs at 37°C, 
n = 8 for all molar ratios. Conjugates were extracted and purified with ultra centrifugal filters 
(30K cut off) and protein concentration determined. 4mg/ml S-conjugates, and medium and 
2mM soluble piperacillin as negative and positive controls, were co-cultured with piperacillin 
specific T-cells and autologous APCs for 96hrs. Proliferation was determined by [3H]-thymidine 
incorporation which was added in the last 16 hours of incubation. (B) Dose response data from 
2 representative clones. Pip-HSA conjugates at a molar ratio of 250:1 and HSA control were 
cultured with T-cell clones and APCs at 0.5, 1 and 2mg/ml. Medium alone (Ø) and 2mM 
piperacillin were included in assay to confirm T-cell activity and specificity. CPM = counts per 
minute. 
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4.4.4.3 Synthetic piperacillin-HSA conjugates generated through MeOH 
precipitation (conjugate 2) stimulate piperacillin-specific T-cell clones. 
The data generated with conjugate 1 is in stark contrast to our previous 
findings in which conjugates prepared at a molar ratio of 50:1 consistently 
stimulated T-cells to proliferate (El-Ghaiesh et al., 2012). However, the latter 
were purified by methanol precipitation of the protein which may have resulted 
in a) sufficient levels of free drug remaining post-precipitation to stimulate a 
response or b) may have caused the protein to be damaged so that alternative 
peptides were available for display by MHC class II expressed on APCs. To 
investigate this further, conjugates were prepared by methanol precipitation to 
remove free drug, conjugate 2. Conjugate 2 was incubated in co-culture with 
piperacillin-responsive T-cell clones and autologous EBV-transformed B-cells, 
and the proliferative responses were recorded. Piperacillin modified conjugate 
2 was found to stimulate the proliferation of T-cells (Figure 4.13A). 
Furthermore, responses to protein concentrations were dose-dependent 
(Figure 4.13B). 
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Figure 4.13 Synthetic piperacillin-HSA conjugates generated through methanol precipitation 
stimulate piperacillin-specific T-cell clones.  
(A) Piperacillin was incubated with HSA at 250:1 molar ratios for 24hrs at 37°C, n = 10. 
Conjugates underwent MeOH precipitation for purification and protein concentration was 
determined. 4mg/ml conjugate 2, and medium and 2mM soluble piperacillin as negative and 
positive controls, were incubated with piperacillin specific T-cells and APCs for 96 hours. 
Proliferation was determined by [3H]-thymidine incorporation. Data was significantly different. 
Piperacillin p = 0.0005, Pip-HSA p = 0.0032. (B) Dose response data from 2 representative 
clones. Pip-HSA conjugates at a molar ratio of 250:1 and HSA control were cultured with T-cell 
clones and APCs at 0.5, 1, 2 and 4mg/ml. Medium alone (Ø) and 2mM piperacillin were included 
in assay to confirm T-cell activity and specificity. CPM = counts per minute. 
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confirmed our findings that conjugates generated through MeOH precipitation 
(C2) stimulated T-cell proliferative responses with representative data from 
one clone shown in Figure 4.14A. However, when the same T-cell clones were 
exposed to conjugate 1 (C1, centrifugal filtration method) proliferation was not 
seen. Furthermore, responses to conjugate 2 were dose dependent (Figure 
4.14B). 
 
 
 
 
Figure 4.14 Synthetic piperacillin-HSA conjugates generated through MeOH precipitation 
stimulate piperacillin-specific T-cell clones in a dose dependent manner.  
(A)Piperacillin was incubated with HSA at a molar ratio of 250:1, n = 4. Conjugates were 
purified either by centrifugal filtration (conjugate 1, C1) or methanol precipitation (conjugate 2, 
C2). Medium alone and 2mM soluble piperacillin were used as negative and positive controls, 
and HSA cultured with phosphate buffer alone was used as a negative control for drug modified 
HSA.  T-cell proliferation was determined by [3H]-thymidine incorporation. Representative data 
from 1 clone of 4 is shown. (B) 0.5 – 4mg/ml of HSA conjugate 2 (control and piperacillin 
modified) were incubated with piperacillin-specific clones and APCs in standard proliferation 
assay, n=19. 
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4.4.4.4 Piperacillin at µM concentrations is required for a proliferative response 
in piperacillin specific T-cell clones 
Experiments aimed to determine the minimum concentration of piperacillin 
(soluble drug) required to stimulate piperacillin specific T-cell clones were 
performed. Clones were co-cultured with EBV-transformed B-cells and exposed 
to piperacillin at a range of low doses; 10nM, 50nM, 100nM, 100µM, 10µM and 
1µM piperacillin. Medium alone and 2mM piperacillin were used as the negative 
and positive control, respectively. In most clones, piperacillin concentrations of 
10µM and over were necessary to stimulate T-cell proliferation to a degree that 
would be considered positive i.e. an SI of 2 or more (Figure 4.15) (Pichler et al., 
2004). A quarter of clones tested (3 out of 12) were stimulated with 10µM 
piperacillin and 7 clones required at least 100µM piperacillin.  However in 2 
highly responsive clones, 1µM piperacillin was sufficient in eliciting a positive 
proliferative response (see clone 411, Figure 4.15B).  
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Figure 4.15 Piperacillin at µM concentrations is required for a proliferative response in 
piperacillin specific T-cell clones. 
Piperacillin specific T-cell clones were co-cultured with EBV-transformed B-cells and exposed to 
piperacillin (10nM-100µM). Medium and 2mM piperacillin were used as negative and positive 
control respectively. T-cell proliferation was determined by [3H]-thymidine incorporation.(A) 
Data from 12 piperacillin specific clones. (B) Individual proliferation data from 6 representative 
clones. 
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Knowing that at least 1µM piperacillin is required to stimulate T-cell clones, the 
next step was to determine the amount of free drug remaining in the conjugates 
used in our assays. This would allow clarification that indeed the drug-protein 
conjugates were responsible for T-cell proliferation and not free, soluble 
piperacillin. Samples of conjugates 1 and 2 were processed and analysed by 
MRM-MS to determine the concentration of unbound piperacillin. The level of 
free drug as would be present in T-cell culture in our in vitro assays in the 
conjugate 1 was 0.99nM. 150nM piperacillin was present in conjugate 2 (Table 
4.4). Quantification of free piperacillin was kindly conducted by Dr Roz Jenkins 
and Dr Xiaoli Meng (MRC, CDSS).   
 
Conjugate free pip/mg HSA 
free pip in culture 
@4mg/ml conjugate 
1 after spin 5 0.248nM 0.99nM 
2 after MeOH wash 3 37.5nM 150nM 
 
Table 4.4 Level of free piperacillin in conjugates 
The amount of free, soluble piperacillin was quantified for each conjugate at a molar ratio of 
50:1, piperacillin:HSA. For conjugate 1 free piperacillin was measure after fifth spin in column, 
this was used in all T-cell assays. Free iperacillin for conjugate 2 was analysed after third 
methanol (MeOH) wash which was used in T-cell assays. 0.5 – 4 mg/ml of conjugate were used 
throughout T-cell assays. 
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With the level of free piperacillin in both conjugates not sufficient to induce 
proliferative T-cell responses, we hypothesised the slightly higher 
concentration of free piperacillin embedded non-covalently in conjugate 2 was 
somehow being utilised to promote the proliferation of piperacillin specific T-
cells. To test this hypothesis, piperacillin specific T-cell clones were cultured in 
three conditions. The standard proliferation assay (cells and drug cultured in 
medium) as the control condition and in parallel, cells were cultured with 
2mg/ml conjugate 1; either HSA control or drug-modified at a molar ratio of 
250:1 of piperacillin to HSA. Free soluble piperacillin (10nM, 100nM, 10µM, 
100µM) was spiked into the wells with 2mM piperacillin used as a positive 
control and T-cell proliferation determined by [3H]-thymidine incorporation. 
The lower concentrations of piperacillin that were spiked into the conjugate 1 
did not result in any T-cell proliferation (Figure 4.16, n=10). However, addition 
of 2mM piperacillin did induce T-cell proliferation as did conjugate 2, which 
served as the control. 
 
 
 
 
 
 
 
Figure 4.16 Low dose piperacillin spiked into cell cultures with conjugate 1 do not result in T-cell 
proliferation. 
Piperacillin specific T-cell clones (n=10) were cultured in three conditions; medium as the 
standard and acting as control, and with 2mg/ml conjugate 1 (C1); either HSA control or 
piperacillin-modified HSA at a molar ratio of 250:1. Soluble piperacillin (10nM – 2mM) was then 
spiked into the wells with 2mM piperacillin used as a positive control. Conjugate 2 (C2) were 
also included in the assay. T-cell proliferation was determined by [3H]-thymidine incorporation. 
Data from 2 representative clones are shown.  
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4.4.5 Generation of T-cell clones specific to a piperacillin-HSA 
conjugate 
Furthering investigations of our synthetic piperacillin-HSA conjugate we 
endeavoured to generate conjugate-specific T-cell clones. PBMCs from 
hypersensitive patient H3 were isolated and incubated with conjugate 1 for two 
weeks. T-cell clones were generated through the standard serial dilution 
protocol. Conjugates at a ratio of 50:1 were used in these experiments.  
We were successful in generating 24 T-cell clones specific to the synthetic 
piperacillin-HSA conjugate with a sample of dose-response data from 14 T-cell 
clones shown in Figure 4.17A. Proliferation with piperacillin-HSA was dose 
dependent. Individual data from 6 representative clones are shown in Figure 
4.17B. Certain clones were activated to proliferate with as little as 0.25mg/ml of 
protein conjugate. However, consistent responses were detected with 2mg/ml 
piperacillin-modified HSA.  
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Figure 4.17 Conjugate primed T-cell clones respond in a dose dependent manner to synthetic 
piperacillin-HSA conjugate 
(A) T-cell clones were co-cultured with antigen presenting cells and piperacillin-HSA conjugate 
at 0 – 4mg/ml for 96 hours. Proliferation was measured with the addition [3H]-thymidine in the 
last 16 hours. Each data point represents mean [3H] incorporation from 14 conjugate specific 
clones. (B) Individual data from 6 representative T-cell clones. 
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To further explore the specificity of the T-cell clones, cells were exposed to a 
control HSA which was cultured in phosphate buffer alone (in the absence of 
piperacillin) and subjected to the normal extraction protocol (HSA control). 
Moreover, soluble piperacillin (2mM) was included in the assay. Proliferation 
was not observed following exposure of the T-cell clones (n = 8) to the HSA 
control (0.25 – 4 mg/ml). However, clones were activated when exposed to the 
synthetic piperacillin-HSA conjugate. Representative clones are shown in Figure 
18. For four of the clones, proliferative responses were seen exclusively with 
drug modified conjugates (Figure 18A). However, the other clones were also 
activated with soluble piperacillin (Figure 18B).  
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Figure 4.18 T-cell clones primed to synthetic piperacillin-HSA conjugate do not respond to HSA 
alone 
(A) T-cell clones (n = 8)were co-cultured with antigen presenting cells and conjugates at 0.25, 1 
and 4mg/ml of synthetic conjugate, HSA control and piperacillin-HSA (pip-HSA) for 96 hours. 
Cells were also exposed to soluble piperacillin at 2mM and medium alone as a control. 
Proliferation was measured with the addition [3H]-thymidine in the last 16 hours. 2 
representative clones are shown. (B) 2 representative clones which were activated following 
exposure to soluble piperacillin. 
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4.5 Discussion 
Administration of antibiotics is essential in the treatment regimen for many 
patients with CF due to the development of regular bacterial infections resulting 
in pulmonary exacerbations (Turcios, 2005). Unfortunately, between 30% and 
50% of patients treated with β-lactam antibiotics develop hypersensitivity 
reactions (Burrows et al., 2007; Parmar et al., 2005) which is in stark contrast 
to the rate of hypersensitivity seen in the general population (up to 10%). 
Hypersensitivity in the CF population is understandably a major health concern 
for patients and medical health professionals. Little is known about the 
mechanisms involved in the development of drug hypersensitivity reactions 
and so the aim of this chapter was to investigate the nature of the piperacillin 
protein interaction involved in the activation of piperacillin specific T-cell 
clones. 
A number of hypotheses have been proposed to explain drug immunogenicity, 
one of which is the hapten hypothesis. This theory has been formed around the 
concept that drugs become immunogenic following covalent binding to larger 
biological macromolecules such as circulating proteins.  Once the haptenic 
structure has been formed, modification of the protein is able to stimulate an 
immunological response (Landsteiner et al., 1935). β-lactam antibiotics have 
been used as a model to study and define this hypothesis (Martin et al., 2014) as 
opening of the β-lactam ring allows the spontaneous covalent binding of the 
penicilloyl group to lysine residues on endogenous proteins. Indeed T-cells 
from penicillin hypersensitive patients have been found to respond to penicillin 
derived designer HLA-DR  binding peptides (Padovan et al., 1997). However, 
the hapten hypothesis has been challenged by an alternative theory; the PI 
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concept. Through the use of T-cells isolated from drug allergic patients, Pichler 
and his co-workers  have found that a direct, reversible interaction between the 
offending drug, MHC molecule and the T-cell receptor itself more accurately 
describes the nature of the T-cell activation (Pichler, 2002). They have shown 
that a number of drugs activate T-cells via the T-cell receptor in an MHC allele 
restricted manner following the blockade of protein processing. Rapid T-cell 
receptor activation which does not correspond to the length of time required 
for processing is also observed. Furthermore, inhibition of protein binding does 
not necessarily inhibit the T-cell response (Gerber et al., 2004; Schnyder et al., 
1997).      
In light of these findings it is important to further define the chemical basis of 
drug hypersensitivity.   
A panel of over 100 piperacillin specific T-cell clones, generated from PBMCs 
isolated from piperacillin hypersensitive patients with CF, were used in our 
assays to investigate (1) the mechanism of piperacillin specific T-cell activation, 
(2) characterise the nature of drug-protein binding and (3) understand the 
relationship between the chemistry of antigen formation and drug 
hypersensitivity. The CD4+ T-cell clones used displayed dose-dependent 
proliferative responses against the parent drug, which were reproducible with 
maximum responses seen with 2mM piperacillin. Clones also secreted IFN-γ in a 
dose dependent manner (Figures 4.1 and 4.2). The Th1 subtype of cells are 
implicated in the pathogenesis of delayed type hypersensitivity reactions 
(Kennedy et al., 2008) and IFN-γ secretion has been reported previously with 
piperacillin specific clones.  
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With our panel of T-cell clones phenotyped and characterized we began by 
investigating the mechanisms of antigen presentation. EBV-transformed B cells 
were used as APCs throughout. Piperacillin-pulsed APCs, with free drug 
removed by extensive washing, were found to stimulate T-cells in a similar 
manner to that with soluble drug. The response with pulsed APCs was time-
dependent with short 1 and 4 hour piperacillin-pulsed APCs not activating T-
cells. In contrast with longer APC piperacillin incubations (48hr), proliferative 
responses even exceeded that seen with soluble piperacillin (Figure 4.3). 24 – 
48 hours is the time required for piperacillin to bind extensively to serum 
protein (Whitaker et al., 2011b). Considering the hapten hypothesis, we would 
presume that piperacillin binds to circulating serum albumin in the culture 
media forming a drug-protein conjugate. APCs would then process the newly 
formed antigen producing drug modified peptides that are presented via class II 
MHC molecules to receptors on CD4+ T-cells thus initiating T-cell expansion, 
differentiation and ultimately resulting in an exaggerated immune response. 
Glutaraldehyde, which prevents antigen processing but conserves the ability of 
APC to present antigens, was used to fix APCs before being transferred to a 
standard proliferation assay with piperacillin and T-cell clones (Shimonkevitz et 
al., 1983). When these were cultured with fixed APCs and piperacillin, 
proliferative responses were generally not detected indicating that processing 
is a requirement for the T-cell proliferative response (Figure 4.4).  However, to 
our surprise, this was not the case for all of the clones tested. Two clones 
responded with the fixed APCs, with one (clone 76) producing T-cell responses 
to the same extent as the control, non-fixed APCs. Upon further investigation 
these T-cell clones were found to self present as the absence of APCs did not 
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diminish the T-cell response. The presentation of antigens is traditionally 
thought to occur via cells whose primary function is to present antigens to T-
cells, hence the name antigen presenting cell (APC). These include professional 
APCs such as dendritic cells and B-cells. However, T-cells themselves have the 
capacity to present antigens made possible due to their ability to synthesize and 
express MHC molecules (Broeren et al., 1995). Though not fully investigated the 
ability of T-cells to self present has been reported (Taams et al., 1999). T-cells 
have been found to possess characteristics associated with professional APCs 
and when activated T-cells are able to process and display antigens inducing 
and augmenting T-cell proliferation (Barnaba et al., 1994; Brandes et al., 2005). 
Indeed, those T-cell clones that were stimulated in spite of fixed APCs appear to 
have the capacity to self-present the piperacillin antigen without APC 
involvement.  
Previously, synthetic piperacillin albumin conjugates modified at specific lysine 
residues have been shown to stimulate drug-specific T-cell clones and we 
wanted to further develop our understanding of the role of drug-protein 
conjugates in the drug-specific T-cell response (Whitaker et al., 2011b). After 24 
hour incubation of piperacillin with HSA (at molar ratios of 50, 250 and 500:1) 
conjugates were processed through ultra centrifugal filters (30K cut off). 
Washes within these spin columns removed free drug, purifying the conjugate. 
However, when T-cells and APCs alongside the synthetic conjugates (conjugate 
1), no responses were seen (Figure 4.12). Upon closer inspection we identified 
differences in the method used to generate said piperacillin-HSA synthetic 
conjugates compared to synthetic conjugate made previously in the 
department. Though both involved incubation of piperacillin with HSA, 
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processing of the conjugates differed. Whilst conjugate 1 utilised spin columns, 
the other method involved the use of MeOH precipitation to clear free drug. A 
second conjugate was generated (conjugate 2) using the MeOH precipitation 
method, similar to previous studies (El-Ghaiesh et al., 2012), this conjugate was 
able to stimulate piperacillin-specific clones (Figure 4.13) and furthermore 
responses were dose-dependent.  
Western blot and mass spectrometry confirmed piperacillin modified HSA with 
each conjugate. Importantly, the epitope profiles (lysines modified and relative 
levels of binding), were similar. Mass spectrometric analysis also revealed that 
piperacillin formed multiple haptenic structures on lysine residues of both 
conjugates. As with other β-lactam antibiotics, piperacillin forms adducts with 
lysine residues through opening of the characteristic β-lactam ring and both 
hydrolysed and cyclised forms of the piperacillin hapten were present.      
Although chemically similar, functionality of the conjugates varied; one 
stimulated clones to proliferate, the other did not. We postulated that the 
different methods involved in preparation of the conjugates may have resulted 
in disparate levels of free drug residing within the conjugate which in turn was 
resulting in the responses seen with conjugate 2 but not with conjugate 1. 
Having established that generally µM concentrations (i.e. at least 1µM and 
normally 10 - 100µM) of piperacillin is required to stimulate piperacillin-
specific clones with an SI of 2 or more, we set out to determine the levels of 
unbound piperacillin in the synthetic conjugates. Mass spectrometric analysis 
revealed that 0.73nM of free drug was present in conjugate 1. Conjugate 2 
contained higher levels of free drug (150nM), however these data clearly do not 
explain the divergent results observed with the two conjugates. In the final 
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experiments varied amounts of free piperacillin were spiked in cultures with 
conjugate 1. We expected to see response at nM concentrations yet to our 
surprise; proliferation was not detected until µM concentrations of piperacillin 
were spiked into the assay. Indeed our data seemed to confirm that free 
piperacillin at levels associated in the conjugates was not stimulating T-cell 
proliferation and we can say with confidence that free piperacillin alone is not 
stimulating proliferative responses. Instead, piperacillin bound HSA (either 
covalently or non-covalently) are clearly playing a pivotal role in the 
development of the immune response and differences in methods to generate 
the conjugates are altering the proteins in such a way to allow different 
functionalities.  
Limited data exists regarding the effect of MeOH and/or ultra filtration on the 
structure of proteins. It is possible that an organic solvent, unlike ultra filtration 
which does not involve such solvents, could alter the structure of HSA, perhaps 
through denaturing of folds. Furthermore, whilst numerous MeOH washes 
would provide a “clean” product a significant proportion of the protein would 
be lost, whilst the advantage of ultra filtration is that the loss of protein with 
many washes is restricted. (Bodzon-Kulakowska et al., 2007). In studies with 
horseradish peroxidise organic solvents were found to affect peroxidise 
function. Though the enzyme was not completely denatured, changes in the 
tertiary structure indirectly affected function (Ryu et al., 1992). More recent 
research has uncovered detailed information regarding structural changes of 
proteins following solvent extraction. Like ethanol, MeOH has both polar (C-O-H 
group) and non-polar (C-H bonds) characteristics and is less miscible than 
water. This enhances protein interactions resulting in reduced protein 
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solubility and precipitation (Cheng et al., 2011). These properties allow 
weakening of the hydrophobic bonds within the protein, thus the protein is able 
to unfold with the extent and reversibility dependent on the solvent used (less 
polar solvent would render unfolding irreversible) and the length of time to 
which the protein is exposed to said solvent. When proteins are exposed to 
more polar solvent like ethanol, and with similar characteristics we can expect 
this of MeOH too. Following the initial unfolding of the protein, refolding into 
rod-like structures containing a significant number of α-helices is often seen 
(Pace et al., 2004). This allows peptide groups to be buried within the structure 
whilst non-polar side chains are free to interact with the solvent and so the 
structure, while altered can retain function and is stabilised. Precipitation with 
MeOH will undoubtedly alter the tertiary structure of HSA during processing of 
the conjugates and this may well contribute to functionality of conjugate 2. In 
contrast, processing through ultra filtration and centrifugation spin columns is 
likely to modify the structure of the conjugates minimally.  
It is also possible that HSA may be involved someway in facilitating piperacillin 
presentation on to MHC molecules thus initiating T-cell activation. Thierse et al. 
investigated the role of HSA in nickel allergy (a common contact allergen), 
where they described HSA as a “shuttling” molecule. Whilst albumin-nickel 
complexes (HSA-Ni) activated nickel specific T-cells, serum albumin or the 
derived peptides were not antigenic (Thierse et al., 2004). Instead HSA-Ni 
appeared to facilitate the transfer of nickel to high affinity sites between the 
TCR and MHC molecule. A similar scenario may be present in our T-cell cultures 
with piperacillin-HSA conjugate 2. The slightly higher levels of free drug may be 
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directed to appropriate binding sites by piperacillin-HSA thus initiating a T-cell 
response. 
Our last experiments showed the precise and specific nature of the piperacillin 
hapten-specific T-cell response. We were able to generate clones specific to 
conjugate 1, where strong proliferative responses were observed in a dose-
dependent manner. Interestingly half of the clones tested were exclusively 
activated by piperacillin-HSA conjugate and not activated by soluble piperacillin 
highlighting fine specificity of T-cell clones. This trait has previously been 
observed in penicillin-specific T-cell clones. Clones primed and generated to 
penicillin G were found to be stimulated with the free drug alone and not to the 
drug modified conjugate (Brander et al., 1995a). In addition the same specificity 
was observed in clones generated to penicillin-HSA, whereby penicillin G did 
not elicit positive proliferative responses. Furthermore, with modifications at 
Lys190, Lys432 and Lys542 exerting such prominence in our mass 
spectrometry data we postulate that peptides around these positions could be 
the principal functional epitopes initiating immune response. 
Our data clearly indicate that the development of hypersensitivity is a 
complicated process. Proteins themselves are complicated in their structure 
which in turn determines their precise properties and functionality. Though we 
may have characterised piperacillin binding to HSA which constitutes the 
majority of circulating protein, the body consists of a vast array of other 
proteins in various quantities, and so there are an infinite number of possible 
drug-derived peptides that could stimulate T-cells and promote 
hypersensitivity.  
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However, what we have shown is the significant role of drug-protein 
conjugation in piperacillin hypersensitivity reactions. APCs and antigen 
processing are pivotal in generating T-cell proliferative responses. 
Furthermore, drug-modified peptides generated from piperacillin-modified 
HSA are likely to represent functional T-cell antigens. Indeed they may function 
as immunogens in patients with CF. 
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5.1 Introduction 
Previous chapters suggest that covalent binding of piperacillin to proteins form 
neo-antigens that play a role in the development of an immune response and 
the overall adverse event (Brander et al., 1995b; Levine et al., 1961a; Park et al., 
1998).  Piperacillin haptenation has been characterised in vitro and in vivo in 
patients exposed to the drug: four types of adducts formed with a core group of 
lysine residues on human serum albumin (HSA) have been identified. Moreover, 
as re-iterated in the previous chapter, synthetic piperacillin-HSA conjugates 
stimulate T cells isolated from patients with piperacillin hypersensitivity in a 
dose-dependent manner (El-Ghaiesh et al., 2012; Whitaker et al., 2011a). 
Utilising this knowledge it was possible to investigate further how piperacillin 
is presented to T-cells and in particular the quantitative relationship between 
covalent binding and drug immunogenicity. As albumin has been identified as a 
major protein target for piperacillin in vivo and in cell culture, piperacillin-
modified HSA was therefore used as a model carrier protein to explore 
piperacillin antigenicity and immunogenicity. 
It has been argued that antigen dose plays a critical role in the incidence and 
severity of hypersensitive reactions (Aguilar-Pimentel et al., 2010; Long et al., 
2011). Furthermore, antigen exposure may have an impact on the 
characteristics of the responding T-cell repertoire (Kim et al., 2006; Oling et al., 
2010). There is a great need to develop sensitive methods to determine the 
absolute quantity of piperacillin antigen formed in vitro and in patients. All of 
our previous mass spectrometric analyses provide a qualitative assessment of 
piperacillin-HSA binding and a semi-quantitative analysis of the level of 
modification at each lysine residue. Quantitative assessment of penicillin hapten 
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density on protein has been attempted previously by either the penamaldate 
assay that measures the molar ratio of penicillin groups to protein (Levine, 
1962) or a trinitrobenzene sulfonic acid assay that indirectly determines the 
level of modification by quantification of the free amino groups on protein 
(Sashidhar et al., 1994). 
Neither of these approaches are sensitive enough to monitor the level of 
piperacillin antigen formed in patients and in cell culture. The use of liquid 
chromatography coupled with mass spectrometry (LC-MS) together with 
suitable internal standards is now one of the most widely used techniques for 
the quantification of conjugates. Over the past two decades advances in mass 
spectrometry (MS) methods has allowed the field of proteomics to emerge 
along with improvements in protein characterisation and quantification 
methods. In particular, MS approaches based on multiple reaction monitoring 
(MRM), first used for the quantification of low molecular weight analytes, have 
developed to allow the precise and quantitative analysis of low abundance 
analytes even in a complex matrix, such as those of protein digests, plasma and 
urine. The MRM approach targets specific subsets of analytes, and is performed 
by isolating ions of interest within the mass spectrometer. This analysis is 
typically operated on tandem quadrupole mass spectrometers (QqQ) that are 
able to monitor several transitions (precursor/fragment ion pairs) over time, 
yielding a set of ion traces with the retention time and signal intensity for a 
specific transition as coordinates. Its targeted nature, high selectivity, and wide 
dynamic range, has therefore made MRM ideal for absolute quantification 
purposes (Holman et al., 2012). In this chapter, a novel MRM based MS method 
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has been developed for quantitative analysis of  piperacillin modification in 
vitro, in patients, and ex vivo in cell culture.  
5.2 Aims and Hypothesis 
 
The aim in this chapter was to develop a quantitative method to evaluate the 
potential association between the antigen dose and piperacillin-specific T cell 
responses. Novel mass spectrometry methods were developed and used to 
detect and quantify piperacillin modified peptides in the plasma of patients with 
CF and from in vitro cell culture samples. The results obtained were then related 
to the immune response seen in in vitro T-cell culture. Using the recently 
established MS techniques in the department I propose the following 
hypothesis: 
There is a clear relationship between the level of piperacillin bound peptides and 
the in vitro T-cell response.  
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5.3 Methods 
The methods used here are described fully in Material and Methods, Chapter 2. 
A brief experimental outline is detailed below. 
 
Scheme 5.1 Experimental plan and methods used in this chapter 
 
 
 
 
 
 
 
Quantification of piperacillin-modified peptides formed 
in vitro and in patients
Establish synthetic peptide standard
Quantify piperacillin-modified peptide
Patient plasma
In vitro T-cell culture; 
proliferation assays
Time 
dependency
Concentration 
dependency
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5.4 Results  
5.4.1 Quantification of drug adduct formation using a synthetic 
modified peptide  
The synthetic piperacillin modified peptide ATK(piperacillin)EQLK (Pip-K541), 
based on the sequence of HSA incorporating lysine 541, is one of the most 
consistently detected peptides in patients’ plasma. This peptide was therefore 
used as a standard to quantify the piperacillin modification at this site in HSA. 
Synthesis of the modified peptide, achieved by Fmoc chemistry in solution 
phase was conducted by Dr Xiaoli Meng (MRC Centre for Drug Safety Science, 
University of Liverpool). Protein concentrations of peptide were determined by 
Bradford assay, and calibration curves for the synthetic standard were 
constructed using Pip-K541 peptide at 0.1, 0.125, 0.2, 0.25, 0.333, 0.5, 1 pmol 
on-column. The K541 containing peptide without piperacillin modification, 
ATKEQLK was used as internal standard in both the modified peptide standard 
curve and in samples to allow normalization of signals across samples (Figure 
5.1). This range of peptide loading was used because it covered the 
concentration ranges typically seen in both patient samples and in vitro. 
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Figure 5.1 Pip-K541 synthetic peptide standard  
(A)Bradford assay was used to determine protein concentration of synthetic peptide standard 
before analysis by mass spectrometry. MRM peaks were identified and areas under the curve 
(AUC) were determined. The ion count was normalised to the UV spectrum (total protein 
y = 3E+06x - 162296 
R² = 0.9947 
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loading) and the internal standard (IS). (B) A standard curve was generated. (C) Chemical 
structure of the Pip-K541 synthetic peptide standard  
 
 
 
5.4.2 Piperacillin modified K541 peptide is detectable and 
quantifiable in vivo 
Piperacillin modification of HSA in patients was determined at lysine 541 from 
plasma obtained from ten piperacillin exposed patients from the Regional Adult 
Cystic Fibrosis Unit at St. James hospital, Leeds. Albumin was isolated from 
patient plasma on day 14 of treatment by affinity chromatography using a 
POROS anti-HSA affinity cartridge (Applied Biosystems, Foster City, CA, USA). 
HSA was processed and analysed by mass spectrometry as described in the 
methods. The concentration of Pip-K541 peptide was quantified against the 
synthetic standard. The percentage of modified peptide in relation to the total 
peptide was also determined (Table 5.1).   
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Patient 
Pip-K541 ion 
count (AUC) 
Normalised ion 
count (AUC) 
Pip-K541 
amount (pmol) 
Percentage total 
modification 
Pip 1 5.80E+05 6.87E+05 0.282932 5.66% 
Pip 2 5.17E+05 5.67E+05 0.243098667 4.86% 
Pip 3 2.64E+05 2.83E+05 0.148432 2.97% 
Pip 4 5.80E+05 6.57E+05 0.273098667 5.46% 
Pip 5 4.74E+05 4.70E+05 0.210598667 4.21% 
Pip 6 4.15E+05 4.07E+05 0.189598667 3.79% 
Pip 7 7.56E+05 6.32E+05 0.264765333 5.30% 
Pip 8 7.45E+05 8.16E+05 0.326098667 6.52% 
Pip 9 3.94E+05 2.24E+05 0.128765333 2.58% 
Pip 10 1.21E+05 5.50E+05 0.237432 4.75% 
Table 5.1 Quantification of Pip-K541 peptide in vivo 
Plasma from10 piperacillin non hypersensitive patients were collected and prepared for 
processing. Pip-K541 peptide was identified by MRM/MS, signal strength was normalised and 
concentration determined against synthetic peptide standard. 5pmol of patient HSA sample was 
loaded and the percentage of K541 peptide that was modified was determined.   
 
 
The Pip-K541 peptide was detected in all ten plasma samples which suggests 
that piperacillin-modification of plasma proteins is universal even in the 
absence of adverse drug reactions. However, it is important to note that this 
protein modification does not equal hypersensitivity and we are yet to 
understand why only a subset of patients become allergic. Using the established 
standard curve for synthetic piperacillin modified peptide (Figure 5.1), the 
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percentage of HSA modified by Piperacillin at K541 in vivo was found to range 
from 3% to 6.5% (Figure 5.2). 
 
 
 
 
 
Figure 5.2 Piperacillin modified K541 peptide in plasma of piperacillin non-hypersensitive 
patients. 
Pip-K541 peptide present in plasma of piperacillin non-hypersensitive patients. Percentage of 
total HSA protein that was modified at lysine 541 is shown.  
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5.4.3 Piperacillin specific T-cell clones  
Having generated piperacillin-specific T-cell clones, well growing clones from 
two patients were selected for use in our assays to relate the level of 
piperacillin-modified protein to the piperacillin-induced T-cell stimulation seen 
in vitro.  Clones responded to soluble piperacillin in a dose-dependent manner. 
Pulsing assays revealed that T-cell clones were stimulated with APCs that had 
been pulsed with piperacillin for 24 – 48 hours. Proliferative responses were 
comparable to that with soluble drug (Chapter 4, Figure 4.3). 
5.4.3.1 Piperacillin modified K541 peptide is detectable in vitro 
The culture supernatants from the T-cell proliferation assays (cultured with 
APCs and drug) were collected and analyzed for the level of piperacillin-
modified K541 peptide. T-cells were treated with 0.1 – 4mM piperacillin to 
investigate how concentration affects piperacillin modification of HSA and if 
this correlated with T-cell responses. Four T-cell clones generated from two 
piperacillin hypersensitive patients were used in a standard proliferation assay 
with EBV-transformed B-cell lines used as APCs. Supernatants were processed 
and analysed by MRM-MS as described in methods chapter. A clear dose 
dependency was observed in the formation of Pip-K541 peptide with the 
percentage of total peptide that was modified reaching up to 4% (Table 5.2, 
Figure 5.3). At lower concentrations, 0.1 and 0.5mM piperacillin, levels of 
modified peptide constituted around 1% of total K541 peptide which coincided 
with the low levels of proliferation observed with T-cell clones exposed to the 
lower concentrations of soluble piperacillin.     
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Piperacillin 
conc. (mM) 
Normalised ion 
count (AUC) 
Pip K541 
amount (pmol) 
Percentage of 
total protein 
0.1 2078.908 0.021690 0.45% 
0.5 57906.205 0.063390 1.25% 
1 77504.17 0.075456 1.5% 
2 167889.1 0.152488 3.05% 
4 256069.3 0.205408 4.1% 
 
Table 5.2 Modification of Pip-K541 peptide from in vitro cell culture supernatants is 
concentration dependent 
Piperacillin specific clones from two hypersensitive patients were exposed to 0.1 – 4mM 
piperacillin in a standard proliferation assay. Combined data is shown. Supernatants from in 
vitro T-cell cultures were collected after 48hrs and processed for mass spectrometric analysis. 
Pip-K541 peptide was identified by MRM/MS, signal strength was normalised and 
concentration was determined using the standard curve of the synthetic peptide standard. 
5pmol digested protein was loaded on-column and the percentage of peptide modified at HSA 
K541 was determined.   
 
Figure 5.3 Percentage of Pip-modified K541 peptide formed in vitro is dependent on 
concentration of piperacillin. 
(A) Pooled supernatants from in vitro proliferation cultures from piperacillin specific T-cell 
clones were analysed by MRM/MS and the concentration of Pip-K5421 peptide quantified. (B) 
Proliferation data from the clones used. T-cell clones were co-cultured with APCs and 
piperacillin at 0 – 4mM for 96 hours. Proliferation was measured with the addition [3H]-
thymidine in the last 16 hours. Supernatants for (A) were collected prior to [3H] addition. ** P < 
0.01, ***P < 0.001 
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Having observed an association between the initial concentration of piperacillin 
exposure and the level of piperacillin modified peptides formed (R2 = 
E0.9515/P0.5192), the effect of incubation time was then investigated. 
Proliferation assays were conducted with 8 piperacillin specific T-cell clones, 
from 2 patients, co-cultured with APCs and exposed to 2mM piperacillin. 
Supernatants were collected after 1, 4, 24 and 48 hours incubation and 
processed for MRM/MS analysis. The formation of modified peptide was shown 
to be time-dependent (Table 5.3 and Figure 5.4). The percentage of Pip-K541 
peptide rose to a maximum of around 4% after a 48 hour time point. 
Piperacillin modified peptide K541 was also detected at low levels at the 
shortest time point of 1 hour, with just over 1% of the total protein consisting of 
this modified peptide. The low levels of haptenation seen at 1 and 4 hours was 
mirrored in the proliferation data from the same clones, whereby positive 
proliferative responses were not recorded at the shorter APC piperacillin pulse 
time points (Figure 5.4B).  
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Time point 
Normalised ion 
count (AUC) 
Pip K541 
amount (pmol) 
Percentage of 
total protein 
1 hour 17882.92 0.01886 1.26% 
4 hours 21090.72 0.022068 1.47% 
24 hours 41600.08 0.042577 2.84% 
48 hours 60843.99 0.061821 4.13% 
 
Table 5.3 Quantification of Pip-K541 peptide from in vitro cell culture supernatants-time course.  
Piperacillin specific clones from two hypersensitive patients were exposed to 2mM piperacillin 
in standard proliferation assay. Supernatants from in vitro T-cell cultures were collected after 1-
48 hrs. Pip-K541 peptide was identified by MRM/MS, signal strength was normalised and 
concentration determined using standard curve of the synthetic peptide standard. 3 pmol 
digested protein from supernatant was loaded and the percentage of modified peptide was 
determined. 
 
 
 
Figure 5.4 Percentage of Pip-modified K541 peptide formed in vitro is time dependent. 
(A) Pooled supernatants from in vitro proliferation cultures from piperacillin specific T-cell 
clones were analysed by MRM/MS and the concentration of Pip-K5421 peptide determined. 
Supernatants were taken at 1, 4, 24 and 48 hour time points. Proliferation data from the clones 
used in assay are shown in (B) APCs were pulsed with 2mM piperacillin for 1-48hrs before 
removal of free drug and culture with T-cell clones. * P=0.0227    
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Time dependency for the formation of Pip-K541 peptide was also observed at 
other concentrations of piperacillin exposure. In parallel to this, concentration 
dependency was again observed in the in vitro cell culture supernatants (Figure 
5.5). 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Formation of Pip-modified peptide K541 is time and concentration dependent. 
Piperacillin specific clones from two hypersensitive patients were exposed to 0.1 – 4mM 
piperacillin in standard proliferation assay. Supernatants from in vitro T-cell cultures were 
collected after 1-48 hrs. Pip-K541 peptide was identified by MRM/MS, signal strength was 
normalised and concentration determined using standard curve of the synthetic peptide 
standard. 3 pmol digested protein from supernatant was loaded and the percentage of modified 
peptide was determined. 
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5.5 Discussion 
The penicillin class of β-lactam antibiotics has been widely studied, yet the 
relationship between levels of circulating drug-protein conjugate and activation 
of a cellular immune response in patients has not been defined.  
Recent studies have shown that piperacillin covalently modifies lysine residues 
on albumin in plasma from hypersensitive and non-hypersensitive patients and 
hapten-modified albumin is able to stimulate piperacillin responsive T-cells 
isolated from hypersensitive patients ex vivo. These observations raise the 
question whether there is a difference in the level of modification in individuals 
and if there is a threshold of piperacillin antigen exposure required for T-cell 
activation. We quantified the level of piperacillin modification in patient plasma 
and in cell culture supernatants using mass spectrometric methods. The level of 
piperacillin-modified albumin in patient plasma was found to range from 2 to 
6%; these figures are similar to the levels of modification needed to activate 
patient lymphocytes ex vivo. Thus, although levels of free drug needed to 
activate T-cells are significantly higher than plasma concentrations, the level of 
piperacillin protein adduct are comparable. Our findings also highlight the 
important roles of antigen dose in the activation of T-cells.  
Historically, quantification of drug-modified protein has always been 
challenging.  Emerging mass spectrometric techniques have made it feasible to 
achieve the relative quantification of protein modification and the absolute 
quantification when combined with synthetic standards (Gallien et al., 2011; 
Lange et al., 2008). However, the synthesis of piperacillin-modified peptides is 
extremely challenging and requires a specific synthetic strategy since direct 
penicilloylation of peptides occurs mainly on the N-terminal amino group. 
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Another major obstacle encountered in the synthesis of piperacillin-modified 
peptides is the acid lability of the piperacillin molecule. Acid treatment of the 
peptides either during chain elongation or during cleavage of the peptides from 
the support is a necessary component of peptide synthesis. Consequently, 
special precautions are required to avoid loss of the piperacillin group during 
the synthesis of piperacillin bearing peptides. We therefore developed a 
stepwise method incorporating a piperacillin-lysine conjugate to synthesize 
piperacillin-modified peptides in which piperacillin is attached to ε-amino 
group of lysine. The novel synthetic method is based on the use of a specific 
protecting group for blocking potentially reactive side chain groups of amino 
acids in the peptide synthesis. Preferred side-chain protecting groups are 
readily removable under mild conditions at the end of the synthesis without 
disturbing the piperacillin molecule. 
With peptide ATK(Pip)EQLK in hand, we sought to quantify piperacillin HSA 
adducts in plasma isolated from10 patients with CF. In addition to the 
quantification of the Pip-K541 peptide we were also able to determine the level 
of modified peptide with relation to total protein. This was found to range from 
as little as 2.5% rising up to 6.5% of total protein consisting of modified peptide.   
The next step was to estimate the minimal quantity of piperacillin haptenation 
necessary to induce T cell activation. Piperacillin-specific T-cell clones 
generated from PBMCs isolated from hypersensitive patients with CF were 
cultured with piperacillin at various concentrations (0.25–4mM), and 25 µl 
supernatant was removed after 1–48 hours to measure the level of piperacillin 
haptenation. Pip-modified K541 was detectable at 0.1 mM after a 48 hour 
incubation; however, the level of modification was low (1%), coinciding with a 
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weak proliferative response (Figure 5.3). A concentration dependent increase in 
the level of modification was associated with the proliferation of piperacillin-
specific T-cell clones. To quantitatively determine the extent of Pip haptenation 
required for triggering immune responses, EBV-transformed B-cells, which are 
used as APCS, were pulsed with piperacillin for 1, 4, 24, and 48 hours prior to 
washing and exposure to clones. The supernatants were removed to determine 
the level of piperacillin haptenation in culture. APCs pulsed with piperacillin for 
1 and 4 hours did not stimulate T-cells to produce a proliferative response, 
corresponding with low levels of haptenation (less than 1.5%). In contrast, 
APCs pulsed with piperacillin for 24 and 48 hours stimulated all clones to 
proliferate and the strength of the response was stronger to that seen with the 
soluble drug. It can therefore be estimated that as little as 2.8% of piperacillin 
haptenation is sufficient for T-cell activation.  
It is worth noting that the level of the piperacillin antigen formed in patients 
(2.58 to 6.52%), was in the same range as that required to activate T-cells in 
vitro, yet not all patients develop an adverse reaction.  The inability of 
piperacillin haptens to induce immune responses in certain patients suggests 
that hapten modification of protein alone is not sufficient to cause 
hypersensitivity reactions.  This poses the key question: what drives some 
patients to be allergic and not others? The outcomes of immune responses may 
be ultimately determined by an orchestral scenario incorporating antigen 
formation, danger signals, immune regulation and genetic factors.  
Accumulative evidence, largely from in vitro studies, demonstrate that a high 
antigen dose favours the development of Th1 cells, whereas a low antigen dose 
favours the development of Th2 cells(Hosken et al., 1995; O'Garra, 1998; 
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O'Garra et al., 2011). In addition, a repeated high-dose of antigen has been 
shown to generate anergy or tolerance of immune responses (Gabrysova et al., 
2010; Meiler et al., 2008; O'Garra et al., 2011). Moreover, the IgE response 
against protein antigens is profoundly influenced by the dose used for 
sensitization (Barwig et al., 2010). Whether the antigen dose will have impact 
on allergic phenotypes in CF patients is currently under investigation. A 
prospective study to monitor the quantitative relationship between antigen 
formation and immunological responses in hypersensitive patients with CF 
during the desensitization process will undoubtedly help improve the safety 
profile of piperacillin in susceptible populations. 
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Chapter 6: Specificity of T-cell responses in patients with 
flucloxacillin-induced liver and skin injury and in HLA-
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6.1 Introduction 
Adverse drug reactions pose major problems both clinically and also in the drug 
development pathway. A number of drug hypersensitivity reactions have been 
linked with HLA molecules, cell surface glycoproteins expressed on professional 
APCs. HLAs represent the loci of genes that encode the MHC complex in 
humans. There are two major classes, MHC I and MHC II, so named due to 
differences in their molecular structure and function. As heterodimers, both 
classes of MHC molecule consist of an anchored heavy α chain (extracellular α1, 
α2 and α3 chain in the case of MHC I and membrane anchored α1 and α2 chain in 
MHC II molecules) and a second light chain β domain. MHC I molecules possess 
a soluble β domain known as β2microglobulin (β2m) which is not membrane 
bound, unlike class II molecules whose β domain (β1 and β2) is anchored 
(Madden, 1995). Structural differences allow the two classes of MHC molecule 
to accommodate different lengths of peptide within their antigen binding 
grooves. MHC I generally holds peptides between 8 and 11 amino acids in 
length whilst the peptide binding groove of MHC II molecules can accommodate 
longer peptides (12-25 amino acids) due to its more open structure 
(Rammensee, 1995; Speir et al., 2001).   
MHC molecules on APCs play a crucial role in the activation of T-cells. They are 
utilised as a means to display peptide antigens. This process is critical as T-cells 
are only able to recognise and respond to antigenic peptides that are bound and 
presented via the MHC complex (Rudolph et al., 2006). In general, peptides 
derived from endogenous antigens are loaded on to MHC I molecules,  which are 
presented to and recognised by receptors on CD8+ T-cells, whereas CD4+ T-
cells express receptors that recognise peptide fragments, which are presented 
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in the context of MHC II, usually derived from extracellular proteins 
(Guermonprez et al., 2002; Pamer et al., 1998).     
As a highly polymorphic region, a wide range of variant HLA alleles exist, which 
in turn interact with the wide range of possible peptides. The MHC region  is 
reported to contain around 100 genes that code for molecules involved in 
antigen presentation and immune regulation (Horton et al., 2004; Mungall et al., 
2003). Indeed, due to this high degree of variety, many drug hypersensitivity 
reactions are directly associated with particular HLA alleles. It is believed that 
HLA molecules play a direct role in the pathogenesis and development of drug 
hypersensitivity and also in the induction of self-tolerance (Bharadwaj et al., 
2010; Yun et al., 2012). Certain HLA alleles pose as risk factors for the 
development of hypersensitivity whereas others can provide protection (Mallal 
et al., 2002; Temajo et al., 2009). The association between HLA-B*57:01 to the 
antiretroviral drug abacavir and the development of hypersensitivity has been 
extensively studied (Adam et al., 2012; Chessman et al., 2008; Illing et al., 2012; 
Ostrov et al., 2012) and results perfectly demonstrate the concept of 
personalised medicine.  Pre-clinical screening of patients to identify the 
presence of the HLA-B*57:01 allele and exclusion of such patients from abacavir 
treatment significantly reduces the incidence of hypersensitivity to abacavir 
and this is now common clinical practice (Hughes et al., 2004; Mallal et al., 
2008; Zucman et al., 2007).  
Carbamazepine-mediated SJS/TEN in Han Chinese and Thai populations has a 
strong selectivity as the drug activates CD8+ T-cells in patients carrying the risk 
allele. Again screening is recommended for possession of HLA B*15:02 (Chen et 
al., 2011; Chung et al., 2004). More recently HLA-A*31:01 has been implicated 
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as a risk allele in Caucasian and Japanese populations (McCormack et al., 2011; 
Ozeki et al., 2011). Drug-specific CD8+ T-cell responses have been detected in 
donors expressing HLA-A*31:01 and the CD8+ T-cell response was HLA-
A*31:01 restricted. However, in the same HLA-A*31:01 positive donors, CD4+ 
T-cells were detected and the drug was presented to the T-cells by a variety of 
HLA class II molecules (Lichtenfels et al., 2014). 
Thus far, our investigations have focussed on delayed type skin reactions, yet 
there is an array of ways in which adverse reactions to drugs can present 
themselves. The β-lactam antibiotic flucloxacillin is widely used for 
Staphylococcus aureus infections. Unfortunately, in Europeans around 8.5 
patients in 100,000 develop cholestatic hepatitis following flucloxacillin 
treatment (Bharadwaj et al., 2010). In 2009 an association between HLA-
B*57:01 and flucloxacillin induced liver injury was identified. Despite the strong 
association only 1 in every 500 – 1000 individuals with HLA-B*57:01 develop 
DILI following treatment with flucloxacillin (Daly et al., 2009b). This clearly 
suggests that a variety of other factors including; age, metabolic capacity and 
underlying disease states contribute to the development of this iatrogenic 
disease (Chalasani et al., 2010). Furthermore, possession of the HLA-B*57:01 
allele should not be used to exclude patients from flucloxacillin treatment as 
most will not develop DILI and therefore be prevented from taking an effective 
drug. This is very different to abacavir where screening is internationally 
accepted as an essential pre-requisite to therapy. Also unlike abacavir, 
flucloxacillin does not alter the repertoire of self-peptides binding to HLA-
B*57:01 and is instead thought to bind covalently to endogenous proteins 
before resultant peptides are processed and presented to drug specific T-cells 
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via HLA-B*57:01 (Monshi et al., 2013; Norcross et al., 2012). It was with the 
association of abacavir and HLA-B*57:01 that the potential role of HLAs in 
personalised medicine really came to the forefront. As stronger and clinically 
relevant HLA associations (unlike flucloxacillin) come to light, personalised 
medicine becoming routine could be a very real possibility in the future.  
Until recently, the role of T-cells in human DILI was not well defined. PBMC 
proliferative responses to drugs in up to 65% of DILI patients was reported in 
an early study, suggesting that liver injury might indeed involve an 
immunopathological mechanism  (Maria et al., 1997). However, these T-cells 
were never characterised in terms of phenotype or function and additional 
studies have not been forthcoming. Furthermore, liver histology from a patient 
suffering from DRESS and fulminant liver failure following sulphasalazine 
treatment revealed an infiltration of granzyme B secreting T-cells in close 
proximity to apoptotic hepatocytes. These T-cells were thought to be the major 
cellular effectors for the tissue necrosis observed and in vitro proliferation tests 
confirmed the T-cells were drug specific (Mennicke et al., 2009). However, few 
studies have taken investigations further in order to fully characterise the role 
of T-cells in DILI, and information relating HLA risk alleles to T-cell responses is 
also limited. A recent study by Monshi et al. took steps to address this (Monshi 
et al., 2013). Flucloxacillin-responsive CD4+ and CD8+ T-cells generated from 
patients with liver injury were characterised in terms of phenotype and 
function and naive CD45RA+CD8+ T-cells from healthy donors expressing HLA-
B*57:01 were shown to be activated with flucloxacillin when the drug antigen 
was presented by DCs. Furthermore, activation of CD8+ T-cell clones was found 
Chapter 6 
181 
 
to be processing dependent and restricted by HLA-B*57:01 and the closely 
related HLA-B*58:01.  
In a recent study, flucloxacillin-responsive CD8+ clones from healthy donors 
with and without the HLA risk allele B*57:01 were generated to evaluate 
mechanisms of drug antigen presentation (Wuillemin et al., 2013b). 
Flucloxacillin degrades spontaneously in cell culture medium liberating a 
hapten that binds covalently to lysine residues on protein (Jenkins et al., 
2009b). Hence, it is possible to differentiate between flucloxacillin and 
flucloxacillin hapten-responsive T-cells through the use of soluble drug and 
drug-pulsed antigen presenting cells as sources of antigen. T-cells from HLA-
B*57:01 negative donors were preferentially activated via a hapten mechanism 
involving protein processing. In contrast, the parent drug was found to activate 
most T-cells in HLA-B*57:01+ donors. These data led the authors to conclude 
that the parent drug drives T-cell responses in HLA-B*57:01+ donors and liver 
reactions in susceptible patients.  In this chapter, we aim to expand on the 
current information and further investigate the relationship between the 
genetic association and immune basis for DILI. 
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6.2 Aims and Hypothesis 
With the discovery of HLA-B*57:01 as a risk factor for flucloxacillin-induced 
liver injury, this chapter aims to further investigate the flucloxacillin-specific T-
cell response in HLA-B*57:01 patients with DILI and a patient expressing the 
risk allele who developed a serious skin reaction. Specific objectives included; 
(1) exploration of T-cell responses in HLA-B*57:01 donors and patients to 
identify differences between patients suffering from different forms of 
hypersensitivity reactions, (2) investigation of HLA specificity by utilising an 
array of different APCs expressing different HLA molecules and finally (3) 
investigation of flucloxacillin binding primary human hepatocytes. With these 
aims and previous literature in mind I propose the following hypotheses: 
(1)Mechanisms for the development of an immune response will differ between patients 
and volunteers. 
(2)Fine specificity to HLA alleles will be observed in flucloxacillin specific T-cells. 
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6.3 Methods  
The methods used in this chapter are described fully in Material and Methods, 
Chapter 2. A brief experimental outline is detailed below.  
Scheme 6.1 Experimental plan and methods used in this chapter 
Specificity of T-cell responses in patients with 
flucloxacillin-induced liver and skin injury and in HLA-
B*57:01 volunteers
T-lymphocyte response to drug → LTT and PBMC ELISpot
Generation of drug-specific T-cell clones for mechanistic studies 
Proliferation assays and IFN-γ ELISpot to confirm specificity
PBMC collection
4 x patients with liver injury, 1 x patient with skin injury
4 x HLA-B*57:01 healthy donors
Characterise T-cell clones from patients and volunteers
MHC restriction Antigen presentation: 
soluble flucloxacillin 
and flucloxacillin 
pulsed APCs
HLA-B allele 
restriction:
APC mismatch 
assays
Primary hepatocyte culture
Determine presence of 
flucloxacillin-modified albumin
Western blot Mass spectrometry
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6.4 Results 
We are fortunate here at the University of Liverpool to have close connections 
to the Royal Liverpool and Broadgreen University Hospital (RLBUHT) enabling 
recruitment of patients with flucloxacillin-induced liver and skin injury. 
Furthermore, the university hosts a unique cohort of 1000 genotyped healthy 
volunteers. Access to this biobank of lymphocytes from HLA-typed volunteers 
has also allowed us examine T-cell responses to flucloxacillin lymphocytes from 
HLA-B*57:01 positive drug naive blood donors.  
6.4.1Flucloxacillin specific PBMC response 
PBMCs were isolated from patients with flucloxacillin-induced liver injury and 
from one patient, patient 018, who developed a severe cutaneous 
hypersensitivity reaction (AGEP) following flucloxacillin exposure. Patient 
characteristics and HLA type are detailed in Table 6.1. It was interesting to 
observe that lymphocyte proliferative responses were not detected in any of the 
DILI patients (Figure 6.1A), though we later used clones generated from these 
patients to explore mechanisms involved in the T-cell response. Proliferative 
responses from patient 018 were detected following PBMC isolation and in vitro 
culture with titrated concentrations of flucloxacillin (Figure 6.1C). PBMC 
responses to flucloxacillin were also detected using an IFN-γ ELISpot, not only 
in the patient with skin injury but also from the PBMCs of patients with DILI 
(Figure 6.1B). As shown in Figure 6.1D secretion of IFN-γ was dose dependent 
and ELISpot assays also showed flucloxacillin induced secretion of IL-13 and 
Granzyme B (Figure 6.1B).   
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Table 6.1 Clinical details and HLA-B*57:01patients  
Patients 1 – 4 are those with flucloxacillin-induced liver injury 
* Patient 018 suffered from a skin reaction following exposure to flucloxacillin. Patient 018 was 
given flucloxacillin twice over the last 10 years and was diagnosed with AGEP on both 
occasions. Details of both reactions are shown and despite lower elevated ALT liver function 
tests were also conducted. 
ULN = upper limit of normal (ALT, alanine aminotransferase – 35, bilirubin – 17, ALP, alkaline 
phosphatase – 125). RUCAM = Roussel Uclaf Causality Assessment Method, cases were 
evaluated by application of the Council for International Organizations of Medical Science scale. 
The pattern of liver injury was classified according to the International Consensus Meeting 
Criteria. 3–5 = possible, 6–8 = probable, >8 = highly Probable. RUCAM score not obtained for 
patient 018. Diagnosis of DILI was done by expert hepatologists.  
 
 
 
 
 
 
 
 
 
 
ID
Age/ 
gender
Peak liver function tests at 
time of liver injury
Time to 
Onset
RUCAM 
Score
Since 
Reaction
ALT Bilirubin ALP weeks years
P1 61/M 23x ULN 3x ULN 9x ULN 3 7 11
P2 73/F 13x ULN 12x ULN 2x ULN 4 3 2
P3 90/F 11x ULN 13x ULN 4.5x ULN 3 6 3
P4 65/F 4x ULN 36x ULN 2x ULN 3 5 3
P018* Reaction 1 2x ULN 0.5x ULN 1.5x ULN 2 - 10
58/M Reaction 2 3x ULN 1x ULN 1x ULN 1 day - 4
Li
ve
r 
in
ju
ry
Sk
in
 in
ju
ry
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Figure 6.1 Flucloxacillin specific stimulation of patient PBMCs   
(A and C) PBMCs were incubated with flucloxacillin (0.05 – 4mM) for 6 days with [3H]-
thymidine added to cultures in the last 16 hours to detect lymphocyte proliferation, as per LTT 
assay. CPM = counts per minute. Culture medium (0) and tetanus toxoid (TT, 0.5mg/ml) were 
used as negative and positive controls respectively. Data from patients with DILI shown in (A 
and B) and LTT of patient 018 with flucloxacillin induced AGEP is shown in (C) Flucloxacillin-
specific IFN-γ secretion from patient PBMCs was detected by ELISpot assay. Cells were cultured 
with flucloxacillin (0.25 – 4mM) for 2 days before plates were developed for spot detection. (B) 
Flucloxacillin-specific (1mM) IFN-γ IL-3 and Granzyme B secretion from DILI patient PBMCs 
using cytokine specific ELISpot assays. (D) IFN-γ ELISpot from skin patient 018. 
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6.4.2 Characterisation of flucloxacillin-specific T-cell clones  
PBMCs from patients who had previously suffered from flucloxacillin-induced 
liver injury and PBMCs from one patient who had experienced a severe skin 
reaction (AGEP, Pt. 018) following administration of flucloxacillin were used to 
generate T-cell clones, specific to flucloxacillin (Table 6.2). Finally, flucloxacillin 
specific clones were also generated from the PBMCS of HLA-B*57:01 positive 
healthy volunteers from our HLA-typed cohort using our recently developed 
DC/T-cell co-culture system that effectively primes naive T-cells. The process of 
T-cell cloning involves the pre-selection of CD8+ T-cells, however magnetic 
bead isolation is not absolute and though most of the T-cell clones generated 
were CD8+, 15% of the total flucloxacillin-specific T-cell clones generated were 
found to be CD4+ T-cells following analysis by flow cytometry. These data agree 
with our previous study showing CD4+ and CD8+ T-cells in patients with DILI 
(Monshi et al., 2013). The clones from the patient with flucloxacillin-mediated 
AGEP were all CD8+.  
 
Chapter 6 
188 
 
 
Table 6.2 Number and phenotype of flucloxacillin-specific T-cell clones generated.  
Patient ID’s are prefixed by the letter P and healthy volunteers with a V. Majority of clones 
generated from patients were from those with liver injury (P1-4, see table 1 for clinical details). 
Patient 018 had previously developed a skin reaction to flucloxacillin. 
 
T-cell clones were assessed for specificity using a standard 72 hour 
proliferation assay. T-cell clones were co-cultured with EBV-transformed B-
cells, which were used as APCs, and flucloxacillin.  Cells were incubated at 37°C 
in an atmosphere of 95%O2/5% CO2 for 48 hours with [3H] thymidine (0.5µCi) 
added in the last 16hrs of the incubation to assess lymphocyte proliferation. 
CD8+ T-cell clones generated from the PBMCs of patients with liver and skin 
injury and healthy volunteers were antigen specific and lymphocyte 
proliferation was dose dependent (Figures 6.2-6.4).  
 
 
 
 
 
ID No. specific 
clones
CD4+
(%)
CD8
(%)
CD4+/CD8+
(%)
Patient clones
P 1 - 4 90 8 88 2
P 018 7 0 100 0
HLA*B57:01+ volunteer clones
V 1 11 100 0 0
V2 28 0 100 0
V3 4 0 100 0
V4 3 0 100 0
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Figure 6.2 Flucloxacillin specific proliferation of T-cell clones  
Each data point represents mean [3H] incorporation as a measure of proliferation from 
flucloxacillin specific clones. T-cell clones were generated from patient with (A), liver injury, 
n=22, (B) one patient with skin reaction, n=5 and from (C) healthy volunteer, n=13. CPM = 
counts per minute. 
 
Individual proliferation data from nine T-cell clones generated from patients 
with liver and skin injury are shown in Figure 6.3 and representative cytokine 
secretion data is presented in Figure 6.4. These data confirm antigen specificity 
and highlight the range in responses seen. Some T-cell clones react readily 
following flucloxacillin exposure whereas others respond less vigorously, 
though still show positive dose dependent proliferative responses and cytokine 
release. Concentrations of 0.25mM and 0.5mM are often sufficient to elicit a 
proliferative response or indeed stimulate cytokine secretion, whilst 4mM 
flucloxacillin appears to be cytotoxic.  
We also observed no difference in the dose-dependent response from patients 
and healthy donors (Figure 6.5). 
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Figure 6.3 T-cell clones proliferate in a dose-dependent manner  
Proliferation following flucloxacillin exposure (0-4mM) was assessed. T-cell clones were co-
cultured with APCs and drug at 37°C in an atmosphere of 95%O2/5% CO2 for 72 hours. [3H] 
thymidine incorporation (0.5µCi) added in the last 16 hours of incubation was used to assess 
antigen specific proliferation. Data from 9 representative clones shown. CPM = counts per 
minute. 
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Figure 6.4 Cytokine secretory response of flucloxacillin specific T-cell clones is dose dependent   
Drug specific secretion of IFN-γ and IL-13 was determined via cytokine specific ELISpot assay. 
Plates were first coated with specific cytokine antibodies and incubated overnight. T-cell clones 
were then co-cultured with APCs and drug for 48 hours after which plates were developed for 
visualisation of spots according to manufacturer’s instructions. Six representative clones shown. 
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Figure 6.5 No difference in proliferation is seen between T-cell clones generated from patients 
and volunteers. Activation of T-cell clones from healthy donors (n=7) and patients (n=7) with 
titrated concentrations of flucloxacillin. Proliferation was measured after 72h through the 
addition of [3H] thymidine. CPM = counts per minute. Mean CPM are shown in the figure. 
Student T-test was used to compare the response of clones from patient and healthy donors at 
each drug concentration. Significant differences were not detected. 
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6.4.3 Activation of flucloxacillin-specific T-cell clones is MHC 
restricted 
Using anti-human MHC I and MHC II blocking antibodies we endeavoured to 
determine if CD4+ and CD8+ T-cell activation (proliferative activity) was 
restricted by MHC I or II. A panel of clones generated from both patients and 
healthy volunteers were tested for MHC-restriction. The proliferation of CD8+ 
T-cell clones was found to be restricted by MHC I, but not MHC class II (Figure 
6.6, clones 764, 122 and 42). The opposite was true of CD4+ flucloxacillin 
specific T-cell clones; addition of MHC I blocking antibody did not negatively 
affect proliferative activity whereas blockade of MHC II inhibited activation 
(Figure 6.6, clones 8 and 3). Finally, MHC I restriction was observed with dual 
positive T-cell clone 14. No decrease in proliferation was seen following 
addition of the MHC II blocking antibody. In fact proliferative activity increased 
suggesting activation of this clone is MHC I restricted. Thus, our results show 
that the proliferation of T-cell clones from patients and healthy donors are 
indeed MHC-restricted according to the phenotypic characteristics of the T-cells 
in question.  
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Figure 6.6 MHC restricted flucloxacillin recognition 
Autologous EBV-transformed B-cells were pre-incubated with or without MHC I or MHC II 
blocking antibodies (5μl/ml) for 30 minutes at 37°C before co-culture with flucloxacillin-
specific T-cell clones in the presence or absence of flucloxacillin. Cells were incubated for 48 
hours at 37°C in an atmosphere of 95%O2/5% CO2. [3H] thymidine (0.5µCi) was added in the 
last 16 hours of incubation to determine antigen specific proliferation. Data from 6 
representative clones from liver patient and healthy volunteer are shown. CPM = counts per 
minute. 
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6.4.4 Activation of clones from healthy donors and DILI patients with 
soluble flucloxacillin and flucloxacillin-pulsed APCs 
The following section focuses on CD8+ T-cell clones from HLA-B*57:01+ DILI 
patients and healthy donors to explore mechanisms of antigen presentation. 
Flucloxacillin degrades spontaneously in cell culture medium liberating a 
hapten that binds covalently to lysine residues on protein (Jenkins et al., 
2009b). It is therefore possible to differentiate between flucloxacillin and 
flucloxacillin hapten-responsive T-cells through the use of soluble flucloxacillin 
and flucloxacillin-pulsed antigen presenting cells as sources of antigen. 
Flucloxacillin-specific T-cell clones were cultured with autologous EBV-
transformed B-cells (APCs) and soluble flucloxacillin (1mM) or APCs that had 
been pulsed for 16 hours with flucloxacillin (1mM). Proliferative responses 
were measured using [3H]-thymidine incorporation after 48 hours. CD8+ T-cell 
clones from healthy donors were activated to proliferate with soluble 
flucloxacillin, but not flucloxacillin-pulsed antigen presenting cells (Figure 6.7).  
The results obtained with T-cell clones obtained from DILI patients somewhat 
contrasted with the results seen from healthy donors; all clones were activated 
with soluble flucloxacillin and flucloxacillin-pulsed antigen presenting cells. 
Binding of flucloxacillin to lysine residues on the model protein human serum 
albumin was measured to confirm that hapten-protein adducts are formed 
during the 16h culture period (Figure 6.8A). Importantly, in our next 
experiment antigen presenting cells were pulsed with flucloxacillin for different 
durations (4-48h) and responses were not detected in T-cell clones from 
healthy donors (Figure 6.8B). However, with MHC class I restricted 
flucloxacillin-specific CD8+ T-cell clones generated from PBMCs of HLA-
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B*57:01+ patients with liver injury, different results were obtained confirming 
the results from Figure 6.7. Clones were activated with soluble flucloxacillin and 
flucloxacillin-pulsed antigen presenting cells and we found that T-cell 
proliferative responses (n=5 clones) were detected consistently when antigen 
presenting cells were pulsed with flucloxacillin for 24-48h (and after 4h, to a 
lesser extent; Figure 6.8B).   
 
 
 
Figure 6.7 Activation of clones generated from healthy donors and patients with flucloxacillin-
induced liver injury with soluble flucloxacillin or flucloxacillin -pulsed APCs.  
Proliferation was measured by the addition of [3H]-thymidine in the last 16 hours of 
experiment. Data as Mean+/-SD (Student T-test was used to compare datasets [***P<0.001])   
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Figure 6.8 Patient T-cell clones are activated by flucloxacillin-pulsed APCs  
(A) Binding of flucloxacillin to lysine residues on human serum albumin. Mass spectrometry 
was used to measure the epitope profile of the lysine residues on albumin modified in antigen 
presenting cell culture after 16h. (B) Activation of flucloxacillin-specific CD8+ T-cell clones from 
patients with liver injury and healthy donors with soluble drug and antigen presenting cells 
pulsed with drug for 4-48h. Proliferation was measured by the addition of [3H] thymidine in last 
16h of culture. 
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6.4.5 Flucloxacillin derived haptens activate CD8+ T-cell clones from 
patients with liver injury in a HLA allele-restricted manner  
To explore further HLA-specific restriction, in particular whether flucloxacillin 
haptens are presented to T-cells in a HLA-B*57:01 restricted manner, 
flucloxacillin-specific T-cell clones from patients with DILI were incubated 
alongside autologous APCs and a variety of APCs expressing different HLA-B 
alleles, allowing us to determine the role of certain HLA alleles in the activation 
of T-cells from DILI patients. All APCs used were transformed B-cells and in 
initial experiments, clones were exposed to flucloxacillin pulsed APCs, but not 
the free drug.  
Three panels of APCs were generated from the PBMCs of healthy donors 
selected from our HLA-typed cohort (Alfirevic et al., 2012). Donors were 
selected to provide APCs that expressed a broad array of HLA-B alleles. 
Individual clones were cultured with flucloxacillin-pulsed APCs from between 5 
and 12 allogeneic donors. T-cell clones were activated in a highly HLA-
restricted fashion; proliferative responses were only detected with antigen 
presenting cells expressing HLA-B*57:01 and in some instances the closely-
related HLA-B*58:01 (Figure 6.9B, C, E).  
 
 
 
 
 
 
 
Chapter 6 
199 
 
6.4.5 Soluble flucloxacillin activates CD8+ T-cell clones from patients 
with liver injury in a HLA unrestricted manner 
In parallel experiments, additional reactivity was tested using soluble drug as a 
source of antigen. Certain clones were activated with flucloxacillin in an allele 
unrestricted fashion (Figure 6.9F; clones 1 and 2); whereas other clones were 
activated in the presence of 15-50% of the APCs expressing different HLA-B 
alleles (Figure 6.9A).  
6.4.6 Flucloxacillin binding to albumin is readily detectable in vitro. 
Primary hepatocytes were cultured with flucloxacillin (0 – 4mM) for 48 hours in 
media containing albumin (R9 media) and serum free media (Williams media) 
to identify formation of flucloxacillin derived haptens. Western blots with a 
flucloxacillin-specific antibody (formed in rabbit, kindly donated by Frank Van 
Pelt, University College Cork, Ireland) confirmed flucloxacillin-modified 
albumin in the supernatant of cells cultured in albumin-containing media 
(Figure 6.10A). Formation of the protein adduct was dose dependent. However 
flucloxacillin-derived haptens were not detected by western blot in viable 
hepatocytes.  
When hepatocytes were cultured with flucloxacillin in serum free Williams 
media, an array of drug modified proteins were detected. Due to the spread of 
bands visible we cannot be certain that the band seen at 66Kda (albumin) is 
indeed flucloxacillin-modified albumin. 
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Figure 6.9 HLA specific recognition of flucloxacillin and activation of antigen-specific patient T-
cell clones varies in pulsed and non-pulsed APCs 
Activation of flucloxacillin-specific CD8+ T-cell patient clones with soluble drug (A, F) and 
flucloxacillin-pulsed APCs (B,C,E) using 3 panels of allogeneic APCs.  (A and F) APCs were co-
cultured with flucloxacillin-specific T-cell clones and soluble flucloxacillin for 72 hours at 37°C 
in an atmosphere of 95%O2/5% CO2. [3H]-thymidine (0.5µCi) was added in the last 16 hours to 
determine T-cell proliferation. (B, C, and E) APCs were pulsed with flucloxacillin for 24 hours 
before three washes were applied to remove free drug. APCs were co-cultured with 
flucloxacillin-specific T-cell clones for 48hours with proliferation measured by the addition of 
[3H-thymidine. CPM= counts per minute. 
 D. Table showing HLA-B alleles expressed on antigen presenting cells used in (A and B). (C and 
F) Data as Mean+/-SD (student T-test was used to compare datasets [*P<0.05]).  
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We therefore continued with a coomassie assay to visualise protein and the 
appropriate section of the gel was cut out and digested for mass spectrometric 
analysis. The mass spectrometery work was conducted by Dr Roz Jenkins (MRC 
Centre for drug safety science). Three flucloxacillin-modified albumin peptides 
were detected; LAK*TYETTLEK, NLGK*VGSK and K*QTALVELVK. The MS/MS 
spectrum for peptide LAK*TYETTLEK is shown (Figure 6.10).  Although drug-
modified peptides were detected at this stage we cannot be certain of the 
formation of flucloxacillin derived haptens in hepatocytes. In our hepatocyte 
cultures, we observed significant cell damage when hepatocytes were cultured 
with 4mM flucloxacillin and in some instances also with 2mM flucloxacillin. 
Such high concentration may be toxic as cells often did not survive in cultures of 
4mM flucloxacillin; these observations mirror the lack of proliferation seen in T-
cell cultures at 4mm flucloxacillin. In these preliminary experiments cell 
damage, breakdown and lysis of cell proteins could provide sites for 
flucloxacillin binding.  
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Figure 6.10 Flucloxacillin-modified albumin can be detected in vitro 
(A) Primary hepatocytes isolated from a liver segment of a consenting patient were seeded onto 
a collagen I coated 6-well plate (1.5 x 106 cells per well) and left to adhere for 3-4 hours. 
Medium was then replaced to remove unattached hepatocytes and cells were left to culture at 
37°C in an atmosphere of 95%O2/5% CO2 overnight. Media was removed and cells dosed with 
flucloxacillin (0 – 4mM) in ether R9 media (supplemented with albumin) or Williams media 
(serum free). Following 48 hours incubation hepatocytes were harvested and supernatants 
collected.  Protein concentration of the lysed cell pellets and supernatants were determined 
using Bradford assay and western blot with anti-flucloxacillin antibody conducted. (B) 
Coomassie stain and western of hepatocyte cell lysates. (C) MS/MS spectra of flucloxacillin 
modified LAK*TYETTLEK. 
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6.5 Discussion 
Adverse drug reactions including cutaneous hypersensitivity reactions and 
DILI, can develop into serious and sometimes fatal problems placing an 
enormous burden on any health care system (Davies et al., 2009; Lazarou et al., 
1998; Pirmohamed et al., 2004). Strong HLA associations for abacavir (Mallal et 
al., 2002), carbamazepine (Chung et al., 2004; McCormack et al., 2011) and 
allopurinol (Hung et al., 2005) reactions have been identified, to name a few. 
Numerous studies have explored the role of HLA alleles in the presentation of 
drugs to T-cells, particularly with the anti-retroviral drug abacavir allowing the 
complex structural interactions between the MHC-peptide complex, the drug 
molecule and the T-cell receptor to be characterised (Illing et al., 2012; Mallal et 
al., 2008; Yun et al., 2012).  
The β-lactam antibiotic flucloxacillin is another drug with a strong HLA-
association with an adverse reaction. However this does not translate to the 
clinical problem. Individuals with the HLA-B*57:01 allele are at an 80-fold 
increased risk of developing flucloxacillin-induced liver injury but only 1 in 
1000 drug-exposed individuals with HLA-B*57:01 would actually develop DILI 
(Daly et al., 2009b). Thus, pre-clinical screening of patients about to embark on 
flucloxacillin treatment is not recommended. This highlights that a variety of 
other risk factors no doubt contribute to the development of most forms of 
idiosyncratic drug reaction. These could include the chemical properties of the 
drug in question, viral infection (i.e. HIV and herpes virus), age and gender, T-
cell repertoire and other genetic predispositions (Coopman et al., 1993; 
Guglielmi et al., 2006; Kim et al., 2010; Ko et al., 2011; Schmid et al., 2006; 
Shiohara et al., 2006; Thong et al., 2011) 
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The aims of this chapter were to generate CD8+ T-cell clones from DILI patients 
and healthy donors expressing HLA-B*57:01 after priming to investigate 
mechanisms of antigen presentation and in particular, how restricted the T-cell 
response is to HLA-B*57:01. The availability of a flucloxacillin AGEP patient 
expressing HLA-B*57:01 allowed us also to investigate whether class I 
restricted CD8+ T-cells circulate in patients with skin reactions. Finally, using 
primary human hepatocytes, it was possible to characterise binding of the 
flucloxacillin hapten to cellular and extracellular protein. 
Proliferation assays with PBMCs from DILI patients and HLA-B*57:01+ 
volunteers were largely negative. Indeed no lymphocyte proliferation was seen 
in any PBMCs aside from those isolated from a patient who developed a severe 
skin reaction (AGEP) following flucloxacillin treatment.   LTT data from this 
patient showed clear dose-dependent proliferation, with SI’s reaching up to 35, 
much greater than the SI of 3.8 recorded with the positive control (TT).  
AGEP, a rare but severe cutaneous adverse reaction, is characterised by its 
typical morphology of an acute edematous erythema or skin eruption with 
dozens of small non-follicular neutrophil-rich sterile pustules. These skin 
symptoms are almost always accompanied by a high fever, leukocytosis 
(neutrophilia and sometimes eosinophilia) and facial swelling (Halevy, 2009; 
Speeckaert et al., 2010). Histological studies, positive skin patch tests and 
positive LTTs have suggested a role for drug-specific T-cells in the pathogenesis 
of AGEP (Halevy, 2009). Furthermore drug-specific CD4+ and CD8+T-cells have 
been isolated from the blood and skin of AGEP patients and more recently drug-
specific Th17 cells have been identified in the peripheral blood of patients 
(Britschgi et al., 2001; Filì et al., 2014). Given the immune pathomechanism 
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involved in the development of AGEP it is perhaps not surprising that PBMCs 
from the patient with flucloxacillin-induced AGEP proliferated vigorously when 
stimulated in vitro in the presence of the drug.  
We should not however rule out immunological involvement in DILI patients,  
as low levels of PBMC activation with flucloxacillin was detected using an IFN-γ 
ELISpot assay; antigen-driven cytokine release was observed in all 4 DILI 
patients with the drug-specific release of IL-13 and granzyme B also detectable 
in one patient where sufficient cells were available to test (Figure 6.1). 
 T-cells from flucloxacillin-treated PBMCs of patients with liver and skin 
reactions were cloned and expanded. Clones were tested for flucloxacillin 
reactivity and used to characterise HLA restriction and mechanism(s) of drug-
specific T-cell activation. In contrast with abacavir, where CD8+ T-cells are 
exclusively activated with the drug, flucloxacillin-specific CD4+ and CD8+ T-cell 
clones were generated (Chessman et al., 2008). Activation of the T-cell clones to 
proliferate and secrete cytokines with flucloxacillin was concentration 
dependent. T-cell clones were highly sensitive to the dose of flucloxacillin used, 
with concentration greater than 2mM likely to be toxic in the majority of clones 
and in some cases even 1mM, whilst doses less than 0.25mM did not often 
induce positive responses. With a 500mg oral dose of flucloxacillin,  peak serum 
concentrations of 14.5mg/l or 31µM has been reported (MHRA, 2014b). These 
concentrations of flucloxacillin are not consistent with those required for 
activation of T-cell clones, yet the antigen formed in vivo may not be formed at 
the same level in vitro.  In addition, with significant biliary excretion local 
concentrations of flucloxacillin in the liver are likely to be higher than the 
recorded plasma concentration. Our first experiments have shown that CD8+ T-
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cells from HLA-B*57:01+ patients with liver injury and flucloxacillin-induced 
skin reaction are activated by the offending drug.  
 
To further explore the functional role of HLA-B*57:01 in the presentation of 
flucloxacillin to T-cells, T-cell clones generated from patients and from HLA-
B*57:01+ volunteers were utilised to define the role of APCs in the T-cell 
response. APCs were first excluded from the T-cell assay and proliferative 
responses to the drug were not detected in the absence of APCs.  
Flucloxacillin-specific T-cell responses were also dependent on the drug derived 
antigen interacting with specific MHC molecules as the proliferative response of 
CD8+ T-cell clones was restricted by MHC I whilst CD4+ T-cells were restricted 
by MHC class II molecules. Thus to activate T-cells, flucloxacillin or 
flucloxacillin-derived antigens must interact with HLA molecules expressed on 
professional APCs.   
Many drug hypersensitivity reactions are now associated with expression of 
specific HLA risk alleles (Daly et al., 2012; Phillips et al., 2011). This has led to a 
renewed interest in characterizing the drug immunological receptor interaction. 
Immunology doctrine states that the activation of T-cells is dependent on the 
binding of MHC bound peptides to specific T-cell receptors. Peptide binding 
stimulates signal transduction events that ultimately lead to the T-cell response. 
In the context of drug hypersensitivity, the drug (or product of metabolic or 
auto oxidation) interacts in some way with this MHC peptide T-cell receptor 
complex to trigger T-cells that wouldn’t be activated in the absence of drug. 
Drug-responsive T-cells are activated by (1) HLA-restricted peptides derived 
from hapten protein conjugates (Whitaker et al., 2011b), (2) peptide sequences 
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displayed by MHC molecules with drugs bound to the antigen binding cleft 
(Illing et al., 2012) and potentially (3) drugs interacting directly with natural 
HLA binding peptides (Ostrov et al., 2012; Yun et al., 2014). We wanted to 
explore these concepts further with respect to (1) the nature of the drug 
antigen presented in the context of the HLA molecules and (2) whether HLA-
B*57:01 is the only HLA molecule that flucloxacillin antigens interact with to 
activate T-cells.  
Wuillemin et al (Wuillemin et al., 2013b) recently generated flucloxacillin-
responsive CD8+ clones from healthy donors with and without the HLA risk 
allele B*57:01 to evaluate mechanisms of flucloxacillin antigen presentation. T-
cells from HLA-B*57:01 negative donors were preferentially activated via a 
hapten mechanism involving protein processing. In contrast, the parent drug 
was found to activate most T-cells in HLA-B*57:01+ donors. These data led the 
authors to conclude that the parent drug drives T-cell responses in HLA-
B*57:01+ donors and liver reactions in susceptible patients. In initial 
experiments, we utilized MHC class I-restricted CD8+ clones generated from 
HLA-B*57:01+ donors after priming naïve T-cells with autologous dendritic 
cells and soluble flucloxacillin. A detailed description of antigen-specificity, 
dose-response profile, cellular phenotype and cytokine secretion of 
flucloxacillin clones generated using this method (and from patients with liver 
injury) has been reported previously (Monshi et al., 2013). In agreement with 
Wuillemin et al. (Wuillemin et al., 2013b) most clones were activated to 
proliferate with soluble flucloxacillin, but not flucloxacillin-pulsed antigen 
presenting cells (Figure 6.7). MHC class I restricted CD8+ T-cells were also 
generated directly from PBMC of patients with liver injury. Using the 
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methodological approach outlined above, we obtained somewhat contrasting 
results with patient clones; all clones were activated with soluble flucloxacillin 
and flucloxacillin-pulsed antigen presenting cells. Collectively, these data 
suggest that flucloxacillin haptens drive T-cell responses in patients, whereas 
the high levels of soluble drug used during in vitro priming drives the expansion 
of clones responsive against the parent drug.  
 
Using CD8+ T-cell clones from patients with liver injury that were activated 
with soluble flucloxacillin and flucloxacillin-pulsed antigen presenting cells we 
could probe the specificity of the drug-HLA binding interaction. With three 
panels of EBV-transformed B-cells, used as APCs, a wide range of HLA-B alleles 
could be investigated. T-cell clones exposed to pulsed APCs were activated in a 
highly HLA-restricted fashion; proliferative responses were only detected with 
antigen presenting cells expressing HLA-B*57:01 and at times the structurally-
similar HLA-B*58:01 (Figure 6.9B, C, E). When soluble flucloxacillin was used as 
the antigen however, additional reactivity was detected with APCs expressing a 
variety of HLA-B alleles. Certain clones were activated with flucloxacillin in an 
allele unrestricted fashion (Figure 6.9F; clones 1 and 2); whist others were 
activated in the presence of a number of APCS expressing different HLA-B 
alleles (Figure 6.9A). Collectively, these data describe a highly HLA-B*57:01 
restricted presentation of flucloxacillin-derived antigens to CD8+ T-cells. 
Experiments using soluble drug show that at the high drug concentrations 
required to activate T-cells, binding interactions occur with multiple HLA 
molecules that are unlikely to occur in patients.     
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Finally, preliminary work utilising freshly isolated primary hepatocytes was 
conducted to investigate flucloxacillin binding in these cells. Flucloxacillin-
modified albumin was easily detected in the supernatants of hepatocyte 
cultures with albumin supplemented media via western blot. In serum free 
media however, binding was only observed in the cell lysates, not the 
supernatant. Mass spectrometry confirmed the presence of three drug-modified 
peptides, however the cell damage observed at the high concentrations of 
flucloxacillin (2-4mM) may have provided binding sites for flucloxacillin that 
are unlikely to be seen in patients without overt liver injury. Further 
investigation is therefore required to confirm the formation of flucloxacillin 
derived haptens in hepatocytes and the relationship between adduct formation 
and the immune response.  
 
In conclusion, through the study of flucloxacillin-induced liver injury, we have 
shown that patient T-cells are preferentially activated via a hapten mechanism. 
Furthermore, the activation of T-cells (presumably by hapten-modified 
peptides) is highly HLA restricted. These data have important implications for 
studies focusing solely on drug-specific T-cells derived from healthy human 
donors. 
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Chapter 7: Final Discussion 
 
ADRs are a major health concern accounting for around 6.5% of hospital 
admissions and costing the NHS in the ukover £466 million each year 
(Pirmohamed et al., 2004). Furthermore, with the time and huge cost involved 
in the development of a new drug (approx. 10 years, $868 million) withdrawal 
of a drug due to an ADR can be crippling (Adams et al., 2006). Scientific 
research, particularly in the early stages of drug development, to predict and 
therefore avoid such reactions is absolutely necessary.  
While Type A reactions are more common, off-target Type B reactions are more 
serious, frequently leading to drug withdrawals and even mortality due to their 
unpredictable, idiosyncratic nature (Routledge et al., 2004). Many of these 
reactions have an immune aetiology and are indeed drug hypersensitivity 
reactions. It is therefore important for susceptible patients to avoid ADRs if they 
are preventable. 
 
Major scientific advances in characterising the nature of the drug-specific 
immune response has led to success stories like the now absent presentation of 
abacavir hypersensitivity syndrome due to patient pre-screening for HLA-
B*57:01 (Mallal et al., 2008). However, there is still some way to go in fully 
understanding the complexity of drug hypersensitivity and with further 
research the hope is to manage this form of immunological ADR successfully. 
 
Two major hypotheses exist that help explain the ability of drugs to initiate an 
immune-mediated response against cells of the host. The first, known as the 
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hapten hypothesis, details how drugs or their metabolites bind covalently to 
host proteins. The haptenated proteins are taken up by specialised antigen 
presenting cells, processed, and cleaved into shorter peptide fragments which 
are presented to T-cells and their receptors via MHC molecules  (Landsteiner et 
al., 1935; Park et al., 2001). On the other hand, the p-i concept proposes that T-
cells can be stimulated without the need for cellular processing. This hypothesis 
states that non-covalent interactions between the drug itself, the T-cell receptor 
and the MHC molecule is sufficient to elicit an immune response (Pichler, 2002). 
Both mechanisms attempt to describe the unique interaction between drug, T-
cell receptor, MHC molecule and/or MHC binding peptide. For a number of 
drugs, years of research have allowed the nature of the interaction to be 
determined. 
 
DNCB and penicillin are known protein reactive chemicals that bind directly to 
nucleophilic amino acid residues to generate novel antigenic determinants that 
activate T-cells via a hapten mechanism (Kitteringham et al., 1985; Landsteiner 
et al., 1935). The field, however, is complicated by the fact that these chemicals 
bind to MHC, potentially modifying the structure of the peptide binding groove, 
and also MHC bound peptides. Thus, drugs that bind covalently to protein have 
the potential to activate T-cells via 4 pathways. Each of these pathways involves 
protein processing to liberate antigenic peptides; however, with one pathway, 
T-cell receptors may be triggered even when protein processing is blocked. 
Pathway 1 (classical hapten mechanism) involves drug-protein binding, 
processing of drug-modified protein, liberation of drug modified and 
unmodified peptides and binding of the modified peptides to MHC molecules 
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(Adam et al., 2011; Landsteiner et al., 1935; Yun et al., 2012). The second 
pathway has essentially the same origin as pathway 1; however, here drug-
protein binding leads to an alteration of the sites of amino acid cleavage during 
processing. This subsequently generates a novel peptide sequence (without 
drug bound), some of which associate with MHC to activate T-cells. Pathway 3 
involves the drug binding directly to MHC outside the MHC peptide binding 
cleft, but in a manner that alters the structure of the cleft. Novel peptides bind 
to this “altered” MHC activating T-cells (Illing et al., 2012; Norcross et al., 2012). 
Finally, pathway 4 involves a direct interaction between drug and MHC bound 
peptide (Gerber et al., 2006; Pichler, 2002; Schnyder et al., 1997). Here, T-cell 
activation might occur in the absence of protein processing if MHC associated 
peptides contain drug binding sites. Alternatively, protein processing may 
liberate “relevant” MHC binding peptides for drug. From this brief discussion 
one can see the complexity of identifying and defining pathways of drug-specific 
T-cell activation in vitro.  
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Figure 7.1 Mechanisms of drug hypersensitivity 
Pathways 1 and 2 involve the formation of haptens and crucially, processing by the antigen 
presenting cell. Both drug modified or unmodified peptides may be presented to the T-cell in 
the classical hapten mechanism (1). Drug modification liberates novel peptides which may 
activate T-cells (2). (3) Altered peptide hypothesis; direct binding of drug to MHC alters 
structure and the repertoire of peptides able to bind and elicit a response. (4) p-i mechanism 
whereby drug binds non-covalently and interacts directly with the TCR (with or without 
peptide present. 
 
 
Moreover, as will become clear below, T-cells from the same patient seem to 
receive drug triggering signals via multiple mechanisms, with the “apparent” 
dominant pathway determined somewhat by the experimental conditions and 
the nature of the antigen added to the experiment (Illing et al., 2012). Hence, 
conclusions relating individual pathways of T-cell activation observed in vitro to 
what occurs in the hypersensitive patient should be made with caution.    
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Drugs such as carbamazepine, allopurinol and sulfamethoxazole are known to 
activate T-cells thorough a pathway best described by the p-i concept 
(Castrejon et al., 2010a; Naisbitt et al., 2003a; Schnyder et al., 1997; Wu et al., 
2006; Yun et al., 2012). The parent compound activates T-cells via formation of 
non-covalent bonds with antigen presenting cells. The response of T-cells is 
incredibly rapid (T-cell activation is detected in minutes); thus, protein 
processing is not a requirement for the generation of antigenic determinants. It 
is MHC-restricted (i.e., specific MHC class I or II blocking antibodies inhibit the 
response), indicating that the drug interacts with the MHC molecules prior to 
activating T-cells (Elsheikh et al., 2011; Lichtenfels et al., 2014; Schnyder et al., 
1997). In vitro assays to diagnose drug hypersensitivity reactions (e.g., the 
lymphocyte transformation test) rely on the p-i concept, since high levels of 
protein-reactive metabolite are not formed in cell culture. For carbamazepine 
and allopurinol, stable metabolites have also been shown to activate T-cells 
from hypersensitive patients (Braden et al., 1994; Wu et al., 2006). The isolation 
and characterization of T-cell clones revealed that certain T-cells are in fact 
activated with the metabolite, but not the parent drug. Thus, one should not 
conclude that a patient is not sensitized against a drug with a negative response 
in in vitro assay. It might be that the cells are exposed to an irrelevant drug-
derived antigen. Sulfamethoxazole is one example where protein-reactive 
metabolites have been synthesized and methods developed to expose patient 
cells to the metabolite in a form that does not cause direct toxicity. T-cell 
responses to metabolites bound covalently to protein and the parent drug 
bound directly to MHC are detected in all hypersensitive patients (Elsheikh et 
al., 2011; Schnyder et al., 2000).  
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Recent studies with abacavir proposed an additional pathway of drug-specific 
T-cell activation, the so called “altered self-peptide repertoire” hypothesis 
(Illing et al., 2012; Norcross et al., 2012; Ostrov et al., 2012). Here the authors 
show that abacavir binds to endogenous MHC molecules (specifically HLA-
B*57:01) altering the structure of the peptide binding site and subsequently the 
peptides that can be incorporated. The authors propose (although are yet to 
prove) that T-cells involved in abacavir hypersensitivity reactions are activated 
via these “altered-self”, newly loaded peptides. In a way, this concept could be 
viewed as an expansion of the p-i concept in that the drug binds directly to MHC 
to activate T-cells. The main difference is that drugs enter antigen presenting 
cells and bind to MHC prior to peptide loading.  
 
The major objective of my project was to utilize β-lactam antibiotic-responsive 
T-cells to further our understanding of the interaction of drugs with immune 
cells. β-lactam hypersensitivity was selected as the paradigm to study since the 
reactivity and interaction of β-lactam antibiotics with protein has been studied 
in detail and there was a good foundation on which to build. The drugs in this 
class of antibiotics all contain the core β-lactam ring structure from which the 
drugs are named and inhibitory effects on bacterial cell wall synthesis occur. 
The β-lactam ring structure is often fused to a five-membered thiazolidine ring, 
as in the case of penicillins, a major class of β-lactam antibiotic, and differing 
side chains form the wide range of antibiotics available (Figure 7.2). The β-
lactam ring is targeted by nucleophilic lysine residues on proteins for antigen 
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formation, leading to the ring opening and binding of the penicilloyl group 
(Batchelor et al., 1965; Levine et al., 1961c).   
 
Figure 7.2 Core structure of penicillin class of β-lactam antibiotics 
 
One of the major issues discussed in the field of drug hypersensitivity is 
whether a drug-peptide adduct is an absolute requirement for the activation of 
T-cells. Martin et al. and Weltzien et al. have shown designer “drug-peptide 
adducts” activate certain T-cells. Thus, these studies provide the framework for 
my investigations (Martin et al., 1992; Ortmann et al., 1992; Thierse et al., 2005; 
Weltzien et al., 1996a). Specifically, the authors were able to demonstrate that 
the location of the hapten on the peptide determines whether or not a T-cell will 
be activated and the magnitude of the response, 
 
Patients with cystic fibrosis were utilized for many studies, as this population 
provided easy access to relevant samples. The nature of the disease leads to 
frequent intake of antibiotics for the maintenance of effective lung function. 
Unfortunately, a high rate of hypersensitivity (between 26 - 50% compared to 3 
β-lactam ring Thiazolidine ringSide chain
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- 10% in the general population) is observed in this patient group (Burrows et 
al., 2007; Parmar et al., 2005; Whitaker et al., 2011c). Hence, the study of β-
lactam hypersensitivity is necessary to aid in not only understanding the 
mechanisms involved in the pathogenesis but also to assist the development of 
clinical tests for diagnosis. Work completed prior to commencement of my 
studies revealed the presence of drug-responsive T-cells in peripheral blood of 
approximately 75% of piperacillin hypersensitive patients. The majority of 
drug-specific T-cells were CD4+ and were found to secrete an array Th1 and 
Th2 cytokines following activation (El-Ghaiesh et al., 2012).  T-cell responses to 
other drugs had not been studied. 
 
My first experimental chapter looked closely at multiple hypersensitivity 
syndrome utilising PBMCs from patients who had developed hypersensitivity to 
2 or more of the following β-lactam antibiotics: piperacillin, meropenem and 
aztreonam. We were able to isolate and expand piperacillin, meropenem and 
aztreonam specific T-clones from each patient and observed a fine specificity in 
the T-cell response. No cross reactivity was observed when clones were 
cultured with the different drugs. Hence, one can conclude that the 
hypersensitivity reactions that develop in these patients following sequential 
drug exposure are each dependent on the priming of naïve T-cells and not 
cross-reactivity. Using mass spectrometric methods we were able to 
characterise the haptenic structures formed by each of the three drugs on HSA 
lysine groups. Each drug bound covalently to the same lysine groups (albeit to 
slightly different extents); thus, the drug-moiety attached to protein and not the 
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site of modification seems to be the primary driver of the drug-specific T-cell 
response.  
 
Opening of the β-lactam ring is common to all β-lactam antibiotics and allows 
for the formation of adducts with proteins including HSA (Batchelor et al., 1965; 
Levine et al., 1961b). Thus, the next objective of my studies was to focus on one 
drug, piperacillin, and generate synthetic HSA adducts essentially free of parent 
drug, and investigate their immunogenicity (i.e., ability to activate T-cell clones 
from hypersensitive patients). Two synthetic piperacillin-HSA conjugates were 
generated; methanol-extracted conjugate 2 (see chapter 4) was able to 
stimulate piperacillin-specific T-cell clones whilst a second conjugate generated 
via the same method but extracted differently (filtration process to remove free 
piperacillin; conjugate 1), failed to induce T-cell proliferation. Mass 
spectrometric analysis of the protein adducts revealed a similar level of 
modification at the same lysine groups; thus, this did not explain the difference 
observed in the T-cell assays. Due to these unexpected results, several months 
of investigation followed in order to define the mechanism of piperacillin-
specific T-cell activation and explain the results observed with the different 
piperacillin HSA conjugates. Despite a strikingly similar mass spectrometric 
appearance of the two conjugates, conjugate 2 was found to contain a higher 
level of “free” or at least non-covalently associated piperacillin. Thus, T-cell 
assays were established utilizing conjugates 1 and 2 and spiked (low) 
concentrations of free drug. From these experiments it was possible to conclude 
that T-cells were not activated with free piperacillin via a p-i pathway. This 
conclusion is further supported by experiments showing that inhibition of 
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protein processing blocked T-cell responses to piperacillin (chapter 4). Thus, 
the clones generated following PBMC expansion with parent drug do not seem 
to be activated with HSA adducts and are not activated with the parent drug.  
Previously, Thierse et al working on mechanisms of contact allergy with nickel 
proposed that HSA may act as a “shuttling molecule” which in essence brings 
the metal allergen through the epidermis towards TCR/MHC binding site for T-
cell activation (Thierse et al., 2004). This phenomenon was mimicked in vitro 
using nickel bound to HSA through a coordinate linkage. It is possible that a 
similar situation occurs with piperacillin. If so, the level of “free” piperacillin in 
conjugate 2 would be shuttled by HSA to relevant protein binding sites, where it 
facilitates hapten transfer and ultimately the formation of antigenic 
determinants to stimulate clones. In contrast, the level of free drug in conjugate 
1 seems to be insufficient for this process to occur. 
In additional experiments the specificity of the piperacillin hapten response was 
further highlighted. T-cell clones specific to conjugate 1 (which did not 
stimulate clones specific to soluble piperacillin) were generated. While 
responses were dose-dependent to conjugate 1, in half of the T-cell clones 
tested proliferative responses to soluble piperacillin were not observed.  
 
Having demonstrated the ability of drug protein adducts to activate T-cells from 
piperacillin hypersensitive patients, we went on to relate the absolute 
concentrations of piperacillin HSA adducts formed in vitro and in patients to the 
activation of T-cells. Utilising mass spectrometric expertise in the department, 
not only could we detect and identify piperacillin modified peptides, 
importantly levels were now quantified. Quantification was achieved through 
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development of a novel method whereby a synthetic piperacillin modified 
peptide was synthesised and used as a standard. Similar levels of piperacillin-
modified peptide were detected in vitro and in patient plasma, with 2% - 6% of 
total protein consisting of modified pip-K541 peptide. With methods in place, 
time and concentration dependency was explored allowing us to conclude that 
2.8% modified peptide was the required threshold to trigger a T-cell response. 
This is the first time a quantitative analysis of drug modification has been 
related to the activation of a drug-specific T-cell response. Taking this further, a 
prospective study would be an ideal next step. Monitoring antigen formation 
and the immunological/clinical response in tolerant and hypersensitive patients 
and in hypersensitive patients during desensitization would help improve the 
safety profile of piperacillin in susceptible populations.  
 
Despite being the first to explore the quantitative relationship between drug 
protein binding and the T-cell response, we are still a fair distance away from 
defining the particular hapten-peptide structure(s) required to ligate MHC and 
activate a primary immune response in patients. Crystallography and computer 
modelling aligned to mass spectrometric analysis of peptides eluted from MHC 
molecules would undoubtedly aid in our structural knowledge. However, these 
studies are complicated because piperacillin-specific T-cell responses are not 
MHC-allele restricted, i.e., drug-peptide adducts bind to proteins encoded by 
multiple HLA alleles to activate T-cells. Furthermore, even if it was possible to 
characterize MHC-binding piperacillin peptide adducts, it is likely that several 
will need to be synthesized to study T-cell responses and peptide synthesis 
using drug-modified lysine as starting material is incredibly difficult.  
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Flucloxacillin, like piperacillin, is from the penicillin class of β-lactam 
antibiotics. It is commonly used to treat staphylococcal infections. Unlike the 
other β-lactams investigated in this thesis, flucloxacillin is a cause of acute liver 
failure, which has a strong association with HLA-B*57:01 (Daly et al., 2009b). 
Interestingly abacavir, also associated with HLA-B*57:01, is not linked with 
DILI and currently similarities in mechanisms of reaction have not been 
determined and so associations with the same allele may be coincidental (Yip et 
al., 2014). Despite the strong association with HLA-B*57:01, pre-clinical 
screening is not possible as almost 14,000 patients would need to be screened 
before DILI is avoided in one patient, thus preventing thousands of patients 
from receiving effective treatment (Karlin et al., 2014). Investigating the 
mechanisms involved in the development of flucloxacillin induced adverse 
reactions would therefore aid our understanding of the disease pathogenesis 
and in turn findings could be applied to the clinic. Though an HLA association 
exists for flucloxacillin-induced liver injury, skin reactions to flucloxacillin have 
not been associated with HLA-B*57:01 or other HLA alleles. In chapter 6 
investigations with flucloxacillin focussed on the immune response in patients 
with skin and liver injury. Experiments with PBMCs showed lymphocyte 
proliferation was easily detected in a patient with skin injury yet patients with 
flucloxacillin induced liver injury yielded largely negative results. It was 
interesting to note that DILI patients and the patient with skin injury were HLA-
B*57:01 positive.  Clones from both patient groups were largely CD8+ and the 
drug-specific response was MHC class I restricted indicating that the HLA risk 
allele may be directly involved in presenting the drug-derived antigen to T-cells. 
Unfortunately, due to limited availability of T-cell clones from the patient with 
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flucloxacillin-induced skin injury, additional experiments were not possible. 
Indeed, a much larger study with an increased number of patients with both 
DILI and skin injury would be required to reach definitive conclusions.  
 
Utilising a bank of HLA-typed volunteers available at the University of Liverpool 
we were able to investigate HLA restriction of the flucloxacillin-specific T-cell 
response in HLA-B*57:01+ donors and compare the findings obtained to 
patients with DILI. It was interesting to find that CD8+ T-cell clones from HLA-
B*57:01+ donors, though activated by soluble flucloxacillin were not stimulated 
by flucloxacillin-pulsed APCs, an observation paralleling the finding of a recent 
study with flucloxacillin whereby clones from HLA-B*57:01+ donors were 
found to be activated preferentially by the parent drug via a p-i pathway 
(Wuillemin et al., 2013a). CD8+ T-cell clones from HLA-B*57:01+ patients with 
liver injury however, were activated by both soluble drug and pulsed APCs. 
Furthermore, the hapten response (i.e., response to drug-pulsed antigen 
presenting cells) showed fine HLA specificity when clones were cultured with a 
panel of antigen presenting cells expressing a range of HLA-B alleles; clones 
exposed to flucloxacillin-pulsed antigen presenting cells only responded in the 
presence of cells expressing HLA-B*57:01+ and in some cases the structurally 
similar HLA-B*58:01. This level of restriction was not observed when clones 
were cultured with the same antigen presenting cells and soluble flucloxacillin, 
possibly due to the multiple HLA binding interactions that occur when the drug 
is added at high concentrations.  
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In final investigations with flucloxacillin we were fortunate to have access to 
primary hepatocytes. Preliminary studies detected flucloxacillin modified 
peptides in hepatocyte cell lysates, which suggests that hepatocyte-modified 
protein may be an important antigen for T-cells and direct the immune 
response to the liver. In support of this argument, flucloxacillin-specific T-cell 
clones have been shown to secrete cytolytic molecules including granzyme B, 
Fas ligand and perforin. Furthermore, CD3+ and CD8+ lymphocytes have 
recently been shown to infiltrate liver in patients with liver failure and kill 
hepatocytes in vitro (Wuillemin et al., 2014). Finally, the expression of 
chemokine receptors CCR2, CCR4 and CCR9 on T-cells from HLAB*57:01+ 
volunteers and patients with DILI suggests that liver injury may result from a 
mass infiltration of flucloxacillin-reactive cytotoxic T-cells as these receptors 
are involved in migration and accumulation of immune cells in liver (Mennicke 
et al., 2009; Monshi et al., 2013). Further work utilising precious liver 
specimens and T-cell/hepatocyte co-cultures will undoubtedly aid our 
understanding of the pathogenesis of DILI particularly the contribution of the 
immune system. 
 
Characterization of drug-modified protein and exploration of the relationship 
between adduct formation and activation of immune cells has been a common 
theme throughout my thesis. Drug-modified protein and the peptides generated 
through protein processing undoubtedly play an important role in the 
development of drug hypersensitivity and perhaps a pivotal role in DILI. As the 
most abundant serum protein, much of my research focused on HSA, yet drugs 
have the potential to bind covalently to a vast number of circulating proteins. 
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Thus, we must take into consideration the great number of peptide fragments 
that are generated naturally and those that might participate in the immune 
response whence modified. Hence, the picture becomes incredibly complicated. 
Indeed the development of an exaggerated immune response is likely to involve 
a wide range of peptides which interact with multiple HLA molecules to activate 
T-cells. Being able to focus directly on the drug-derived peptides which bind to 
the HLA molecule and trigger the immune response is a natural next step. 
Abacavir, like flucloxacillin, has an association with HLA-B*57:01 (Hetherington 
et al., 2002; Mallal et al., 2002). Studies by Chessman et al have defined the role 
of HLA-B*57:01 and the fine specificity of the MHC interaction with abacavir 
was mapped to the drug-binding F-pocket (Chessman et al., 2008). In recent 
years Illing et al have successfully eluted peptides bound to HLA-B*57:01. Using 
mass spectrometry they were able to characterise the peptides bound to these 
HLA molecules. Examination of the peptide repertoire presented by HLA-
B*57:01 saw a shift in the nature of peptides bound in abacavir treated cells 
compared to untreated control cells (Illing et al., 2012). Illing et al proposed 
that abacavir bound specifically to the antigen-binding cleft of HLA-B*57:01 
meaning the usual repertoire of peptides able to bond to HLA-B*57:01 was 
somewhat hindered. From this work the altered self-peptide repertoire 
hypothesis of drug hypersensitivity was put forward. The methods used here 
can be transferred and used to build upon the work in this thesis. Indeed, in the 
final months of the PhD, preliminary work was conducted and methods 
researched in order to apply elution and mass spectrometry methods to 
flucloxacillin and so methods are now in place to elute peptides bound to HLA-B 
alleles from cells cultured with and without flucloxacillin. Figure 3 details the 
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work flow and methods used to analyze the vast number of MHC binding 
peptides that are eluted off antigen presenting cells. It will therefore be possible 
in the very near future, in a similar manner to Illing et al, to characterise the 
repertoire of drug-modified and unmodified peptides which bind to the specific 
HLA.  
Chapter 7 
225 
 
 
Figure 7.3 Method flow for peptide elution  
FlucloxacillinControl
Cell culture 
C1R cells transfected with HLA-
B*57:01, +/- flucloxacillin, 
109 cells
Spin to form pellets
Snap freeze in liquid 
nitrogen. Store @ -80°C 
until required
Grind frozen cell pellets with cryogenic mill and lyse. 
Incubate in lysis buffer for 1hr @ 4°C 
Run supernatant through affinity column
Immunoaffinity resin
Column with purified 
monoclonal antibody 
against HLA-B
Washes to remove detergent, non-specifically 
bound material and to prevent crystal formation
Bound complexes eluted with 10% acetic acid
Peptides/class I heavy chain/β2-microglobulin
Reverse-phase HPLC column to separate
LC-MS/MS to identify MHC-bound peptides
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Drug hypersensitivity is an ever evolving field of research. Whilst new findings 
continue to emerge often further questions arise as a result. Much of the work 
in this thesis has detailed the in vitro situation; thus, findings should be 
interpreted with some caution as other pathways of drug-specific T-cell 
activation may occur in patients. Ideally models would provide a situation 
where the effect of multiple mechanisms can be studied thus providing deeper 
understanding of the pathogenesis of drug hypersensitivity. Unfortunately the 
complex nature of the immune system makes the development of in vitro 
models difficult. The situation is further complicated when metabolism is a 
prerequisite for adduct formation and when investigations with HLA alleles are 
included.  The precise nature of the genetics involved in susceptibility often 
rules out the development of animal models. Nonetheless, focussing on 
particular stages in the development of hypersensitivity, as done here, can help 
piece together and further our understanding of this complex iatrogenic 
disease.  Continuing research will not only lead to improved drug design and 
development but also translate through to the clinic aiding patient diagnosis in 
the hope of continually reducing the risk of drug hypersensitivity. 
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